



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 317/62, 319/18, 311/58, 339/06, 307/79</p>	<p>A1</p>	<p>(11) International Publication Number: WO 99/59989</p> <p>(43) International Publication Date: 25 November 1999 (25.11.99)</p>
<p>(21) International Application Number: PCT/US99/07047</p> <p>(22) International Filing Date: 18 May 1999 (18.05.99)</p> <p>(30) Priority Data: 09/080,928 19 May 1998 (19.05.98) US</p> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/080,928 (CON) Filed on 19 May 1998 (19.05.98)</p> <p>(71) Applicant (for all designated States except US): G.D. SEARLE & CO. [US/US]; Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): KUNDA, Sastry, A. [IN/US]; 1302 Stillhouse Road, Chesterfield, MO 63017 (US). LETENDRE, Leo, J. [US/US]; 267 Glander Drive, Manchester, MO 63021 (US). DE CRESCENZO, Gary, A. [US/US]; 7345 Spruse Hill Court, St. Charles, MO 63304 (US).</p>	<p>(74) Agents: KEANE, Timothy, J. et al.; G.D. Searle & Co., Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>	
<p>(54) Title: PROCESS FOR THE PREPARATION OF A BENZO FUSED HETEROCYCLO SULFONYL HALIDE INTERMEDIATE</p>		
<p>(57) Abstract</p> <p>Process for preparing a benzo fused heterocyclo sulfonyl halide intermediate, comprising reacting a benzo fused heterocyclic compound with a -SO₃- complex in the presence of a solvent and then adding oxalyl halide.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PROCESS FOR THE PREPARATION OF A BENZO FUSED HETEROCYCLO SULFONYL HALIDE INTERMEDIATE

BACKGROUND OF THE INVENTION

5 The present invention relates to retroviral
protease inhibitors and, more particularly, relates to
novel compounds, composition and method for inhibiting
retroviral proteases, such as human immunodeficiency
virus (HIV) protease. This invention, in particular,
relates to amino acid hydroxyethylamine sulfonamide
10 protease inhibitor compounds, composition and method for
inhibiting retroviral proteases, prophylactically
preventing retroviral infection or the spread of a
retrovirus, and treatment of a retroviral infection,
e.g., an HIV infection. The subject invention also
15 relates to processes for making such compounds as well
as to intermediates useful in such processes.

 During the replication cycle of retroviruses, gag
and gag-pol gene transcription products are translated
as proteins. These proteins are subsequently processed
20 by a virally encoded protease (or proteinase) to yield
viral enzymes and structural proteins of the virus
core. Most commonly, the gag precursor proteins are
processed into the core proteins and the pol precursor
proteins are processed into the viral enzymes, e.g.,
25 reverse transcriptase and retroviral protease. It has

been shown that correct processing of the precursor proteins by the retroviral protease is necessary for assembly of infectious virions. For example, it has been shown that frameshift mutations in the protease region of the pol gene of HIV prevents processing of the gag precursor protein. It has also been shown through site-directed mutagenesis of an aspartic acid residue in the HIV protease active site that processing of the gag precursor protein is prevented. Thus, attempts have been made to inhibit viral replication by inhibiting the action of retroviral proteases.

Retroviral protease inhibition typically involves a transition-state mimetic whereby the retroviral protease is exposed to a mimetic compound which binds (typically in a reversible manner) to the enzyme in competition with the gag and gag-pol proteins to thereby inhibit specific processing of structural proteins and the release of retroviral protease itself. In this manner, retroviral replication proteases can be effectively inhibited.

Several classes of compounds have been proposed, particularly for inhibition of proteases, such as for inhibition of HIV protease. Such compounds include hydroxyethylamine isosteres and reduced amide isosteres. See, for example, EP 0346847; EP 0342541; Roberts et al, "Rational Design of Peptide-Based Proteinase Inhibitors," Science, 248, 358 (1990); and Erickson et al, "Design Activity, and 2.8Å Crystal Structure of a C₂ Symmetric Inhibitor Complexed to HIV-1 Protease," Science, 249, 527 (1990). US 5,157,041, WO 94/04491, WO 94/04492, WO 94/04493, WO 94/05639, WO 92/08701 and US Patent Application Serial No. 08/294,468, filed August 23, 1994, (each of which is incorporated herein by reference

in its entirety) for example describe hydroxyethylamine, hydroxyethylurea or hydroxyethyl sulfonamide isostere containing retroviral protease inhibitors.

5 Several classes of compounds are known to be useful as inhibitors of the proteolytic enzyme renin. See, for example, U.S. No. 4,599,198; U.K. 2,184,730; G.B. 2,209,752; EP 0264795; G.B. 2,200,115 and U.S. SIR H725. Of these, G.B. 2,200,115, GB 2,209,752, EP
10 0264795, U.S. SIR H725 and U.S. 4,599,198 disclose urea-containing hydroxyethylamine renin inhibitors. EP 468641 discloses renin inhibitors and intermediates for the preparation of the inhibitors, which include sulfonamide-containing hydroxyethylamine compounds,
15 such as 3-(t-butoxycarbonyl)amino-cyclohexyl-1-(phenylsulfonyl)amino-2(5)-butanol. G.B. 2,200,115 also discloses sulfamoyl-containing hydroxyethylamine renin inhibitors, and EP 0264795 discloses certain sulfonamide-containing hydroxyethylamine renin
20 inhibitors. However, it is known that, although renin and HIV proteases are both classified as aspartyl proteases, compounds which are effective renin inhibitors generally are not predictive for effective HIV protease inhibition.

25


BRIEF DESCRIPTION OF THE INVENTION

The present invention relates to selected retroviral protease inhibitor compounds, analogs and
30 pharmaceutically acceptable salts, esters and prodrugs thereof. The subject compounds are characterized as amino acid hydroxyethylamine sulfonamide inhibitor compounds. The invention compounds advantageously inhibit retroviral proteases, such as human
35 immunodeficiency virus (HIV) protease. Therefore, this

invention also encompasses pharmaceutical compositions, methods for inhibiting retroviral proteases and methods for treatment or prophylaxis of a retroviral infection, such as an HIV infection. The subject invention also
 5 relates to processes for making such compounds as well as to intermediates useful in such processes.

DETAILED DESCRIPTION OF THE INVENTION

10 In accordance with the present invention, there is provided a retroviral protease inhibiting compound of the formula:



15

or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein n represents 1 or 2;

R¹ represents alkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cyanoalkyl, imidazolylmethyl, -CH₂CONH₂,
 20 -CH₂CH₂CONH₂, -CH₂S(O)₂NH₂, -CH₂SCH₃, -CH₂S(O)CH₃,
 -CH₂S(O)₂CH₃, -C(CH₃)₂SCH₃, -C(CH₃)₂S(O)CH₃ or
 -(CH₃)₂S(O)₂CH₃ radicals; preferably, R¹ represents
 alkyl of 1-5 carbon atoms, alkenyl of 2-5 carbon atoms,
 25 alkynyl of 2-5 carbon atoms, hydroxyalkyl of 1-3 carbon
 atoms, alkoxyalkyl of 1-3 alkyl and 1-3 alkoxy carbon
 atoms, cyanoalkyl of 1-3 alkyl carbon atoms,
 imidazolylmethyl, -CH₂CONH₂, -CH₂CH₂CONH₂, -CH₂S(O)₂NH₂,
 -CH₂SCH₃, -CH₂S(O)CH₃, -CH₂S(O)₂CH₃, -C(CH₃)₂SCH₃,
 30 -C(CH₃)₂S(O)CH₃ or -C(CH₃)₂S(O)₂CH₃ radicals; more
 preferably, R¹ represents alkyl of 1-4 carbon atoms,


alkenyl of 2-3 carbon atoms, alkynyl of 3-4 carbon atoms, cyanomethyl, imidazolylmethyl, $-\text{CH}_2\text{CONH}_2$, $-\text{CH}_2\text{CH}_2\text{CONH}_2$, $-\text{CH}_2\text{S}(\text{O})_2\text{NH}_2$, $-\text{CH}_2\text{SCH}_3$, $-\text{CH}_2\text{S}(\text{O})\text{CH}_3$, $-\text{CH}_2\text{S}(\text{O})_2\text{CH}_3$, $-\text{C}(\text{CH}_3)_2\text{SCH}_3$, $-\text{C}(\text{CH}_3)_2\text{S}(\text{O})\text{CH}_3$ or
5 $-\text{C}(\text{CH}_3)_2\text{S}(\text{O})_2\text{CH}_3$ radicals; and most preferably, R^1 represents sec-butyl, tert-butyl, iso-propyl, 3-propynyl or $-\text{C}(\text{CH}_3)_2\text{S}(\text{O})_2\text{CH}_3$ radicals;

R^2 represents alkyl, aralkyl, alkylthioalkyl,
10 arylthioalkyl or cycloalkylalkyl radicals; preferably, R^2 represents radicals of alkyl of 1-5 carbon atoms, aralkyl of 1-3 alkyl carbon atoms, alkylthioalkyl of 1-3 alkyl carbon atoms, arylthioalkyl of 1-3 alkyl carbon atoms or cycloalkylalkyl of 1-3 alkyl carbon atoms and
15 3-6 ring member carbon atoms; more preferably, R^2 represents radicals of alkyl of 3-5 carbon atoms, arylmethyl, alkylthioalkyl of 1-3 alkyl carbon atoms, arylthiomethyl or cycloalkylmethyl of 5-6 ring member carbon atoms radicals; even more preferably, R^2
20 represents isobutyl, n-butyl, $\text{CH}_3\text{SCH}_2\text{CH}_2-$, benzyl, phenylthiomethyl, (2-naphthylthio)methyl, 4-methoxy phenylmethyl, 4-hydroxyphenylmethyl, 4-fluorophenylmethyl or cyclohexylmethyl radicals; even more preferably, R^2 represents benzyl, 4-fluorophenylmethyl or cyclohexylmethyl radicals; most
25 preferably, R^2 represents benzyl;

R^3 represents alkyl, cycloalkyl or cycloalkylalkyl radicals; preferably, R^3 represents radicals of alkyl
30 radical of 1-5 carbon atoms, cycloalkyl of 5-8 ring members or cycloalkylmethyl radical of 3-6 ring members; more preferably, R^3 represents propyl, isoamyl, isobutyl, butyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexyl or cycloheptyl radicals; more preferably R^3
35 represents isobutyl or cyclopentylmethyl radicals;

R⁴ represents aryl, heteroaryl or heterocyclo radicals;
preferably, R⁴ represents aryl, benzo fused 5 to 6 ring
member heteroaryl or benzo fused 5 to 6 ring member
5 heterocyclo radicals; or

R⁴ represents a radical of the formula




10 wherein A and B each independently represent O, S, SO or
SO₂; preferably, A and B each represent O;

R⁶ represents hydrogen deuterium, alkyl or halogen
radicals; preferably, R⁶ represents hydrogen deuterium,
15 alkyl of 1-5 carbon atoms, fluoro or chloro radicals;
more preferably R⁶ represents hydrogen deuterium,
methyl, ethyl, propyl, isopropyl or fluoro radicals;


R⁷ represents hydrogen, deuterium, alkyl or halogen
20 radicals; preferably, R⁷ represents hydrogen, deuterium,
alkyl of 1-3 carbon atoms, fluoro or chloro radicals;
more preferably, R⁷ represents hydrogen, deuterium,
methyl or fluoro radicals; or R⁶ and R⁷ each
independently represent fluoro or chloro radicals; and
25 preferably, R⁶ and R⁷ each represent a fluoro radical;
or

R⁴ represents a radical of the formula



30

wherein Z represents O, S or NH; and R⁹ represents a
radical of formula



wherein Y represents O, S or NH; X represents a bond, O
 5 or NR²¹;

R²⁰ represents hydrogen, alkyl, alkenyl, alkynyl,
 aralkyl, heteroaralkyl, heterocycloalkyl, aminoalkyl, N-
 mono-substituted or N,N-disubstituted aminoalkyl wherein
 10 said substituents are alkyl or aralkyl radicals,
 carboxyalkyl, alkoxycarbonylalkyl, cyanoalkyl or
 hydroxyalkyl radicals; preferably, R²⁰ represents
 hydrogen, alkyl of 1 to 5 carbon atoms, alkenyl of 2 to
 5 carbon atoms, alkynyl of 2 to 5 carbon atoms, aralkyl
 15 of 1 to 5 alkyl carbon atoms, heteroaralkyl of 5 to 6
 ring members and 1 to 5 alkyl carbon atoms,
 heterocycloalkyl of 5 to 6 ring members and 1 to 5 alkyl
 carbon atoms, aminoalkyl of 2 to 5 carbon atoms, N-mono-
 substituted or N,N-disubstituted aminoalkyl of 2 to 5
 20 alkyl carbon atoms wherein said substituents are
 radicals of alkyl of 1 to 3 carbon atoms, aralkyl of 1
 to 3 alkyl carbon atoms radicals, carboxyalkyl of 1 to 5
 carbon atoms, alkoxycarbonylalkyl of 1 to 5 alkyl carbon
 atoms, cyanoalkyl of 1 to 5 carbon atoms or hydroxyalkyl
 25 of 2 to 5 carbon atoms; more preferably, R²⁰ represents
 hydrogen, alkyl of 1 to 5 carbon atoms, phenylalkyl of 1
 to 3 alkyl carbon atoms, heterocycloalkyl of 5 to 6 ring
 members and 1 to 3 alkyl carbon atoms, or N-mono-
 substituted or N,N-disubstituted aminoalkyl of 2 to 3
 30 carbon atoms wherein said substituents are alkyl
 radicals of 1 to 3 carbon atoms; and most preferably,
 R²⁰ represents hydrogen, methyl, ethyl, propyl,
 isopropyl, isobutyl, benzyl, 2-(1-pyrrolidinyl)ethyl, 2-

(1-piperidinyl)ethyl, 2-(1-piperazinyl)ethyl, 2-(4-methylpiperazin-1-yl)ethyl, 2-(1-morpholinyl)ethyl, 2-(1-thiamorpholinyl)ethyl or 2-(N,N-dimethylamino)ethyl radicals;

5

R^{21} represents hydrogen or alkyl radicals; preferably, R^{21} represents hydrogen radical or alkyl radical of 1 to 3 carbon atoms; more preferably, R^{21} represents hydrogen or methyl radicals; and most preferably, R^{21} represents
10 a hydrogen radical; or

the radical of formula $-NR^{20}R^{21}$ represents a heterocyclo radical; preferably, the radical of formula $-NR^{20}R^{21}$ represents a 5 to 6 ring member heterocyclo radical;
15 more preferably, the radical of formula $-NR^{20}R^{21}$ represents pyrrolidinyl, piperidinyl, piperazinyl, 4-methylpiperazinyl, 4-benzylpiperazinyl, morpholinyl or thiamorpholinyl radicals; and

20 R^{22} represents alkyl or $R^{20}R^{21}N$ -alkyl radicals; preferably, R^{22} represents alkyl or $R^{20}R^{21}N$ -alkyl radicals wherein alkyl is 1 to 3 carbon atoms; and more preferably, R^{22} represents alkyl radical of 1 to 3 carbon atoms; and

25

preferably R^4 represents phenyl, 2-naphthyl, 4-methoxyphenyl, 4-hydroxyphenyl, 3,4-dimethoxyphenyl, 3-aminophenyl, 4-aminophenyl, benzothiazol-5-yl, benzothiazol-6-yl, 2-amino-benzothiazol-5-yl, 2-
30 (methoxycarbonylamino)benzothiazol-5-yl, 2-amino-benzothiazol-6-yl, 2-(methoxycarbonylamino)benzothiazol-6-yl, 5-benzoxazolyl, 6-benzoxazolyl, 6-benzopyranyl, 3,4-dihydrobenzopyran-6-yl, 7-benzopyranyl, 3,4-dihydrobenzopyran-7-yl, 2,3-
35 dihydrobenzofuran-5-yl, benzofuran-5-yl, 1,3-

benzodioxol-5-yl, 2-methyl-1,3-benzodioxol-5-yl, 2,2-dimethyl-1,3-benzodioxol-5-yl, 2,2-dideutero-1,3-benzodioxol-5-yl, 2,2-difluoro-1,3-benzodioxol-5-yl, 1,4-benzodioxan-6-yl, 5-benzimidazolyl, 2-
5 (methoxycarbonylamino)benzimidazol-5-yl, 6-quinolinyl, 7-quinolinyl, 6-isoquinolinyl or 7-isoquinolinyl radicals; more preferably, R⁴ represents phenyl, 2-naphthyl, 4-methoxyphenyl, 4-hydroxyphenyl, benzothiazol-5-yl, benzothiazol-6-yl, benzoxazol-5-yl,
10 2,3-dihydrobenzofuran-5-yl, benzofuran-5-yl, 1,3-benzodioxol-5-yl, 2-methyl-1,3-benzodioxol-5-yl, 2,2-dimethyl-1,3-benzodioxol-5-yl, 2,2-dideutero-1,3-benzodioxol-5-yl, 2,2-difluoro-1,3-benzodioxol-5-yl, 1,4-benzodioxan-6-yl, 2-(methoxycarbonylamino)
15 benzothiazol-5-yl, 2-(methoxycarbonylamino)benzothiazol-6-yl or 2-(methoxycarbonylamino)benzimidazol-5-yl radicals; and most preferably, R⁴ represents phenyl, 4-methoxyphenyl, 4-hydroxyphenyl, benzothiazol-5-yl, benzothiazol-6-yl,
20 2,3-dihydrobenzofuran-5-yl, benzofuran-5-yl, 1,3-benzodioxol-5-yl, 2-methyl-1,3-benzodioxol-5-yl, 2,2-dimethyl-1,3-benzodioxol-5-yl, 2,2-dideutero-1,3-benzodioxol-5-yl, 2,2-difluoro-1,3-benzodioxol-5-yl, 1,4-benzodioxan-6-yl, 2-
25 (methoxycarbonylamino)benzothiazol-6-yl or 2-(methoxycarbonylamino)benzimidazol-5-yl radicals;

R¹⁰ represents hydrogen, alkyl, hydroxyalkyl or alkoxyalkyl radicals, wherein alkyl is 1-3 carbon
30 atoms; preferably R¹⁰ represents a hydrogen radical;

R¹¹ represents alkyl radical of 1-5 carbon atoms, preferably methyl, isopropyl, butyl, secbutyl or isobutyl radicals; hydroxyalkyl radical of 1-4 carbon
35 atoms, preferably hydroxymethyl or hydroxyethyl

radicals; alkoxyalkyl radical of 1-4 alkyl carbon atoms, preferably methoxymethyl or methoxyethyl radicals; or hydrogen, benzyl, imidazolylmethyl, -CH₂CH₂CONH₂, -CH₂CONH₂, -CH₂CH₂SCH₃ or -CH₂SCH₃ radicals
5 or the sulfone or sulfoxide derivatives thereof; more preferably R¹¹ represents a hydrogen radical;

R¹² represents hydrogen, hydroxyalkyl or alkoxyalkyl radicals; preferably, R¹² represents hydrogen,
10 hydroxyalkyl or alkoxyalkyl radicals, wherein alkyl is 1-3 carbon atoms; preferably R¹² represents a hydrogen radical; and


R¹³ and R¹⁴ each independently represent hydrogen,
15 hydroxy, alkoxy, hydroxyalkoxy, hydroxyalkyl or alkoxyalkyl radicals; preferably, R¹³ and R¹⁴ each independently represent hydrogen, hydroxy, alkoxy, 2-hydroxyethoxy, hydroxyalkyl or alkoxyalkyl radicals, wherein alkyl is 1-3 carbon atoms; more preferably, R¹³
20 and R¹⁴ each independently represent hydrogen, hydroxy, methoxy or ethoxy radicals; or

R¹² and R¹³ or R¹³ and R¹⁴ along with the carbon atoms to which they are attached represent 5-6 ring membered
25 heteroaryl or benzo radical, each of which is optionally substituted with at least one hydroxy or alkoxy radical of 1-3 carbon atoms; preferably R¹² and R¹³ or R¹³ and R¹⁴ along with the carbon atoms to which they are attached represent benzo radical, which is
30 optionally substituted with at least one hydroxy or methoxy radical.

The absolute stereochemistry of the carbon atom of -CH(OH)- group is preferably (R). The absolute
35 stereochemistry of the carbon atom of -CH(R¹)- group is


preferably (S). The absolute stereochemistry of the carbon atom of $-\text{CH}(\text{R}^2)-$ groups is preferably (S).

A family of compounds of particular interest within
5 Formula I are compounds embraced by the formula



or a pharmaceutically acceptable salt, prodrug or ester
10 thereof, wherein n , R^1 , R^2 , R^3 , and R^4 are as defined
above.

A family of compounds of further interest within
15 Formula II are compounds embraced by the formula



or a pharmaceutically acceptable salt, prodrug or ester
20 thereof, wherein R^1 , R^2 , R^3 , R^4 and n are as defined
above.

A more preferred family of compounds within Formula
III consists of compounds or a pharmaceutically
acceptable salt, prodrug or ester thereof, wherein n
25 represents 1;

R^1 represents sec-butyl, tert-butyl, iso-propyl, 3-propynyl or $-\text{C}(\text{CH}_3)_2\text{S}(\text{O})_2\text{CH}_3$ radicals;

R² represents a benzyl radical;

R³ represents propyl, isoamyl, isobutyl, butyl,
5 cyclohexyl, cycloheptyl, cyclopentylmethyl or
cyclohexylmethyl radicals; and

R⁴ is as defined above.

10 Compounds of interest include the following:

2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
[[(1,3-benzodioxol-5-yl) sulfonyl] (2-
methylpropyl) amino]-1S-(phenylmethyl) propyl]-3,3-
15 dimethyl-butanamide;

2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
[[(1,3-benzodioxol-5-yl) sulfonyl] (2-
methylpropyl) amino]-1S-(phenylmethyl) propyl]-3-methyl-
20 butanamide;

2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
[[(1,3-benzodioxol-5-yl) sulfonyl] (2-
methylpropyl) amino]-1S-(phenylmethyl) propyl]-3S-methyl-
25 pentanamide;

2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
[[(1,3-benzodioxol-5-yl) sulfonyl] (2-
methylpropyl) amino]-1S-(phenylmethyl) propyl]-4-
30 pentynamide;

2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
[[phenylsulfonyl] (2-methylpropyl) amino]-1S-
(phenylmethyl) propyl]-3,3-dimethyl-butanamide;

35

- 2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
[[phenylsulfonyl] (2-methylpropyl) amino]-1S-
(phenylmethyl) propyl]-3-methyl-butanamide;
- 5 2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
[[phenylsulfonyl] (2-methylpropyl) amino]-1S-
(phenylmethyl) propyl]-3S-methyl-pentanamide;
- 2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
10 [[phenylsulfonyl] (2-methylpropyl) amino]-1S-
(phenylmethyl) propyl]-4-pentynamide;
- 2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
[[(4-methoxyphenyl-sulfonyl) (2-methylpropyl) amino]-1S-
15 (phenylmethyl) propyl]-3,3-dimethyl-butanamide;
- 2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
[[(4-methoxyphenyl) sulfonyl] (2-methylpropyl) amino]-1S-
(phenylmethyl) propyl]-3-methyl-butanamide;
- 20 2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
[[(4-methoxyphenyl) sulfonyl] (2-methylpropyl) amino]-1S-
(phenylmethyl) propyl]-3S-methyl-pentanamide;
- 25 2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
[[(4-methoxyphenyl) sulfonyl] (2-methylpropyl) amino]-1S-
(phenylmethyl) propyl]-4-pentynamide;
- 2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
30 [[(2,3-dihydrobenzofuran-5-yl) sulfonyl] (2-methylpropyl)
amino]-1S-(phenylmethyl) propyl]-3,3-dimethyl-
butanamide;

- 2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
[[(2,3-dihydrobenzofuran-5-yl) sulfonyl] (2-methylpropyl)
amino]-1S-(phenylmethyl)propyl]-3-methyl-butanamide;
- 5 2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
[[(2,3-dihydrobenzofuran-5-yl) sulfonyl] (2-methylpropyl)
amino]-1S-phenylmethyl)propyl]-3S-methyl-pentanamide;
- 10 2S-[[(pyrrolidin-1-yl) acetyl] amino])N-[2R-hydroxy-3-
[[(2,3-dihydrobenzofuran-5-yl) sulfonyl] (2-methylpropyl)
amino]-1S-phenylmethyl)propyl]-4-pentynamide;
- 15 2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
[[(benzothiazol-6-yl) sulfonyl] (2-methylpropyl) amino]-
1S-(phenylmethyl)propyl]-3,3-dimethyl-butanamide;
- 20 2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
[[(benzothiazol-6-yl) sulfonyl] (2-methylpropyl) amino]-
1S-(phenylmethyl)propyl]-3-methyl-butanamide;
- 25 2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
[[(benzothiazol-6-yl) sulfonyl] (2-methylpropyl) amino]-
1S-(phenylmethyl)propyl]-4-pentynamide;
- 30 2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
[[(2-naphthyl) sulfonyl] (2-methylpropyl) amino]-1S-
(phenylmethyl)propyl]-3,3-dimethyl-butanamide;
- 35 2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
[[(2-naphthyl) sulfonyl] (2-methylpropyl) amino]-1S-
(phenylmethyl)propyl]-3-methyl-butanamide;

- 2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
[[(2-naphthyl) sulfonyl] (2-methylpropyl) amino]-1S-
(phenylmethyl) propyl]-3S-methyl-pentanamide;
- 5
- 2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
[[(2-naphthyl) sulfonyl] (2-methylpropyl) amino]-1S-
(phenylmethyl) propyl]-4-pentynamide;
- 10
- 2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
[[(1,4-benzodioxan-6-yl) sulfonyl] (2-
methylpropyl) amino]-1S-(phenylmethyl) propyl]-3,3-
dimethyl-butanamide;
- 15
- 2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
[[(1,4-benzodioxan-6-yl) sulfonyl] (2-
methylpropyl) amino]-1S-(phenylmethyl) propyl]-3-methyl-
butanamide;
- 20
- 2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
[[(1,4-benzodioxan-6-yl) sulfonyl] (2-
methylpropyl) amino]-1S-(phenylmethyl) propyl]-3S-methyl-
pentanamide; and
- 25
- 2S-[[(pyrrolidin-1-yl) acetyl] amino]-N-[2R-hydroxy-3-
[[(1,4-benzodioxan-6-yl) sulfonyl] (2-
methylpropyl) amino]-1S-(phenylmethyl) propyl]-4-
pentynamide.
- 30
- As utilized herein, the term "alkyl", alone or in
combination, means a straight-chain or branched-chain
alkyl radical containing preferably from 1 to 8 carbon
atoms, more preferably from 1 to 5 carbon atoms, most
preferably 1 to 3 carbon atoms. Examples of such
- 35
- radicals include methyl, ethyl, n-propyl, isopropyl, n-

butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-
amyl, hexyl, octyl and the like. The term "alkenyl",
alone or in combination, means a straight-chain or
branched-chain hydrocarbon radical having one or more
5 double bonds and containing preferably from 2 to 10
carbon atoms, more preferably from 2 to 8 carbon atoms,
most preferably from 2 to 5 carbon atoms. Examples of
suitable alkenyl radicals include ethenyl, propenyl, 2-
methylpropenyl, 1,4-butadienyl and the like. The term
10 "alkynyl", alone or in combination, means a straight-
chain or branched chain hydrocarbon radical having one
or more triple bonds and containing preferably from 2 to
10 carbon atoms, more preferably from 2 to 5 carbon
atoms. Examples of alkynyl radicals include ethynyl,
15 propynyl (propargyl), butynyl and the like. The term
"alkoxy", alone or in combination, means an alkyl ether
radical wherein the term alkyl is as defined above.
Examples of suitable alkyl ether radicals include
methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-
20 butoxy, sec-butoxy, tert-butoxy and the like. The term
"cycloalkyl", alone or in combination, means a saturated
or partially saturated monocyclic, bicyclic or tricyclic
alkyl radical wherein each cyclic moiety contains
preferably from 3 to 8 carbon atom ring members, more
25 preferably from 3 to 7 carbon atom ring members, most
preferably from 5 to 6 carbon atom ring members, and
which may optionally be a benzo fused ring system which
is optionally substituted as defined herein with respect
to the definition of aryl. Examples of such cycloalkyl
30 radicals include cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, cycloheptyl, octahydronaphthyl, 2,3-dihydro-
1H-indenyl, adamantyl and the like. "Bicyclic" and
"tricyclic" as used herein are intended to include both
fused ring systems, such as naphthyl and β -carbolinyl,
35 and substituted ring systems, such as biphenyl,

phenylpyridyl, naphthyl and diphenylpiperazinyl. The term "cycloalkylalkyl" means an alkyl radical as defined above which is substituted by a cycloalkyl radical as defined above. Examples of such cycloalkylalkyl radicals include cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, 1-cyclopentylethyl, 1-cyclohexylethyl, 2-cyclopentylethyl, 2-cyclohexylethyl, cyclobutylpropyl, cyclopentylpropyl, cyclohexylbutyl and the like. The term "benzo", alone or in combination, means the divalent radical $C_6H_4=$ derived from benzene. The term "aryl", alone or in combination, means a phenyl or naphthyl radical which is optionally substituted with one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, nitro, cyano, haloalkyl, carboxy, alkoxy-carbonyl, cycloalkyl, heterocyclo, alkanoylamino, amido, amidino, alkoxy-carbonylamino, N-alkylamidino, alkylamino, dialkylamino, N-alkylamido, N,N-dialkylamido, aralkoxy-carbonylamino, alkylthio, alkylsulfinyl, alkylsulfonyl and the like. Examples of aryl radicals are phenyl, p-tolyl, 4-methoxyphenyl, 4-(tert-butoxy)phenyl, 3-methyl-4-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 3-nitrophenyl, 3-aminophenyl, 3-acetamidophenyl, 4-acetamidophenyl, 2-methyl-3-acetamidophenyl, 4-CF₃-phenyl, 2-methyl-3-aminophenyl, 3-methyl-4-aminophenyl, 2-amino-3-methylphenyl, 2,4-dimethyl-3-aminophenyl, 4-hydroxyphenyl, 3-methyl-4-hydroxyphenyl, 1-naphthyl, 2-naphthyl, 3-amino-1-naphthyl, 2-methyl-3-amino-1-naphthyl, 6-amino-2-naphthyl, 4,6-dimethoxy-2-naphthyl, piperazinylphenyl and the like. The terms "aralkyl" and "aralkoxy", alone or in combination, means an alkyl or alkoxy radical as defined above in which at least one hydrogen atom is replaced by an aryl radical as defined above, such as benzyl, benzyloxy, 2-phenylethyl,

dibenzylmethyl, hydroxyphenylmethyl, methylphenylmethyl, diphenylmethyl, diphenylmethoxy, 4-methoxyphenylmethoxy and the like. The term "aralkoxycarbonyl", alone or in combination, means a radical of the formula aralkyl-O-C(O)- in which the term "aralkyl" has the significance given above. Examples of an aralkoxycarbonyl radical are benzyloxycarbonyl and 4-methoxyphenylmethoxycarbonyl. The term "aryloxy" means a radical of the formula aryl-O- in which the term aryl has the significance given above. The term "alkanoyl", alone or in combination, means an acyl radical derived from an alkanecarboxylic acid, examples of which include acetyl, propionyl, butyryl, valeryl, 4-methylvaleryl, and the like. The term "cycloalkylcarbonyl" means an acyl radical of the formula cycloalkyl-C(O)- in which the term "cycloalkyl" has the significance give above, such as cyclopropylcarbonyl, cyclohexylcarbonyl, adamantylcarbonyl, 1,2,3,4-tetrahydro-2-naphthoyl, 2-acetamido-1,2,3,4-tetrahydro-2-naphthoyl, 1-hydroxy-1,2,3,4-tetrahydro-6-naphthoyl and the like. The term "aralkanoyl" means an acyl radical derived from an aryl-substituted alkanecarboxylic acid such as phenylacetyl, 3-phenylpropionyl (hydrocinnamoyl), 4-phenylbutyryl, (2-naphthyl)acetyl, 4-chlorohydrocinnamoyl, 4-aminohydrocinnamoyl, 4-methoxyhydrocinnamoyl, and the like. The term "aroyl" means an acyl radical derived from an arylcarboxylic acid, "aryl" having the meaning given above. Examples of such aroyl radicals include substituted and unsubstituted benzoyl or naphthoyl such as benzoyl, 4-chlorobenzoyl, 4-carboxybenzoyl, 4-(benzyloxycarbonyl)benzoyl, 1-naphthoyl, 2-naphthoyl, 6-carboxy-2-naphthoyl, 6-(benzyloxycarbonyl)-2-naphthoyl, 3-benzyloxy-2-naphthoyl, 3-hydroxy-2-naphthoyl, 3-(benzyloxyformamido)-2-naphthoyl, and the like. The term "heterocyclo," alone or in combination, means a

saturated or partially unsaturated monocyclic, bicyclic or tricyclic heterocycle radical containing at least one, preferably 1 to 4, more preferably 1 to 2, nitrogen, oxygen or sulfur atom ring members and having
5 preferably 3 to 8 ring members in each ring, more preferably 3 to 7 ring members in each ring and most preferably 5 to 6 ring members in each ring.

"Heterocyclo" is intended to include sulfones, sulfoxides, N-oxides of tertiary nitrogen ring members,
10 and carbocyclic fused and benzo fused ring systems.

Such heterocyclo radicals may be optionally substituted on at least one, preferably 1 to 4, more preferably 1 to 2, carbon atoms by halogen, alkyl, alkoxy, hydroxy, oxo, aryl, aralkyl, heteroaryl, heteroaralkyl, amidino, N-
15 alkylamidino, alkoxycarbonylamino, alkylsulfonylamino and the like, and/or on a secondary nitrogen atom (i.e., -NH-) by hydroxy, alkyl, aralkoxycarbonyl, alkanoyl, heteroaralkyl, phenyl or phenylalkyl, and/or on a tertiary nitrogen atom (i.e., =N-) by oxido.

20 "Heterocycloalkyl" means an alkyl radical as defined above in which at least one hydrogen atom is replaced by a heterocyclo radical as defined above, such as pyrrolidinylmethyl, tetrahydrothienylmethyl, pyridylmethyl and the like. The term "heteroaryl", alone
25 or in combination, means an aromatic heterocyclo radical as defined above, which is optionally substituted as defined above with respect to the definitions of aryl and heterocyclo. Examples of such heterocyclo and heteroaryl groups are pyrrolidinyl, piperidinyl,
30 piperazinyl, morpholinyl, thiamorpholinyl, pyrrolyl, imidazolyl (e.g., imidazol 4-yl, 1-benzyloxycarbonylimidazol-4-yl, etc.), pyrazolyl, pyridyl, (e.g., 2-(1-piperidinyl)pyridyl and 2-(4-benzyl piperazin-1-yl-1-pyridinyl, etc.), pyrazinyl,
35 pyrimidinyl, furyl, tetrahydrofuryl, thienyl,

tetrahydrothienyl and its sulfoxide and sulfone derivatives, triazolyl, oxazolyl, thiazolyl, indolyl (e.g., 2-indolyl, etc.), quinolinyl, (e.g., 2-quinolinyl, 3-quinolinyl, 1-oxido-2-quinolinyl, etc.),
5 isoquinolinyl (e.g., 1-isoquinolinyl, 3-isoquinolinyl, etc.), tetrahydroquinolinyl (e.g., 1,2,3,4-tetrahydro-2-quinolyl, etc.), 1,2,3,4-tetrahydroisoquinolinyl (e.g., 1,2,3,4-tetrahydro-1-oxo-isoquinolinyl, etc.),
10 quinoxalinyl, β -carbolinyl, 2-benzofurancarbonyl, 1-, 2-, 4- or 5-benzimidazolyl, methylenedioxyphen-4-yl, methylenedioxyphen-5-yl, ethylenedioxyphenyl, benzothiazolyl, benzopyranyl, benzofuryl, 2,3-dihydrobenzofuryl, benzoxazolyl, thiophenyl and the like. The term "cycloalkylalkoxycarbonyl" means an acyl
15 group derived from a cycloalkylalkoxycarboxylic acid of the formula cycloalkylalkyl-O-COOH wherein cycloalkylalkyl has the meaning given above. The term "aryloxyalkanoyl" means an acyl radical of the formula aryl-O-alkanoyl wherein aryl and alkanoyl have the
20 meaning given above. The term "heterocycloalkoxycarbonyl" means an acyl group derived from heterocycloalkyl-O-COOH wherein heterocycloalkyl is as defined above. The term "heterocycloalkanoyl" is an acyl radical derived from a heterocycloalkylcarboxylic
25 acid wherein heterocyclo has the meaning given above. The term "heterocycloalkoxycarbonyl" means an acyl radical derived from a heterocycloalkyl-O-COOH wherein heterocyclo has the meaning given above. The term "heteroaryloxy carbonyl" means an acyl radical derived
30 from a carboxylic acid represented by heteroaryl-O-COOH wherein heteroaryl has the meaning given above. The term "aminocarbonyl" alone or in combination, means an amino-substituted carbonyl (carbamoyle) group wherein the amino group can be a primary, secondary or tertiary
35 amino group containing substituents selected from alkyl,


aryl, aralkyl, cycloalkyl, cycloalkylalkyl radicals and the like. The term "aminoalkanoyl" means an acyl group derived from an amino-substituted alkylcarboxylic acid wherein the amino group can be a primary, secondary or tertiary amino group containing substituents selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl radicals and the like. The term "halogen" means fluorine, chlorine, bromine or iodine. The term "haloalkyl" means an alkyl radical having the meaning as defined above wherein one or more hydrogens are replaced with a halogen. Examples of such haloalkyl radicals include chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 1,1,1-trifluoroethyl and the like. The term "leaving group" (L or W) generally refers to groups readily displaceable by a nucleophile (such as an amine, a thiol or an alcohol nucleophile). Such leaving groups are well known in the art. Examples of such leaving groups include, but are not limited to, N-hydroxysuccinimide, N-hydroxybenzotriazole, halides, triflates, tosylates and the like. Preferred leaving groups are indicated herein where appropriate.

Procedures for preparing the compounds of Formula I are set forth below. It should be noted that the general procedure is shown as it relates to preparation of compounds having the specified stereochemistry, for example, wherein the absolute stereochemistry about the hydroxyl group is designated as (R). However, such procedures are generally applicable to those compounds of opposite configuration, e.g., where the stereochemistry about the hydroxyl group is (S). In addition, the compounds having the (R) stereochemistry can be utilized to produce those having the (S) stereochemistry. For example, a compound having the


(R) stereochemistry can be inverted to the (S) stereochemistry using well-known methods.

Preparation of Compounds of Formula I

5 The compounds of the present invention represented by Formula I above can be prepared utilizing the following general procedures as schematically shown in Schemes I and II.


SCHEME I

a) deprotection; X = Cl or Br.


SCHEME II

a) deprotection; X = Cl or Br; L = leaving group.

25

SCHEME IIA

An N-protected chloroketone derivative of an amino acid having the formula:



5

wherein P represents an amino protecting group, and R² is as defined above, is reduced to the corresponding alcohol utilizing an appropriate reducing agent.


Suitable amino protecting groups are well known in the art and include carbobenzoxy, t-butoxycarbonyl, and the like. A preferred amino protecting group is carbobenzoxy. A preferred N-protected chloroketone is N-benzyloxycarbonyl-L-phenylalanine chloromethyl ketone. A preferred reducing agent is sodium borohydride. The reduction reaction is conducted at a temperature of from -10°C to about 25°C, preferably at about 0°C, in a suitable solvent system such as, for example, tetrahydrofuran, and the like. The N-protected chloroketones are commercially available, e.g., such as from Bachem, Inc., Torrance, California. Alternatively, the chloroketones can be prepared by the procedure set forth in S. J. Fittkau, *J. Prakt. Chem.*, 315, 1037 (1973), and subsequently N-protected utilizing procedures which are well known in the art.

25

The halo alcohol can be utilized directly, as described below, or, preferably, is reacted, preferably at room temperature, with a suitable base in a suitable solvent system to produce an N-protected amino epoxide of the formula:


30

27



wherein P and R² are as defined above. Suitable solvent systems for preparing the amino epoxide include ethanol, methanol, isopropanol, tetrahydrofuran, dioxane, and the like including mixtures thereof. Suitable bases for producing the epoxide from the reduced chloroketone include potassium hydroxide, sodium hydroxide, potassium t-butoxide, DBU and the like. A preferred base is potassium hydroxide.

Alternatively, a protected amino epoxide can be prepared, such as in co-owned and co-pending PCT Patent Application Serial No. PCT/US93/04804 (WO 93/23388) and PCT/US94/12201, and US Patent Application Attorney Docket No. C-2860, each of which is incorporated herein by reference in their entirety) disclose methods of preparing chiral epoxide, chiral cyanohydrin, chiral amine and other chiral intermediates useful in the preparation of retroviral protease inhibitors, starting with a DL-, D- or L-amino acid which is reacted with a suitable amino-protecting group in a suitable solvent to produce an amino-protected amino acid ester. For the purposes of illustration, a protected L-amino acid with the following formula will be used to prepare the inhibitors of this invention:



wherein P^3 represents carboxyl-protecting group, e.g., methyl, ethyl, benzyl, tertiary-butyl, 4-methoxyphenylmethyl and the like; R^2 is as defined above; and P^1 and P^2 independently are selected from
5 amine protecting groups, including but not limited to, aralkyl, substituted aralkyl, cycloalkenylalkyl and substituted cycloalkenylaloyl, allyl, substituted allyl, acyl, alkoxy carbonyl, aralkoxy carbonyl and silyl. Examples of aralkyl include, but are not limited to
10 benzyl, ortho-methylbenzyl, trityl and benzhydryl, which can be optionally substituted with halogen, alkyl of C_1 - C_8 , alkoxy, hydroxy, nitro, alkylene, amino, alkylamino, acylamino and acyl, or their salts, such as phosphonium and ammonium salts. Examples of aryl groups include
15 phenyl, naphthalenyl, indanyl, anthracenyl, durenyl, 9-(9-phenylfluorenyl) and phenanthrenyl, cycloalkenylalkyl or substituted cycloalkenylalkyl radicals containing cycloalkyls of C_6 - C_{10} . Suitable acyl groups include
20 carbobenzoxy, t-butoxycarbonyl, iso-butoxycarbonyl, benzoyl, substituted benzoyl, butyryl, acetyl, trifluoroacetyl, tri-chloroacetyl, phthaloyl and the like. Preferably P^1 and P^2 are independently selected from aralkyl and substituted aralkyl. More preferably, each of P^1 and P^2 is benzyl.

25


Additionally, the P^1 and/or P^2 protecting groups can form a heterocyclic ring with the nitrogen to which they are attached, for example, 1,2-bis(methylene)benzene, phthalimidyl, succinimidyl,
30 maleimidyl and the like and where these heterocyclic groups can further include adjoining aryl and cycloalkyl rings. In addition, the heterocyclic groups can be mono-, di- or tri-substituted, e.g., nitrophthalimidyl. The term silyl refers to a silicon atom optionally

substituted by one or more alkyl, aryl and aralkyl groups.

Suitable silyl protecting groups include, but are not limited to, trimethylsilyl, triethylsilyl, tri-isopropylsilyl, tert-butyldimethylsilyl, dimethylphenylsilyl, 1,2-bis(dimethylsilyl)benzene, 1,2-bis(dimethylsilyl)ethane and diphenylmethylsilyl. Silylation of the amine functions to provide mono- or bis-disilylamine can provide derivatives of the aminoalcohol, amino acid, amino acid esters and amino acid amide. In the case of amino acids, amino acid esters and amino acid amides, reduction of the carbonyl function provides the required mono- or bis-silyl aminoalcohol. Silylation of the aminoalcohol can lead to the N,N,O-tri-silyl derivative. Removal of the silyl function from the silyl ether function is readily accomplished by treatment with, for example, a metal hydroxide or ammonium fluoride reagent, either as a discrete reaction step or in situ during the preparation of the amino aldehyde reagent. Suitable silylating agents are, for example, trimethylsilyl chloride, tert-butyl-dimethylsilyl chloride, phenyldimethylsilyl chloride, diphenylmethylsilyl chloride or their combination products with imidazole or DMF. Methods for silylation of amines and removal of silyl protecting groups are well known to those skilled in the art. Methods of preparation of these amine derivatives from corresponding amino acids, amino acid amides or amino acid esters are also well known to those skilled in the art of organic chemistry including amino acid/amino acid ester or aminoalcohol chemistry.

The amino-protected L-amino acid ester is then reduced, to the corresponding alcohol. For example, the

amino-protected L-amino acid ester can be reduced with diisobutylaluminum hydride at -78°C in a suitable solvent such as toluene. Preferred reducing agents include lithium aluminium hydride, lithium borohydride, sodium borohydride, borane, lithium tri-ter-butoxyaluminum hydride, borane/THF complex. Most preferably, the reducing agent is diisobutylaluminum hydride (DiBAL-H) in toluene. The resulting alcohol is then converted, for example, by way of a Swern oxidation, to the corresponding aldehyde of the formula:



wherein P^1 , P^2 and R^2 are as defined above. Thus, a dichloromethane solution of the alcohol is added to a cooled (-75 to -68°C) solution of oxalyl chloride in dichloromethane and DMSO in dichloromethane and stirred for 35 minutes.

Acceptable oxidizing reagents include, for example, sulfur trioxide-pyridine complex and DMSO, oxalyl chloride and DMSO, acetyl chloride or anhydride and DMSO, trifluoroacetyl chloride or anhydride and DMSO, methanesulfonyl chloride and DMSO or tetrahydro thiaphene-S-oxide, toluenesulfonyl bromide and DMSO, trifluoromethanesulfonyl anhydride (triflic anhydride) and DMSO, phosphorus pentachloride and DMSO, dimethylphosphoryl chloride and DMSO and isobutyl chloroformate and DMSO. The oxidation conditions reported by Reetz et al (Angew Chem., 99, p. 1186, (1987), Angew Chem. Int. Ed. Engl., 26, p. 1141, 1987) employed oxalyl chloride and DMSO at -78°C .

The preferred oxidation method described in this invention is sulfur trioxide pyridine complex, triethylamine and DMSO at room temperature. This system provides excellent yields of the desired chiral protected amino aldehyde usable without the need for purification i.e., the need to purify kilograms of intermediates by chromatography is eliminated and large scale operations are made less hazardous. Reaction at room temperature also eliminated the need for the use of low temperature reactor which makes the process more suitable for commercial production.


The reaction may be carried out under an inert atmosphere such as nitrogen or argon, or normal or dry air, under atmospheric pressure or in a sealed reaction vessel under positive pressure. Preferred is a nitrogen atmosphere. Alternative amine bases include, for example, tri-butyl amine, tri-isopropyl amine, N-methylpiperidine, N-methyl morpholine, azabicyclononane, diisopropylethylamine, 2,2,6,6-tetramethylpiperidine, N,N-dimethylaminopyridine, or mixtures of these bases. Triethylamine is a preferred base. Alternatives to pure DMSO as solvent include mixtures of DMSO with non-protic or halogenated solvents such as tetrahydrofuran, ethyl acetate, toluene, xylene, dichloromethane, ethylene dichloride and the like. Dipolar aprotic co-solvents include acetonitrile, dimethylformamide, dimethylacetamide, acetamide, tetramethyl urea and its cyclic analog, N-methylpyrrolidone, sulfolane and the like. Rather than N,N-dibenzylphenylalaninol as the aldehyde precursor, the phenylalaninol derivatives discussed above can be used to provide the corresponding N-monosubstituted (either P^1 or $P^2 = H$) or N,N-disubstituted aldehyde.

In addition, hydride reduction of an amide or ester derivative of the corresponding benzyl (or other suitable protecting group) nitrogen protected phenylalanine, substituted phenylalanine or cycloalkyl analog of phenylalanine derivative can be carried out to provide the aldehydes. Hydride transfer is an additional method of aldehyde synthesis under conditions where aldehyde condensations are avoided, cf, Oppenauer Oxidation.

The aldehydes of this process can also be prepared by methods of reducing protected phenylalanine and phenylalanine analogs or their amide or ester derivatives by, e.g., sodium amalgam with HCl in ethanol or lithium or sodium or potassium or calcium in ammonia. The reaction temperature may be from about -20°C to about 45°C, and preferably from about 5°C to about 25°C. Two additional methods of obtaining the nitrogen protected aldehyde include oxidation of the corresponding alcohol with bleach in the presence of a catalytic amount of 2,2,6,6-tetramethyl-1-pyridyloxy free radical. In a second method, oxidation of the alcohol to the aldehyde is accomplished by a catalytic amount of tetrapropylammonium perruthenate in the presence of N-methylmorpholine-N-oxide.

Alternatively, an acid chloride derivative of a protected phenylalanine or phenylalanine derivative as disclosed above can be reduced with hydrogen and a catalyst such as Pd on barium carbonate or barium sulphate, with or without an additional catalyst moderating agent such as sulfur or a thiol (Rosenmund Reduction).

The aldehyde resulting from the Swern oxidation is then reacted with a halomethyl lithium reagent, which reagent is generated in situ by reacting an alkyl lithium or aryllithium compound with a dihalomethane represented
 5 by the formula $X^1CH_2X^2$ wherein X^1 and X^2 independently represent I, Br or Cl. For example, a solution of the aldehyde and chloriodomethane in THF is cooled to -78°C and a solution of n-butyllithium in hexane is added. The resulting product is a mixture of diastereomers of
 10 the corresponding amino-protected epoxides of the formulas:



15 The diastereomers can be separated e.g., by chromatography, or, alternatively, once reacted in subsequent steps the diastereomeric products can be separated. A D-amino acid can be utilized in place of the L-amino acid in order to prepare compounds having an
 20 (S) stereochemistry at the carbon bonded to R^2 .

The addition of chloromethyl lithium or bromomethyl lithium to a chiral amino aldehyde is highly diastereoselective. Preferably, the chloromethyl lithium
 25 or bromomethyl lithium is generated in-situ from the reaction of the dihalomethane and n-butyllithium. Acceptable methyleneating halomethanes include chloriodomethane, bromochloromethane, dibromomethane, diiodomethane, bromofluoromethane and the like. The
 30 sulfonate ester of the addition product of, for example, hydrogen bromide to formaldehyde is also a methyleneating agent. Tetrahydrofuran is the preferred

solvent, however alternative solvents such as toluene, dimethoxyethane, ethylene dichloride, methylene chloride can be used as pure solvents or as a mixture. Dipolar aprotic solvents such as acetonitrile, DMF, N-

5 methylpyrrolidone are useful as solvents or as part of a solvent mixture. The reaction can be carried out under an inert atmosphere such as nitrogen or argon. For n-butyl lithium can be substituted other organometallic reagents reagents such as methyl lithium, tert-butyl

10 lithium, sec-butyl lithium, phenyllithium, phenyl sodium and the like. The reaction can be carried out at temperatures of between about -80°C to 0°C but preferably between about -80°C to -20°C. The most preferred reaction temperatures are between -40°C to -

15 15°C. Reagents can be added singly but multiple additions are preferred in certain conditions. The preferred pressure of the reaction is atmospheric however a positive pressure is valuable under certain conditions such as a high humidity environment.

20

Alternative methods of conversion to the epoxides of this invention include substitution of other charged methylenation precursor species followed by their treatment with base to form the analogous anion.

25 Examples of these species include trimethylsulfoxonium tosylate or triflate, tetramethylammonium halide, methyldiphenylsulfoxonium halide wherein halide is chloride, bromide or iodide.

30 The conversion of the aldehydes of this invention into their epoxide derivative can also be carried out in multiple steps. For example, the addition of the anion of thioanisole prepared from, for example, a butyl or aryl lithium reagent, to the protected aminoaldehyde,


35 oxidation of the resulting protected aminosulfide.

alcohol with well known oxidizing agents such as hydrogen peroxide, tert-butyl hypochlorite, bleach or sodium periodate to give a sulfoxide. Alkylation of the sulfoxide with, for example, methyl iodide or bromide, methyl tosylate, methyl mesylate, methyl triflate, ethyl bromide, isopropyl bromide, benzyl chloride or the like, in the presence of an organic or inorganic base Alternatively, the protected aminosulfide alcohol can be alkylated with, for example, the alkylating agents above, to provide a sulfonium salts that are subsequently converted into the subject epoxides with tert-amine or mineral bases.

The desired epoxides formed, using most preferred conditions, diastereoselectively in ratio amounts of at least about an 85:15 ratio (S:R). The product can be purified by chromatography to give the diastereomerically and enantiomerically pure product but it is more conveniently used directly without purification to prepare retroviral protease inhibitors. The foregoing process is applicable to mixtures of optical isomers as well as resolved compounds. If a particular optical isomer is desired, it can be selected by the choice of starting material, e.g., L-phenylalanine, D-phenylalanine, L-phenylalaninol, D-phenylalaninol, D-hexahydrophenylalaninol and the like, or resolution can occur at intermediate or final steps. Chiral auxiliaries such as one or two equivalents of camphor sulfonic acid, citric acid, camphoric acid, 2-methoxyphenylacetic acid and the like can be used to form salts, esters or amides of the compounds of this invention. These compounds or derivatives can be crystallized or separated chromatographically using either a chiral or achiral column as is well known to those skilled in the art.

The amino epoxide is then reacted, in a suitable solvent system, with an equal amount, or preferably an excess of, a desired amine of the formula R^3NH_2 , wherein R^3 is hydrogen or is as defined above. The reaction can be conducted over a wide range of temperatures, e.g., from about $10^\circ C$ to about $100^\circ C$, but is preferably, but not necessarily, conducted at a temperature at which the solvent begins to reflux. Suitable solvent systems include protic, non-protic and dipolar aprotic organic solvents such as, for example, those wherein the solvent is an alcohol, such as methanol, ethanol, isopropanol, and the like, ethers such as tetrahydrofuran, dioxane and the like, and toluene, *N,N*-dimethylformamide, dimethyl sulfoxide, and mixtures thereof. A preferred solvent is isopropanol. The resulting product is a 3-(*N*-protected amino)-3-(R^2)-1-(NHR^3)-propan-2-ol derivative (hereinafter referred to as an amino alcohol) can be represented by the formulas:

20




wherein P , P^1 , P^2 , R^2 and R^3 are as described above. Alternatively, a haloalcohol can be utilized in place of the amino epoxide.

25

The amino alcohol defined above is then reacted in a suitable solvent with an activated sulfonyl function such as the sulfonyl chloride R^4SO_2Cl , the sulfonyl bromide R^4SO_2Br , the sulfonate ester or the corresponding sulfonyl anhydride, preferably in the presence of an acid scavenger. Suitable solvents in which the reaction can be

30

conducted include methylene chloride, dichloromethane, ethyl acetate, tetrahydrofuran and the like. Suitable acid scavengers include triethylamine, pyridine as well as hindered amine bases such as diazabicyclooctane, diazabicycloundecene, 2,6 disubstituted pyridine derivatives, di-isopropylamine and the like. Inorganic bases such as sodium carbonate, potassium bicarbonate, calcium carbonate and the like may also be used if desired. The process of preparing the sulfonamide can be carried out as a discrete step following isolation of, for example, a sulfonyl chloride reagent or as part of a single pot process during the preparation of the activated sulfonyl function. Isolation of the sulfonyl chloride is preferred. The resulting sulfonamide derivative can be represented, depending on the epoxide utilized by the formulas



wherein P, P¹, P², R², R³ and R⁴ are as defined above. These intermediates are useful for preparing inhibitor compounds of the present invention.

The sulfonyl halides of the formula R⁴SO₂X can be prepared by the reaction of a suitable aryl, heteroaryl and benzo fused heterocyclo Grignard or lithium reagents with sulfuryl chloride, or sulfur dioxide followed by oxidation with a halogen, preferably chlorine. Aryl, heteroaryl and benzo fused heterocyclo Grignard or lithium reagents can be prepared from their corresponding halide (such as chloro or bromo) compounds which are commercially available or readily

prepared from commercially available starting materials using known methods in the art. Also, thiols may be oxidized to sulfonyl chlorides using chlorine in the presence of water under carefully controlled

5 conditions. Additionally, sulfonic acids, such as arylsulfonic acids, heteroaryl and benzo fused heterocyclosulfonic acids, may be converted into sulfonyl halides using reagents such as PCl_5 , SOCl_2 , ClC(O)C(O)Cl and the like, and also to anhydrides using

10 suitable dehydrating reagents. The sulfonic acids may in turn be prepared using procedures well known in the art. Some sulfonic acids are commercially available. In place of the sulfonyl halides, sulfinyl halides (R^4SOX) or sulfenyl halides (R^4SX) can be utilized to

15 prepare compounds wherein the $-\text{SO}_2-$ moiety is replaced by an $-\text{SO}-$ or $-\text{S}-$ moiety, respectively. Arylsulfonic acids, benzo fused heterocyclo sulfonic acids or heteroaryl sulfonic acids can be prepared by

20 sulfonation of the aromatic ring by well known methods in the art, such as by reaction with sulfuric acid, SO_3 , SO_3 complexes, such as $\text{DMF}(\text{SO}_3)$ (also depicted as SO_3DMF , $\text{SO}_3\cdot\text{DMF}$, DMFSO_3 and the like), pyridine(SO_3), N,N -dimethylacetamide(SO_3), and the like. Preferably, arylsulfonyl halides are prepared from aromatic

25 compounds by reaction with $\text{DMF}(\text{SO}_3)$ and SOCl_2 or ClC(O)C(O)Cl . Most preferably, benzo fused heterocyclo sulfonyl halides are prepared from aromatic compounds by reaction with $\text{DMF}(\text{SO}_3)$ and ClC(O)C(O)Cl . The reactions may be performed step wise or in a single

30 pot. A single pot reaction is understood to mean a single reaction system, reaction vessel, kettle, bomb, flask, and the like.

The use of the two pot process may be desirable

35 when sulfonic acids are available commercially. Should

the desired sulfonic, sulfinic or sulfenic acid or activated acid be commercially available, amidation of the amine intermediate discussed above and used to prepare, for example, the sulfonamide, may be carried
5 out in either a one pot or two pot reaction or reaction series as indicated.

The reactions used in the method of converting a aromatic compound, including heteroaryl compounds and
10 benzo fused heterocycles, into sulfonic acids, activated sulfonic acids or sulfonamides is generally carried out under an inert atmosphere such as nitrogen, argon, or helium. The use of dry air is possible in some cases where it does not decrease the yield(s) or
15 present a safety hazard. The solvent or solvent mixtures are water immiscible, for example, dichloroethane (ethylene dichloride), methylene chloride, trichloroethane, toluene, tetrachloroethane and the like. A co-solvent may be used that is water
20 miscible if desired. The temperatures of the various stages of the process or processes can vary depending upon reagents and other conditions. In general, the process exemplified, for example, by the preparation of 1,3-benzodioxolesulfonyl chloride is started by mixing
25 reagents at room temperature although a range of about 0°C to about 45°C when SO₃ is used or to about 75°C when SO₃•DMF is used with dichloromethane. The SO₃•DMF reagent, with its higher melting point, is an especially desirable reagent allowing a range of
30 reaction temperatures that can be controlled by rationing the amount of heat provided to the reaction vessel or the reflux temperature of the solvent(s). When analysis indicates that the conversion is as complete as desired, or at a later time if desired, the
35 reaction can be worked up by methods know in the art,

e.g., cooling, addition of water and/or an acid such as hydrochloric acid or sulfuric acid, to provide the sulfonic acid.


5 It may be chemically and economically desirable and/or efficient with respect to, for example, the use of chemist and equipment time, to prepare an intermediate such as the sulfonyl chloride by cooling the reaction mixture to a temperature of between about
10 -25°C to about 65°C. The preferred range is between about 0°C and room temperature. The amount of cooling that is necessary will depend on the type of oxalyl halide that is added in the next step. When the reaction mixture is cooled, an oxalyl halide such as
15 oxalyl chloride or oxalyl bromide can be added to the reaction vessel at such a rate as to control the reaction temperature. The temperature can range from about 0°C to about 50°C but preferably between about 0°C and room temperature. Most preferred is a range of
20 between about 10°C and about 40°C. The reaction can be sampled for analysis. When analysis indicates that the conversion has been carried out, the excess reagents, if present, can be decomposed by the controlled addition of water. Care, such as that which would be
25 expected of a trained person, is indicated in this operation. Isolation of the sulfonyl chloride proceeds by separation of the phases, washing, if desired, the aqueous phase with a water non-miscible solvent such as dichloroethane one to four times and drying the organic
30 phases separately, in batches or as a single, combined solution. The drying agent can be a chemical such as magnesium sulfate or sodium sulfate or the water can be removed via an azeotrope. The solution remaining, which may or may not be mixed with various amounts of
35 drying agent, may be filtered if desired. The solvent

can be removed by distillation at atmospheric pressure or below or evaporation under reduced pressure using, for example, a rotary evaporator. It is also possible in some cases to crystallize the product at room
5 temperature or below directly from the solvent or from a mixture of solvents such as, for example, ethylene dichloride and hexane, heptane, pentane, decane, cyclohexane, methylcyclohexane, decalin, toluene, xylene (mixed xylenes or pure xylenes) or the like. If
10 a solid is obtained, it may be washed further if desired with, for example, hexane, and the dissolved product recovered otherwise it can be used directly in the next step. A crystallizing or washing process may provide product that is superior on an economic or
15 scientific basis when used for the preparation of a intermediate substrate for catalytic processes such as reductive deprotection via removal of benzyl groups from an amine nitrogen. The isolated activated sulfonic acid product may be added directly as a solid
20 or dissolved in a solvent prior to addition as a reagent to the next reaction. Isolation of, for example, a benzo fused heterocyclo sulfonyl chloride such as 1,3-benzodioxole-5-sulfonyl chloride, prior to its reaction with an amine is preferred and the yield
25 is high and may exceed 95%.

The conversion of the activated oxidized sulfur acid product into the sulfonamide, sulfinamide or sulfeneamide can be carried out in the same pot as its
30 preparation if desired. Addition of the amine following reaction, decomposition or removal of the oxalyl chloride reagent with or without the addition of a hydrogen ion (H^+) scavenger discussed above produces the amide product. The same product is obtained when the
35 reaction is partially worked up by the addition of water

as presented above. Again, the activated sulfur acid such as the sulfonyl chloride discussed above is used to form the sulfonamide with or without the addition of a proton scavenging agent. These conditions, for example, the Hinsberg Test, are known in the art. If desired, an excess of an amine intermediate of this invention can be used rather than one or more of the usual proton scavenging agents. The amine salt formed in this process can be isolated and reused according to the methods below. Should the product of, for example, the sulfonamide forming reaction be itself a basic amine, it may be isolated as a salt or as an amine.


Arylsulfonic acids, benzo fused heterocyclic sulfonic acids, heteroaryl sulfonic acids, arylmercaptans, benzo fused heterocyclic mercaptans, heteroarylmercaptans, arylhalides, benzo fused heterocyclic halides, heteroarylhalides, and the like are commercially available or can be readily prepared from starting materials commercially available using standard methods well known in the art. For example, a number of sulfonic acids (R^4SO_3H) represented by the formulas



wherein A, B, Z, R^6 , R^7 and R^9 are as defined above, have been prepared from 1,2-benzenedithiol, 2-mercaptanphenol, 1,2-benzenediol, 2-aminobenzothiazole, benzothiazole, 2-aminobenzimidazole, benzimidazole, and the like, which are commercially available, by Carter, US Patent 4,595,407; Ehrenfreund et al., US Patent 4,634,465; Yoder et al., J. Heterocycl. Chem. 4:166-167 (1967); Cole et al., Aust. J. Chem. 33:675-680 (1980);

30


Cabiddu et al., Synthesis 797-798 (1976); Ncube et al., Tet. Letters 2345-2348 (1978); Ncube et al., Tet. Letters 255-256 (1977); Ansink & Cerfontain, Rec. Trav. Chim.Pays-Bas 108:395-403 (1989); and Kajihara & Tsuchiya, EP 638564 A1, each of which are incorporated herein by reference in their entirety. For example, 1,2-benzenedithiol, 2-mercaptanphenol or 1,2-benzenediol can be reacted with $R^6R^7C(L')_2$, where L' is as defined below, preferably, Br or I, in the presence of a base, such as hydroxide, or $R^6R^7C=Q$ in the presence of acid, such as toluenesulfonic acid, or P_2O_5 , to prepare the substituted benzo fused heterocycle of formula



15

which can then be sulfonylated to the sulfonic acid above. For example, CF_2Br_2 or CD_2Br_2 can be reacted with 1,2-benzenedithiol, 2-mercaptanphenol or 1,2-benzenediol in the presence of base to produce the compounds

20



respectively, wherein A and B are O or S and D is a deuterium atom. Also, when A and/or B represent S, the sulfur can be oxidized using the methods described below to the sulfone or sulfoxide derivatives.


25

Following preparation of the sulfonamide derivative, the amino protecting group P or P^1 and P^2 amino protecting groups are removed under conditions which will not affect the remaining portion of the molecule. These methods are well known in the art and


30

include acid hydrolysis, hydrogenolysis and the like. A preferred method involves removal of the protecting group, e.g., removal of a carbobenzoxy group, by hydrogenolysis utilizing palladium on carbon in a suitable solvent system such as an alcohol, acetic acid, and the like or mixtures thereof. Where the protecting group is a t-butoxycarbonyl group, it can be removed utilizing an inorganic or organic acid, e.g., HCl or trifluoroacetic acid, in a suitable solvent system, e.g., dioxane or methylene chloride. The resulting product is the amine salt derivative.


Following neutralization of the salt, the amine is then coupled to the DL-, D-, or L-amino acid corresponding to the formula $\text{PNHCH}(\text{R}^1)\text{COOH}$, wherein P and R^1 are as defined above, followed by deprotection of the amine as described above, and coupling to



wherein R^{10} and R^{11} are as defined above, W is a leaving group, such as mesylate, bromo or chloro, and L is leaving group such as halide, anhydride, active ester, and the like. For example when R^{10} and R^{11} are both hydrogen radical, bromoacetyl halide, chloroacetyl halide or the corresponding anhydride can be used. Finally, reacting the above intermediate with the cyclic-amine of formula




can produce the antiviral compounds of the present invention having the formula



5

wherein n , R^1 , R^2 , R^3 , R^4 , R^{10} , R^{11} , R^{12} , R^{13} and R^{14} are as defined above. Amines of formula




10

are commercially available, such as pyrrolidine, 2-pyrrolidinemethanol, 3-pyrrolidinol, 2-(methoxymethyl)pyrrolidine, kainic acid, piperidine, 3-hydroxypiperidine, 4-hydroxypiperidine, 2-piperidinemethanol, 2,3-dihydroindole, isoindoline, 1,2,3,4-tetrahydroisoquinoline, 1,2,3,4-tetrahydroquinoline, and the like; or can readily be prepared from commercially available starting materials using standard methods well known in the art, such as 4-hydroxyproline, 3-hydroxypiperidine, 4-hydroxypiperidine, 3-pyrroline, isonipecotic acid, 5-hydroxyindole, 5-hydroxyindole-3-acetic acid, 5,6-dimethoxyindole, isoquinoline, quinoline, 5-hydroxyisoquinoline, 8-hydroxy-5-nitroquinoline, 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline, and the like.

25


Alternatively, following neutralization of the salt, the amine is then coupled to the DL-, D-, or L-amino acid corresponding to the formula $\text{PNHCH}(\text{R}^1)\text{COOH}$, wherein P and R^1 are as defined above, followed by
 5 deprotection of the amine as described above and coupling the deprotected amine to the cyclic-amino acid of formula




10 wherein n , R^{10} , R^{11} , R^{12} , R^{13} and R^{14} are as defined above, such as pyrrolidin-1-ylacetic acid, piperidin-1-ylacetic acid and the like, to produce the antiviral compounds of the present invention. The cyclic-amino acids are commercially available or are readily prepared
 15 from a protected carboxylic acid with a leaving group W (defined above) by reaction with the cyclic-amine as shown in Scheme III or alternatively, by reacting the cyclic-amine with the appropriate substituted ketone in the presence of cyanide anion followed by hydrolysis of
 20 the cyano group to the corresponding carboxylic acid as shown in Scheme IV, wherein n , P^3 , R^{10} , R^{11} , R^{12} , R^{13} and R^{14} are as defined above..

Scheme III


25



Scheme IV

5

Alternatively, following neutralization of the salt, the amine is then coupled to the DL-, D-, or L-amino acid corresponding to the formula



10

wherein n , R^1 , R^{10} , R^{11} , R^{12} , R^{13} and R^{14} are as defined above, which can be prepared in a similar fashion to the coupling methods described above from DL-, D-, or L-amino acid corresponding to the formula $\text{NH}_2\text{CH}(R^1)\text{COOP}^3$,
 15 wherein P^3 and R^1 are as defined above.


The DL-, D-, or L-amino acid corresponding to the formula $\text{PNHCH}(R^1)\text{COOH}$ or $\text{NH}_2\text{CH}(R^1)\text{COOP}^3$, wherein P, P^3
 20 and R^1 are as defined above, are commercially available (Sigma Chemical Co.), or readily prepared using standard

methods well known in the art from readily available starting materials. Preferably, P is a benzyloxycarbonyl or t-butoxycarbonyl radical and P³ is benzyl or tert-butyl radicals. Standard coupling procedures can be used to couple the amino acids and amines. The carboxylic acid group is reacted to form an anhydride, mixed anhydride, acid halide, such as chloride or bromide, or active ester, such as esters of N-hydroxysuccinimide, HOBT and the like, using well known procedures and conditions. Appropriate solvent systems include tetrahydrofuran, ethylether, methyl-tert-butylether, methylene chloride, N,N-dimethylformamide and the like, including mixtures thereof.

15


Alternatively, the protected amino alcohol from the epoxide opening can be further protected at the newly introduced amino group with a protecting group P' which is not removed with the removal of the amino protecting groups P or P¹ and P². One skilled in the art can choose appropriate combinations of P', P, P¹ and P². For example, suitable combinations are P = Cbz and P' = Boc; P' = Cbz and P = Boc; P¹ = Cbz, P² = benzyl and P' = Boc; and P¹ = P² = benzyl and P' = Boc. The resulting compound represented by the formula

25



can be carried through the remainder of the synthesis to provide a compound of the formula

30



wherein n , P' , R^1 , R^2 , R^3 , R^{10} , R^{11} , R^{12} , R^{13} and R^{14} are
 5 as defined above. The protecting group P' is then
 selectively removed and the resulting amine is reacted
 with the sulfonyl chloride R^4SO_2Cl , the sulfonyl bromide
 R^4SO_2Br or the corresponding sulfonyl anhydride,
 preferably in the presence of an acid scavenger, to form
 the compounds of the present invention. This selective
 10 deprotection and conversion to the sulfonamide can be
 accomplished at either the end of the synthesis or at
 any appropriate intermediate step if desired.

The chemical reactions described above are
 15 generally disclosed in terms of their broadest
 application to the preparation of the compounds of this
 invention. Occasionally, the reactions may not be
 applicable as described to each compound included
 within the disclosed scope. The compounds for which
 20 this occurs will be readily recognized by those skilled
 in the art. In all such cases, either the reactions
 can be successfully performed by conventional
 modifications known to those skilled in the art, e.g.,
 by appropriate protection of interfering groups, by
 25 changing to alternative conventional reagents, by
 routine modification of reaction conditions, and the
 like, or other reactions disclosed herein or otherwise
 conventional, will be applicable to the preparation of
 the corresponding compounds of this invention. In all
 30 preparative methods, all starting materials are known
 or readily prepared from known starting materials.


Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its
5 fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

10 All reagents were used as received without purification. All proton and carbon NMR spectra were obtained on either a Varian VXR-300 or VXR-400 nuclear magnetic resonance spectrometer.

15 The following Examples illustrate the preparation of inhibitor compounds of the present invention and intermediates useful in preparing the inhibitor compounds of the present invention.

20

EXAMPLE 1



Preparation of

25 2S-[Bis(phenylmethyl)amino]benzenepropanol

METHOD 1: 2S-[Bis(phenylmethyl)amino]benzenepropanol from the DIBAL Reduction of N,N-bis(phenylmethyl)-L-Phenylalanine phenylmethyl ester

30

Step 1:

A solution of L-phenylalanine (50.0 g, 0.302 mol), sodium hydroxide (24.2 g, 0.605 mol) and potassium carbonate (83.6 g, 0.605 mol) in water (500 mL) was heated to 97°C. Benzyl bromide (108.5 mL, 0.605 mol) was then slowly added (addition time -25 min). The mixture was stirred at 97°C for 30 minutes under a nitrogen atmosphere. The solution was cooled to room temperature and extracted with toluene (2 x 250 mL). The combined organic layers were washed with water and brine, dried over magnesium sulfate, filtered and concentrated to an oil. The identity of the product was confirmed as follows. Analytical TLC (10% ethyl acetate/hexane, silica gel) showed major component at R_f value = 0.32 to be the desired tribenzylated compound, N,N-bis(phenylmethyl)-L-phenylalanine phenylmethyl ester. This compound can be purified by column chromatography (silica gel, 15% ethyl acetate/hexane). Usually the product is pure enough to be used directly in the next step without further purification. ¹H NMR spectrum was in agreement with published literature. ¹H NMR (CDCl₃) δ, 3.00 and 3.14 (ABX-system, 2H, J_{AB}=14.1 Hz, J_{AX}=7.3 Hz and J_{BX}= 5.9 Hz), 3.54 and 3.92 (AB-System, 4 H, J_{AB}=13.9 Hz), 3.71 (t, 1H, J=7.6 Hz), 5.11 and 5.23 (AB-System, 2H, J_{AB}=12.3 Hz), and 7.18 (m, 20 H). EIMS: m/z 434 (M-1).

Step 2:


The benzylated phenylalanine phenylmethyl ester (0.302 mol) from the previous reaction was dissolved in toluene (750 mL) and cooled to -55°C. A 1.5 M solution of DIBAL in toluene (443.9 mL, 0.666 mol) was added at a rate to maintain the temperature between -55 to -50°C (addition time -1 hr). The mixture was stirred for 20 minutes under a nitrogen atmosphere and then quenched

at -55°C by the slow addition of methanol (37 ml). The cold solution was then poured into cold (5°C) 1.5 N HCl solution (1.8 L). The precipitated solid (approx. 138 g) was filtered off and washed with toluene. The solid material was suspended in a mixture of toluene (400 mL) and water (100 ml). The mixture was cooled to 5°C and treated with 2.5 N NaOH (186 mL) and then stirred at room temperature until solid dissolved. The toluene layer was separated from the aqueous phase and washed with water and brine, dried over magnesium sulfate, filtered and concentrated to a volume of 75 mL (89 g). Ethyl acetate (25 mL) and hexane (25 mL) were added to the residue upon which the desired alcohol product began to crystallize. After 30 min, an additional 50 mL hexane were added to promote further crystallization. The solid was filtered off and washed with 50 mL hexane to give 34.9 g of first crop product. A second crop of product (5.6 g) was isolated by refiltering the mother liquor. The two crops were combined and recrystallized from ethyl acetate (20 mL) and hexane (30 mL) to give 40 g of BS-2-[Bis(phenylmethyl)amino]benzenepropanol, 40% yield from L-phenylalanine. An additional 7 g (7%) of product can be obtained from recrystallization of the concentrated mother liquor. TLC of product $R_f = 0.23$ (10% ethyl acetate/hexane, silica gel); $^1\text{H NMR}$ (CDCl_3) δ 2.44 (m, 1H), 3.09 (m, 2H), 3.33 (m, 1H), 3.48 and 3.92 (AB-System, 4H, $J_{AB} = 13.3$ Hz), 3.52 (m, 1H) and 7.23 (m, 15H); $[\alpha]_{\text{D}}^{25} +42.4$ (c 1.45, CH_2Cl_2); DSC 77.67°C; Anal. Calcd. for $\text{C}_{23}\text{H}_{25}\text{ON}$: C, 83.34; H, 7.60; N, 4.23. Found: C, 83.43; H, 7.59; N, 4.22. HPLC on chiral stationary phase: Cyclobond I SP column (250 x 4.6 mm I.D.), mobile phase: methanol/triethyl ammonium acetate buffer pH 4.2 (58:42, v/v), flow-rate of 0.5 ml/min, detection with detector at 230nm and a temperature of 0°C.

Retention time: 11.25 min., retention time of the desired product enantiomer: 12.5 min.

METHOD 2: Preparation of β S-2-[Bis(phenylmethyl)amino] benzene-propanol from the N,N-Dibenylation of L-Phenylalaninol

L-phenylalaninol (176.6 g, 1.168 mol) was added to a stirred solution of potassium carbonate (484.6 g, 3.506 mol) in 710 mL of water. The mixture was heated to 65°C under a nitrogen atmosphere. A solution of benzyl bromide (400 g, 2.339 mol) in 3A ethanol (305 mL) was added at a rate that maintained the temperature between 60-68°C. The biphasic solution was stirred at 65°C for 55 min and then allowed to cool to 10°C with vigorous stirring. The oily product solidified into small granules. The product was diluted with 2.0 L of tap water and stirred for 5 minutes to dissolve the inorganic by products. The product was isolated by filtration under reduced pressure and washed with water until the pH is 7. The crude product obtained was air dried overnight to give a semi-dry solid (407 g) which was recrystallized from 1.1 L of ethyl acetate/heptane (1:10 by volume). The product was isolated by filtration (at -8°C), washed with 1.6 L of cold (-10°C) ethyl acetate/heptane (1:10 by volume) and air-dried to give 339 g (88% yield) of β S-2-[Bis(phenylmethyl)amino]benzene-propanol, Mp = 71.5-73.0°C. More product can be obtained from the mother liquor if necessary. The other analytical characterization was identical to compound prepared as described in Method 1.

EXAMPLE 2

5 Preparation of 2S-[Bis(phenylmethyl)amino]
benzenepropanaldehyde

METHOD 1: 2S-[Bis(phenylmethyl)amino]benzene-propanol
(200 g, 0.604 mol) was dissolved in triethylamine (300
10 mL, 2.15 mol). The mixture was cooled to 12°C and a
solution of sulfur trioxide/pyridine complex (380 g,
2.39 mol) in DMSO (1.6 L) was added at a rate to
maintain the temperature between 8-17°C (addition time
-1.0 h). The solution was stirred at ambient
15 temperature under a nitrogen atmosphere for 1.5 hour at
which time the reaction was complete by TLC analysis
(33% ethyl acetate/hexane, silica gel). The reaction
mixture was cooled with ice water and quenched with 1.6
L of cold water (10-15°C) over 45 minutes. The
20 resultant solution was extracted with ethyl acetate
(2.0 L), washed with 5% citric acid (2.0 L), and brine
(2.2 L), dried over MgSO₄ (280 g) and filtered. The
solvent was removed on a rotary evaporator at 35-40°C
and then dried under vacuum to give 198.8 g of 2S-[Bis-
25 (phenylmethyl)amino]-benzenepropanaldehyde as a pale
yellow oil (99.9%). The crude product obtained was
pure enough to be used directly in the next step
without purification. The analytical data of the
compound were consistent with the published
30 literature. $[\alpha]_{D25} = -92.9^{\circ}\text{C}$ (c 1.87, CH₂Cl₂); ¹H NMR

(400 MHz, CDCl_3) δ , 2.94 and 3.15 (ABX-System, 2H, $J_{AB} = 13.9$ Hz, $J_{AX} = 7.3$ Hz and $J_{BX} = 6.2$ Hz), 3.56 (t, 1H, 7.1 Hz), 3.69 and 3.82 (AB-System, 4H, $J_{AB} = 13.7$ Hz), 7.25 (m, 15 H) and 9.72 (s, 1H); HRMS Calcd for (M+1)

5 $\text{C}_{23}\text{H}_{24}\text{NO}$ 330.450, found: 330.1836. Anal. Calcd. for $\text{C}_{23}\text{H}_{23}\text{ON}$: C, 83.86; H, 7.04; N, 4.25. Found: C, 83.64; H, 7.42; N, 4.19. HPLC on chiral stationary phase:(S,S) Pirkle-Whelk-O 1 column (250 x 4.6 mm I.D.), mobile phase: hexane/isopropanol (99.5:0.5, v/v), flow-rate: 1.5 ml/min, detection with UV detector

10 at 210nm. Retention time of the desired S-isomer: 8.75 min., retention time of the R-enantiomer 10.62 min.

METHOD 2: A solution of oxalyl chloride (8.4 ml, 0.096 mol) in dichloromethane (240 ml) was cooled to -74°C .

15 A solution of DMSO (12.0 ml, 0.155 mol) in dichloromethane (50 ml) was then slowly added at a rate to maintain the temperature at -74°C (addition time ~1.25 hr). The mixture was stirred for 5 min. followed

20 by addition of a solution of BS-2-[bis(phenylmethyl)amino]benzene-propanol (0.074 mol) in 100 ml of dichloromethane (addition time -20 min., temp. -75°C to -68°C). The solution was stirred at -78°C for 35 minutes under a nitrogen atmosphere.

25 Triethylamine (41.2 ml, 0.295 mol) was then added over 10 min. (temp. -78° to -68°C) upon which the ammonium salt precipitated. The cold mixture was stirred for 30 min. and then water (225 ml) was added. The dichloromethane layer was separated from the aqueous

30 phase and washed with water, brine, dried over magnesium sulfate, filtered and concentrated. The residue was diluted with ethyl acetate and hexane and then filtered to further remove the ammonium salt. The filtrate was concentrated to give α S-

35 [bis(phenylmethyl)amino] benzenepropanaldehyde. The


aldehyde was carried on to the next step without purification.

METHOD 3: To a mixture of 1.0 g(3.0 mmoles) of β S-2-
5 [bis(phenylmethyl)amino]benzenepropanol 0.531 g(4.53
mmoles) of N-methyl morpholine, 2.27 g of molecular
sieves(4A) and 9.1 mL of acetonitrile was added 53 mg
(0.15 mmoles) of tetrapropylammonium
perruthenate(TPAP). The mixture was stirred for 40
10 minutes at room temperature and concentrated under
reduced pressure. The residue was suspended in 15 mL
of ethyl acetate, filtered through a pad of silica gel.
The filtrate was concentrated under reduced pressure to
give a product containing approximately 50% of α S-2-
15 [bis(phenylmethyl)amino]benzene propanaldehyde as a
pale yellow oil.

METHOD 4: To a solution of 1.0 g (3.02 mmoles) of β S-
2-[bis(phenylmethyl)amino]benzenepropanol in 9.0 mL of
20 toluene was added 4.69 mg(0.03 mmoles) of 2,2,6,6-
tetramethyl-1-piperidinyloxy, free radical (TEMPO),
0.32g(3.11 mmoles) of sodium bromide, 9.0 mL of ethyl
acetate and 1.5 mL of water. The mixture was cooled to
0 °C and an aqueous solution of 2.87 mL of 5% household
25 bleach containing 0.735 g(8.75 mmoles) of sodium
bicarbonate and 8.53 mL of water was added slowly over
25 minutes. The mixture was stirred at 0°C for 60
minutes. Two more additions (1.44 mL each) of bleach
was added followed by stirring for 10 minutes. The two
30 phase mixture was allowed to separate. The aqueous
layer was extracted twice with 20 mL of ethyl acetate.
The combined organic layer was washed with 4.0 mL of a
solution containing 25 mg of potassium iodide and
water(4.0 mL), 20 mL of 10% aqueous sodium thiosulfate
35 solution and then brine solution. The organic solution

was dried over magnesium sulfate, filtered and concentrated under reduced pressure to give 1.34g of crude oil containing a small amount of the desired product aldehyde, α S-[bis(phenylmethyl)amino] benzenepropanaldehyde.

METHOD 5: Following the same procedures as described in Method 1 of this Example except 3.0 equivalents of sulfur trioxide pyridine complex was used and α S-[bis(phenylmethyl)amino]benzenepropanaldehyde was isolated in comparable yields.

EXAMPLE 3

5 Preparation of N,N-dibenzyl-3(S)-amino-1,2-(S)-epoxy-4-phenylbutane

METHOD 1: A solution of α S-
[Bis(phenylmethyl)amino]benzene-propanaldehyde (191.7g,
0.58 mol) and chloriodomethane (56.4 mL, 0.77 mol) in
10 tetrahydrofuran (1.8 L) was cooled to -30 to -35°C
(colder temperature such as -70°C also worked well but
warmer temperatures are more readily achieved in large
scale operations) in a stainless steel reactor under a
nitrogen atmosphere. A solution of n-butyl lithium in
15 hexane (1.6 M, 365 mL, 0.58 mol) was then added at a
rate that maintained the temperature below -25°C. After
addition the mixture was stirred at -30 to -35°C for 10
minutes. More additions of reagents were carried out in
the following manner: (1) additional chloriodomethane
20 (17 mL) was added, followed by n-butyl lithium (110 mL)
at <-25°C. After addition the mixture was stirred at
-30 to -35°C for 10 minutes. This was repeated once.
(2) Additional chloriodomethane (8.5 mL, 0.11 mol) was
added, followed by n-butyl lithium (55 mL, 0.088 mol) at
25 <-25°C. After addition the mixture was stirred at -30
to -35°C for 10 minutes. This was repeated 5 times.
(3) Additional chloriodomethane (8.5 mL, 0.11 mol) was
added, followed by n-butyl lithium (37 mL, 0.059 mol) at
30 <-25°C. After addition the mixture was stirred at -30
to -35°C for 10 minutes. This was repeated once. The
external cooling was stopped and the mixture warmed to

ambient temp. over 4 to 16 hours when TLC (silica gel, 20% ethyl acetate/hexane) indicated that the reaction was completed. The reaction mixture was cooled to 10°C and quenched with 1452g of 16% ammonium chloride solution (prepared by dissolving 232g of ammonium chloride in 1220 mL of water), keeping the temperature below 23°C. The mixture was stirred for 10 minutes and the organic and aqueous layers were separated. The aqueous phase was extracted with ethyl acetate (2x 500 mL). The ethyl acetate layer was combined with the tetrahydrofuran layer. The combined solution was dried over magnesium sulfate (220g), filtered and concentrated on a rotary evaporator at 65°C. The brown oil residue was dried at 70°C *in vacuo* (0.8 bar) for 1 h to give 222.8g of crude material. (The crude product weight was >100%. Due to the relative instability of the product on silica gel, the crude product is usually used directly in the next step without purification). The diastereomeric ratio of the crude mixture was determined by proton NMR: (2S)/(2R): 86:14. The minor and major epoxide diastereomers were characterized in this mixture by tlc analysis (silica gel, 10% ethyl acetate/hexane), $R_f = 0.29$ & 0.32 , respectively. An analytical sample of each of the diastereomers was obtained by purification on silica-gel chromatography (3% ethyl acetate/hexane) and characterized as follows:

N,N,αS-Tris(phenylmethyl)-2S-oxiranemethanamine

^1H NMR (400 MHz, CDCl_3) δ 2.49 and 2.51 (AB-System, 1H, $J_{AB} = 2.82$), 2.76 and 2.77 (AB-System, 1H, $J_{AB} = 4.03$), 2.83 (m, 2H), 2.99 & 3.03 (AB-System, 1H, $J_{AB} = 10.1$ Hz), 3.15 (m, 1H), 3.73 & 3.84 (AB-System, 4H, $J_{AB} = 14.00$), 7.21 (m, 15H); ^{13}C NMR (400 MHz, CDCl_3) δ 139.55, 129.45, 128.42, 128.14, 128.09, 126.84, 125.97, 60.32,

54.23, 52.13, 45.99, 33.76; HRMS Calcd for C₂₄H₂₆NO
(M+1) 344.477, found 344.2003.

N,N,αS-Tris(phenylmethyl)-2R-oxiranemethanamine

5

¹H NMR (300 MHz, CDCl₃) δ 2.20 (m, 1H), 2.59 (m, 1H),
2.75 (m, 2H), 2.97 (m, 1H), 3.14 (m, 1H), 3.85 (AB-
System, 4H), 7.25 (m, 15H). HPLC on chiral stationary
phase: Pirkle-Whelk-O 1 column (250 x 4.6 mm I.D.),
10 mobile phase: hexane/isopropanol (99.5:0.5, v/v), flow-
rate: 1.5 ml/min, detection with UV detector at 210nm.
Retention time of (8): 9.38 min., retention time of
enantiomer of (4): 13.75 min.

15 METHOD 2: A solution of the crude aldehyde 0.074 mol
and chloriodomethane (7.0 ml, 0.096 mol) in
tetrahydrofuran (285 ml) was cooled to -78°C, under a
nitrogen atmosphere. A 1.6 M solution of n-butyl
lithium in hexane (25 ml, 0.040 mol) was then added at a
20 rate to maintain the temperature at -75°C (addition time
- 15 min.). After the first addition, additional
chloriodomethane (1.6 ml, 0.022 mol) was added again,
followed by n-butyl lithium (23 ml, 0.037 mol), keeping
the temperature at -75°C. The mixture was stirred for
25 15 min. Each of the reagents, chloriodomethane
(0.70 ml, 0.010 mol) and n-butyl lithium (5 ml,
0.008 mol) were added 4 more times over 45 min. at
-75°C. The cooling bath was then removed and the
solution warmed to 22°C over 1.5 hr. The mixture was
30 poured into 300 ml of saturated aq. ammonium chloride
solution. The tetrahydrofuran layer was separated. The
aqueous phase was extracted with ethyl acetate (1 x 300
ml). The combined organic layers were washed with
brine, dried over magnesium sulfate, filtered and
35 concentrated to give a brown oil (27.4g). The product
could be used in the next step without purification.

The desired diastereomer can be purified by recrystallization at a subsequent step. The product could also be purified by chromatography.

5 METHOD 3: A solution of α S-
[Bis(phenylmethyl)amino]benzene-propanaldehyde (178.84g,
0.54 mol) and bromochloromethane (46 mL, 0.71 mol) in
tetrahydrofuran (1.8 L) was cooled to -30 to -35°C
(colder temperature such as -70°C also worked well but
10 warmer temperatures are more readily achieved in large
scale operations) in a stainless steel reactor under a
nitrogen atmosphere. A solution of n-butyl lithium in
hexane (1.6 M, 340 mL, 0.54 mol) was then added at a
rate that maintained the temperature below -25°C. After
15 addition the mixture was stirred at -30 to -35°C for 10
minutes. More additions of reagents were carried out in
the following manner: (1) additional bromochloromethane
(14 mL) was added, followed by n-butyl lithium (102 mL)
at < -25°C. After addition the mixture was stirred at
20 -30 to -35°C for 10 minutes. This was repeated once.
(2) Additional bromochloromethane (7 mL, 0.11 mol) was
added, followed by n-butyl lithium (51 mL, 0.082 mol) at
<-25°C. After addition the mixture was stirred at -30
to -35°C for 10 minutes. This was repeated 5 times.
25 (3) Additional bromochloromethane (7 mL, 0.11 mol) was
added, followed by n-butyl lithium (51 mL, 0.082 mol) at
<-25°C. After addition the mixture was stirred at -30
to -35°C for 10 minutes. This was repeated once. The
external cooling was stopped and the mixture warmed to
30 ambient temp. over 4 to 16 hours when TLC (silica gel,
20% ethyl acetate/hexane) indicated that the reaction
was completed. The reaction mixture was cooled to 10°C
and quenched with 1452g of 16% ammonium chloride
solution (prepared by dissolving 232g of ammonium
35 chloride in 1220 mL of water), keeping the temperature
below 23°C. The mixture was stirred for 10 minutes and

the organic and aqueous layers were separated. The aqueous phase was extracted with ethyl acetate (2x 500 mL). The ethyl acetate layer was combined with the tetrahydrofuran layer. The combined solution was dried
5 over magnesium sulfate (220g), filtered and concentrated on a rotary evaporator at 65°C. The brown oil residue was dried at 70°C *in vacuo* (0.8 bar) for 1 h to give 222.8g of crude material.

10 METHOD 4: Following the same procedures as described in Method 3 of this Example except the reaction temperatures were at -20°C. The resulting N,N, α S-tris(phenylmethyl)-2S-oxiranemethanamine was a diastereomeric mixture of lesser purity than that of
15 Method 3.

METHOD 5: Following the same procedures as described in Method 3 of this Example except the reaction temperatures were at -70 to -78°C. The resulting
20 N,N, α S-tris(phenylmethyl)-2S-oxiranemethanamine was a diastereomeric mixture, which was used directly in the subsequent steps without purification.


METHOD 6: Following the same procedures as described in
25 Method 3 of this Example except a continuous addition of bromochloromethane and n-butyl lithium was used at -30 to -35°C. After the reaction and work up procedures as described in Method 3 of this Example, the desired N,N, α S-tris(phenylmethyl)-2S-oxiranemethanamine was
30 isolated in comparable yields and purities.

METHOD 7: Following the same procedures as described in Method 2 of this Example except dibromomethane was used instead of chloriodomethane. After the reaction and
35 work up procedures as described in Method 2 of this

Example, the desired *N,N*, α *S*-tris(phenylmethyl)-2*S*-oxirane-methanamine was isolated.

EXAMPLE 4

5




Preparation of *N*-[3(*S*)-[*N,N*-bis(phenylmethyl)amino]-2(*R*)-hydroxy-4-phenylbutyl]-*N*-isobutylamine

10 To a solution of crude *N,N*-dibenzyl-3(*S*)-amino-1,2(*S*)-epoxy-4-phenylbutane (388.5g, 1.13 mol) in isopropanol (2.7 L) (or ethyl acetate) was added isobutylamine (1.7 kgm, 23.1 mol) over 2 min. The temperature increased from 25°C and to 30°C. The
15 solution was heated to 82°C and stirred at this temperature for 1.5 hours. The warm solution was concentrated under reduced pressure at 65°C, The brown oil residue was transferred to a 3-L flask and dried *in vacuo* (0.8 mm Hg) for 16 h to give 450g of 3*S*-[*N,N*-
20 bis(phenylmethyl)amino-4-phenylbutan-2*R*-ol as a crude oil.

An analytical sample of the desired major diastereomeric product was obtained by purifying a small
25 sample of crude product by silica gel chromatography (40% ethyl acetate/hexane). Tlc analysis: silica gel, 40% ethyl acetate/hexane; R_f = 0.28; HPLC analysis: ultrasphere ODS column, 25% triethylamino-/phosphate buffer pH 3-acetonitrile, flow rate 1 mL/min, UV
30 detector; retention time 7.49 min.; HRMS Calcd for

C₂₈H₂₇N₂O (M + 1) 417.616, found 417.2887. An analytical sample of the minor diastereomeric product, 3S-[N,N-bis(phenylmethyl)amino]1-(2-methylpropyl)amino-4-phenylbutan-2S-ol was also obtained by purifying a small sample of crude product by silica gel chromatography (40% ethyl acetate/hexane).

EXAMPLE 5



Preparation of N-[3(S)-[N,N-bis(phenylmethyl)amino]-2(R)-hydroxy-4-phenylbutyl]-N-isobutylamine•oxalic acid salt

15

To a solution of oxalic acid (8.08g, 89.72 mmol) in methanol (76 mL) was added a solution of crude 3(S)-[N,N-bis(phenylmethyl)amino]-1-(2-methylpropyl)amino-4-phenylbutan-2(R)-ol {39.68g, which contains about 25.44g (61.06 mmol) of 3(S),2(R) isomer and about 4.49g (10.78 mmol) of 3(S),2(S) isomer} in ethyl acetate (90 mL) over 15 minutes. The mixture was stirred at room temperature for about 2 hours. Solid was isolated by filtration, washed with ethyl acetate (2 x 20 mL) and dried *in vacuo* for about 1 hour to yield 21.86g (70.7% isomer recovery) of 97% diastereomerically pure salt (based on HPLC peak areas). HPLC analysis: Vydec-peptide/protein C18 column, UV detector 254 nm, flow rate 2 mL/min., gradient {A = 0.05% trifluoroacetic acid in water, B = 0.05% trifluoroacetic acid in

20

25

30

acetonitrile, 0 min. 75% A/25% B, 30 min. 10% A/90% B, 35 min. 10% A/90% B, 37 min. 75% A/25% B}; Retention time 10.68 min. (3(S),2(R) isomer) and 9.73 min. (3(S),2(S) isomer). Mp = 174.99°C; Microanalysis:
5 Calc.: C 71.05%, H 7.50%, N 5.53%; Found: C 71.71%, H 7.75%, N 5.39%.

Alternatively, oxalic acid dihydrate (119g, 0.94 mole) was added to a 5000 mL round bottom flask
10 fitted with a mechanical stirrer and a dropping funnel. Methanol (1000 ml) was added and the mixture stirred until dissolution was complete. A solution of crude 3(S)-[N,N-bis(phenylmethyl)amino]-1-(2-methylpropyl) amino-4-phenylbutan-2(R)-ol in ethyl acetate (1800 ml,
15 0.212g amino alcohol isomers/mL, 0.9160 moles) was added over a twenty minute period. The mixture was stirred for 18 hours and the solid product was isolated by centrifugation in six portions at 400G. Each portion was washed with 125 mL of ethyl acetate. The salt was
20 then collected and dried overnight at 1 torr to yield 336.3g of product (71% based upon total amino alcohol). HPLC/MS (electrospray) was consistent with the desired product (m/z 417 [M+H]⁺).

25 Alternatively, crude 3(S)-[N,N-bis(phenylmethyl) amino]-1-(2-methylpropyl)amino-4-phenylbutan-2(R)-ol (5g) was dissolved in methyl-tert-butylether (MTBE) (10 mL) and oxalic acid (1g) in methanol (4 mL) was added. The mixture was stirred for about 2 hours. The
30 resulting solid was filtered, washed with cold MTBE and dried to yield 2.1g of white solid of about 98.9% diastereomerically pure (based on HPLC peak areas).

EXAMPLE 6

5 Preparation of N-[3(S)-[N,N-bis(phenylmethyl)
amino]-2(R)-hydroxy-4-phenylbutyl]-N-
isobutylamine•acetic acid salt

To a solution of crude 3(S)-[N,N-bis(phenylmethyl) amino]-1-(2-methylpropyl)amino-4-phenylbutan-2(R)-ol in methyl-tert-butylether (MTBE) (45 mL, 1.1g amino alcohol
10 isomers/mL) was added acetic acid (6.9 mL) dropwise. The mixture was stirred for about 1 hour at room temperature. The solvent was removed *in vacuo* to yield a brown oil about 85% diastereomerically pure product (based on HPLC peak areas). The brown oil was
15 crystallized as follows: 0.2g of the oil was dissolved in the first solvent with heat to obtain a clear solution, the second solvent was added until the solution became cloudy, the mixture was heated again to clarity, seeded with about 99% diastereomerically pure
20 product, cooled to room temperature and then stored in a refrigerator overnight. The crystals were filtered, washed with the second solvent and dried. The diastereomeric purity of the crystals was calculated from the HPLC peak areas. The results are shown in
25 Table 1.

TABLE 1

First Solvent	Second Solvent	Solvent Ratio	Recovery Weight (g)	Diastereomeric Purity (%)
MTBE	Heptane	1:10	0.13	98.3
MTBE	Hexane	1:10	0.03	99.6
Methanol	Water	1:1.5	0.05	99.5
Toluene	Heptane	1:10	0.14	98.7
Toluene	Hexane	1:10	0.10	99.7

Alternatively, crude 3(S)-[N,N-bis(phenylmethyl) amino]-1-(2-methylpropyl)amino-4-phenylbutan-2(R)-ol {50.0g, which contains about 30.06g (76.95 mmol) of 3(S),2(R) isomer and about 5.66g (13.58 mmol) of 3(S),2(S) isomer} was dissolved in methyl-tert-butylether (45.0 mL). To this solution was added acetic acid (6.90 mL, 120.6 mmol) over a period of about 10 min. The mixture was stirred at room temperature for about 1 hour and concentrated under reduced pressure. The oily residue was purified by recrystallization from methyl-tert-butylether (32 mL) and heptane (320 mL). Solid was isolated by filtration, washed with cold heptane and dried *in vacuo* for about 1 hour to afford 21.34c (58.2% isomer recovery) of 96% diastereomerically pure monoacetic acid salt (based on HPLC peak areas). Mp = 105-106°C; Microanalysis: Calc.: C 75.53%, H 8.39%, N 5.87%; Found: C 75.05%, H 8.75%, N 5.71%.

EXAMPLE 7

20

Preparation of N-[3(S)-[N,N-bis(phenylmethyl) amino]-2(R)-hydroxy-4-phenylbutyl]-N-isobutylamine•L-tartaric acid salt

Crude 3(S)-[N,N-bis(phenylmethyl)amino]-1-(2-methylpropyl)amino-4-phenylbutan-2(R)-ol {10.48g, which contains about 6.72g (16.13 mmol) of 3(S),2(R) isomer and about 1.19g (2.85 mmol) of 3(S),2(S) isomer} was dissolved in tetrahydrofuran (10.0 mL). To this solution was added a solution of L-tartaric acid (2.85g, 19 mmol) in methanol (5.0 mL) over a period of about 5 min. The mixture was stirred at room temperature for about 10 min. and concentrated under reduced pressure. Methyl-tert-butylether (20.0 mL) was added to the oily residue and the mixture was stirred at room temperature for about 1 hour. Solid was isolated by filtration to

afford 7.50g of crude salt. The crude salt was purified by recrystallization from ethyl acetate and heptane at room temperature to yield 4.13g (45.2% isomer recovery) of 95% diastereomerically pure L-tartaric acid salt
5 (based on HPLC peak areas). Microanalysis: Calc.: C 67.76%, H 7.41%, N 4.94%; Found: C 70.06%, H 7.47%, N 5.07%.

EXAMPLE 8

10

Preparation of N-[3(S)-[N,N-bis(phenylmethyl)amino]-2(R)-hydroxy-4-phenylbutyl]-N-isobutylamine dihydrochloric acid salt

15 Crude 3(S)-[N,N-bis(phenylmethyl) amino]-1-(2-methylpropyl)amino-4-phenylbutan-2(R)-ol {10.0g, which contains about 6.41g (15.39 mmol) of 3(S),2(R) isomer and about 1.13g (2.72 mmol) of 3(S),2(S) isomer} was dissolved in tetrahydrofuran (20.0 mL). To this
20 solution was added hydrochloric acid (20 mL, 6.0 N) over a period of about 5 min. The mixture was stirred at room temperature for about 1 hour and concentrated under reduced pressure. The residue was recrystallized from ethanol at 0°C to yield 3.20g (42.7% isomer recovery) of
25 98% diastereomerically pure dihydrochloric acid salt (based on HPLC peak areas). Microanalysis: Calc.: C 68.64%, H 7.76%, N 5.72%; Found: C 68.79%, H 8.07%, N 5.55%.

EXAMPLE 9

5 Preparation of N-[3(S)-[N,N-bis(phenylmethyl)amino]-
2(R)-hydroxy-4-phenylbutyl]-N-
isobutylamine•toluenesulfonic acid salt

Crude 3(S)-[N,N-bis(phenylmethyl) amino]-1-(2-
methylpropyl)amino-4-phenylbutan-2(R)-ol {5.0g, which
contains about 3.18g (7.63 mmol) of 3(S),2(R) isomer and
10 about 0.56g (1.35 mmol) of 3(S),2(S) isomer} was
dissolved in methyl-tert-butylether (10.0 mL). To this
solution was added a solution of toluenesulfonic acid
(2.28g, 12 mmol) in methyl-tert-butylether (2.0 mL) and
methanol (2.0 mL) over a period of about 5 min. The
15 mixture was stirred at room temperature for about 2
hours and concentrated under reduced pressure. The
residue was recrystallized from methyl-tert-butylether
and heptane at 0°C, filtered, washed with cold heptane
and dried *in vacuo* to yield 1.85g (40.0% isomer
20 recovery) of 97% diastereomerically pure
monotoluenesulfonic acid salt (based on HTLC peak
areas).

EXAMPLE 10

25

Preparation of N-[3(S)-[N,N-bis(phenylmethyl)amino]-
2(R)-hydroxy-4-phenylbutyl]-N-
isobutylamine•methanesulfonic acid salt

30 Crude 3(S)-[N,N-bis(phenylmethyl) amino]-1-(2-
methylpropyl)amino-4-phenylbutan-2(R)-ol {10.68g, which
contains about 6.85g (16.44 mmol) of 3(S),2(R) isomer
and about 1.21g (2.90 mmol) of 3(S),2(S) isomer} was
dissolved in tetrahydrofuran (10.0 mL). To this
35 solution was added methanesulfonic acid (1.25 mL,
19.26 mmol). The mixture was stirred at room

temperature for about 2 hours and concentrated under reduced pressure. The oily residue was recrystallized from methanol and water at 0°C, filtered, washed with cold methanol/water (1:4) and dried *in vacuo* to yield
5 2.40g (28.5% isomer recovery) of 98% diastereomerically pure monomethanesulfonic acid salt (based on HPLC peak areas).

EXAMPLE 11

10

Preparation of N-benzyl-L-phenylalaninol

METHOD 1: L-Phenylalaninol (89.51g, 0.592 moles) was dissolved in 375 mL of methanol under inert atmosphere,
15 35.52g (0.592 moles) of glacial acetic acid and 50 mL of methanol was added followed by a solution of 62.83g (0.592 moles) of benzaldehyde in 100 mL of methanol. The mixture was cooled to approximately 15°C and a solution of 134.6g (2.14 moles) of sodium
20 cyanoborohydride in 700 mL of methanol was added in approximately 40 minutes, keeping the temperature between 15°C and 25°C. The mixture was stirred at room temperature for 18 hours. The mixture was concentrated under reduced pressure and partitioned between 1 L of 2M
25 ammonium hydroxide solution and 2 L of ether. The ether layer was washed with 1 L of 1M ammonium hydroxide solution, twice with 500 mL water, 500 mL of brine and dried over magnesium sulfate for 1 hour. The ether layer was filtered, concentrated under reduced pressure
30 and the crude solid product was recrystallized from 110 mL of ethyl acetate and 1.3 L of hexane to give 115g (81% yield) of N-benzyl-L-phenylalaninol as a white solid.

35 METHOD 2: L-Phenylalaninol (5g, 33 mmoles) and 3.59g (33.83 mmoles) of benzaldehyde were dissolved in 55 mL

of 3A ethanol under inert atmosphere in a Parr shaker and the mixture was warmed to 60°C for 2.7 hours. The mixture was cooled to approximately 25°C and 0.99g of 5% platinum on carbon was added and the mixture was
5 hydrogenated at 60 psi of hydrogen and 40°C for 10 hours. The catalyst was filtered off, the product was concentrated under reduced pressure and the crude solid product was recrystallized from 150 mL of heptane to give 3.83g (48 % yield) of N-benzyl-L-phenylalaninol as
10 a white solid.

EXAMPLE 12

Preparation of N-(t-Butoxycarbonyl)-N-benzyl-L-phenylalaninol

15

N-benzyl-L-phenylalaninol (2.9g, 12 mmoles) was dissolved in 3 mL of triethylamine and 27 mL of methanol and 5.25g (24.1 mmoles) of di-tert-butyl dicarbonate was
20 added. The mixture was warmed to 60°C for 35 minutes and concentrated under reduced pressure. The residue was dissolved in 150 mL of ethyl acetate and washed twice with 10 mL of cold (0-5°C), dilute hydrochloric acid (pH 2.5 to 3), 15 mL of water, 10 mL of brine,
25 dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude product oil was purified by silica gel chromatography (ethyl acetate: hexane, 12:3 as eluting solvent) to give 3.98g (97% yield) of colorless oil.

30

EXAMPLE 13


Preparation of N-(t-Butoxycarbonyl)-N-benzyl-L-phenylalaninal

35

METHOD 1: To a solution of 0.32 g(0.94 mmoles) of N-(t-butoxycarbonyl)-N-benzyl-L-phenylalaninol in 2.8 mL of

toluene was added 2.4 mg (0.015 mmoles) of 2,2,6,6-tetramethyl-1-piperidinyloxy, free radical (TEMPO), 0.1g (0.97 mmoles) of sodium bromide, 2.8 mL of ethyl acetate and 0.34 mL of water. The mixture was cooled to 0°C and
5 an aqueous solution of 4.2 mL of 5% household bleach containing 0.23g (3.0 mL, 2.738 mmoles) of sodium bicarbonate was added slowly over 30 minutes. The mixture was stirred at 0°C for 10 minutes. Three more additions (0.4 mL each) of bleach was added followed by
10 stirring for 10 minutes after each addition to consume all the starting material. The two phase mixture was allowed to separate. The aqueous layer was extracted twice with 8 mL of toluene. The combined organic layer was washed with 1.25 mL of a solution containing 0.075g
15 of potassium iodide, sodium bisulfate(0.125 g) and water(1.1 mL), 1.25 mL of 10% aqueous sodium thiosulfate solution, 1.25 mL of pH 7 phosphate buffer and 1.5 mL of brine solution. The organic solution was dried over magnesium sulfate, filtered and concentrated under
20 reduced pressure to give 0.32g (100% yield) of N-(t-Butoxycarbonyl)-N-benzyl-L-phenylalaninal.

METHOD 2: To a solution of 2.38 g(6.98 mmoles) of N-(t-butoxycarbonyl)-N-benzyl-L-phenylalaninol in 3.8 mL
25 (27.2 mmoles) of triethylamine at 10°C was added a solution of 4.33g (27.2 mmoles) of sulfur trioxide pyridine complex in 17 mL of dimethyl sulfoxide. The mixture was warmed to room temperature and stirred for one hour. Water (16 mL) was added and the mixture was
30 extracted with 20 mL of ethyl acetate. The organic layer was washed with 20 mL of 5% citric acid, 20 mL of water, 20 mL of brine, dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to give 2.37g (100% yield) of N-(t-
35 Butoxycarbonyl)-N-benzyl-L-phenylalaninal.

EXAMPLE 14

5 Preparation of 3(S)-[N-(t-butoxycarbonyl)-N-
benzylamino]-1,2-(S)-epoxy-4-phenylbutane

METHOD 1: A solution of 2.5g (7.37 mmoles) of N-(t-butoxycarbonyl)-N-benzyl-L-phenylalaninal and 0.72 mL of chloriodomethane in 35 mL of THF was cooled to -78°C.

10 A 4.64 mL of a solution of n-butyllithium (1.6 M in hexane, 7.42 mmoles) was added slowly, keeping the temperature below -70°C. The mixture was stirred for 10 minutes between -70 to -75°C. Two additional portions of 0.22 mL of chloriodomethane and 1.4 mL of n-

15 butyllithium was added sequentially and the mixture was stirred for 10 minutes between -70 to -75°C after each addition. Four additional portions of 0.11 mL of chloriodomethane and 0.7 mL of n-butyllithium was added

20 between -70 to -75°C after each addition. The mixture was warmed to room temperature for 3.5 hours. The product was quenched at below 5°C with 24 mL of ice-cold water. The biphasic layers were separated and the aqueous layer was extracted twice with 30 mL of ethyl

25 acetate. The combined organic layers was washed three times with 10 mL water, then with 10 mL brine, dried over sodium sulfate, filtered and concentrated under reduced pressure to give 2.8g of a yellow crude oil. This crude oil (>100% yield) is a mixture of the

30 diastereomeric epoxides N, α S-bis(phenylmethyl)-N-(t-

butoxycarbonyl)-2S-oxiranemethanamine and N, α S-bis(phenylmethyl)-N-(t-butoxycarbonyl)-2R-oxiranemethanamine. The crude mixture is used directly in the next step without purification.


5

METHOD 2: To a suspension of 2.92g (13.28 mmoles) of trimethylsulfoxonium iodide in 45 mL of acetonitrile was added 1.49g (13.28 mmoles) of potassium t-butoxide. A solution of 3.0g (8.85 mmoles) of N-(t-butoxycarbonyl)-
10 N-benzyl-L-phenylalaninal in 18 mL of acetonitrile was added and the mixture was stirred at room temperature for one hour. The mixture was diluted with 150 mL of water and extracted twice with 200 mL of ethyl acetate. The organic layers were combined and washed with 100 mL
15 water, 50 mL brine, dried over sodium sulfate, filtered and concentrated under reduced pressure to give 3.0g of a yellow crude oil. The crude product was purified by silica gel chromatography (ethyl acetate/hexane: 1: 8 as eluting solvent) to give 1.02g (32.7% yield) of a
20 mixture of the two diastereomers N, α S-bis(phenylmethyl)-N-(t-butoxycarbonyl)-2S-oxiranemethanamine and N, α S-bis(phenylmethyl)-N-(t-butoxycarbonyl)-2R-oxiranemethanamine.

25 METHOD 3: To a suspension of 0.90g (4.42 mmoles) of trimethylsulfonium iodide in 18 mL of acetonitrile was added 0.495g (4.42 mmoles) of potassium t-butoxide. A solution of 1.0g (2.95 mmoles) of N-(t-butoxycarbonyl)-
30 N-benzyl-L-phenylalaninal in 7 mL of acetonitrile was added and the mixture was stirred at room temperature for one hour. The mixture was diluted with 80 mL of water and extracted twice with 80 mL of ethyl acetate. The organic layers were combined and washed with 100 mL
35 water, 30 mL brine, dried over sodium sulfate, filtered and concentrated under reduced pressure to give 1.04g of a yellow crude oil. The crude product was a mixture of

the two diastereomers *N*, α *S*-bis(phenylmethyl)-*N*-(*t*-butoxycarbonyl)-2*S*-oxiranemethanamine and *N*, α *S*-bis(phenylmethyl)-*N*-(*t*-butoxycarbonyl)-2*R*-oxiranemethanamine.

5


EXAMPLE 15

Preparation of 3*S*-[*N*-(*t*-Butoxycarbonyl)-*N*-(phenylmethyl) amino]-1-(2-methylpropyl) amino-4-phenylbutan-2*R*-ol

To a solution of 500 mg (1.42 mmoles) of the crude epoxide (a mixture of the two diastereomers *N*, α *S*-bis(phenylmethyl)-*N*-(*t*-butoxycarbonyl)-2*S*-oxiranemethanamine and *N*, α *S*-bis(phenylmethyl)-*N*-(*t*-butoxycarbonyl)-2*R*-oxiranemethanamine) in 0.98 mL of isopropanol was added 0.71 mL (7.14 mmoles) of isobutylamine. The mixture was warmed to reflux at 85°C to 90°C for 1.5 hours. The mixture was concentrated under reduced pressure and the product oil was purified by silica gel chromatography (chloroform:methanol, 100:6 as eluting solvents) to give 330 mg of 3*S*-[*N*-(*t*-butoxycarbonyl)-*N*-(phenylmethyl) amino]-1-(2-methylpropyl) amino-4-phenylbutan-2*R*-ol as a colorless oil (54.5% yield). 3*S*-[*N*-(*t*-Butoxycarbonyl)-*N*-(phenylmethyl) amino]-1-(2-methylpropyl) amino-4-phenylbutan-2*S*-ol was also isolated. When purified *N*, α *S*-bis(phenylmethyl)-*N*-(*t*-butoxycarbonyl)-2*S*-oxiranemethanamine was used as starting material, 3*S*-[*N*-


(t-butoxycarbonyl)-N-(phenylmethyl)amino]-1-(2-methylpropyl)amino-4-phenylbutan-2R-ol was isolated after purification by chromatography in an 86% yield.

5

EXAMPLE 16Preparation of 3S-(N-t-Butoxycarbonyl)amino-4-phenylbutan-1,2R-diol


10

To a solution of 1g (3.39 mmoles) of 2S-(N-t-butoxycarbonyl)amino-1S-hydroxy-3-phenylbutanoic acid (commercially available from Nippon Kayaku, Japan) in 50 mL of THF at 0°C was added 50 mL of borane-THF complex (liquid, 1.0 M in THF), keeping the temperatures below 15 5°C. The reaction mixture was warmed to room temperature and stirred for 16 hours. The mixture was cooled to 0°C and 20 mL of water was added slowly to destroy the excess BH₃ and to quench the product 20 mixture, keeping the temperature below 12°C. The quenched mixture was stirred for 20 minutes and concentrated under reduced pressure. The product mixture was extracted three times with 60 mL of ethyl acetate. The organic layers were combined and washed 25 with 20 mL of water, 25 mL of saturated sodium chloride solution and concentrated under reduced pressure to give 1.1g of crude oil. The crude product was purified by silica gel chromatography (chloroform/methanol, 10:6 as eluting solvents) to give 900 mg (94.4% yield) of 3S-(N-t-butoxycarbonyl)amino-4-phenylbutan-1,2R-diol as a 30 white solid.

EXAMPLE 17


5 Preparation of 3S-(N-t-Butoxycarbonyl)amino-2R-hydroxy-
4-phenylbut-1-yl Toluenesulfonate

To a solution of 744.8 mg (2.65 mmoles) of 3S-(N-t-butoxycarbonyl)amino-4-phenylbutan-1,2R-diol in 13 mL of pyridine at 0°C was added 914 mg of toluenesulfonyl
10 chloride in one portion. The mixture was stirred at 0°C to 5°C for 5 hours. A mixture of 6.5 mL of ethyl acetate and 15 mL of 5% aqueous sodium bicarbonate solution was added to the reaction mixture and stirred for 5 minutes. The product mixture was extracted three
15 times with 50 mL of ethyl acetate. The organic layers were combined and washed with 15 mL of water, 10 mL of saturated sodium chloride solution and concentrated under reduced pressure to give about 1.1g of a yellow chunky solid. The crude product was purified by silica
20 gel chromatography (ethyl acetate/hexane 1:3 as eluting solvents) to give 850 mg (74% yield) of 3S-(N-t-butoxycarbonyl)amino-2R-hydroxy-4-phenylbut-1-yl toluenesulfonate as a white solid.

EXAMPLE 18

5 Preparation of 3S-[N-(t-Butoxycarbonyl)amino]-1-(2-
methylpropyl)amino-4-phenylbutan-2R-ol

To a solution of 90 mg (0.207 mmol) of 3S-(N-t-butoxycarbonyl)amino-2R-hydroxy-4-phenylbut-1)yl toluanesulfonate in 4.143 mL of isopropanol and 0.5 mL of toluene was added 0.103 mL (1.034 mmol) of isobutylamine. The mixture was warmed to 80 to 85°C and stirred for 1.5 hours. The product mixture was concentrated under reduced pressure at 40 to 50°C and purified by silica gel chromatography (chloroform/methanol, 10:1 as eluting solvents) to give 54.9 mg (76.8% yield) of 3S-[N-(t-butoxycarbonyl)amino]-1-(2-methylpropyl)amino-4-phenylbutan-2R-ol as a white solid.

EXAMPLE 19

5 Preparation of N-[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenylbutyl]-N-isoamylamine


Part A: To a solution of 75.0g (0.226 mol) of N-benzyloxycarbonyl-L-phenylalanine chloromethyl ketone in a mixture of 807 mL of methanol and 807 mL of
10 tetrahydrofuran at -2°C, was added 13.17g (0.348 mol, 1.54 equiv.) of solid sodium borohydride over one hundred minutes. The solvents were removed under reduced pressure at 40°C and the residue dissolved in ethyl acetate (approx. 1L). The solution was washed
15 sequentially with 1M potassium hydrogen sulfate, saturated sodium bicarbonate and then saturated sodium chloride solutions. After drying over anhydrous magnesium sulfate and filtering, the solution was removed under reduced pressure. To the resulting oil
20 was added hexane (approx. 1L) and the mixture warmed to 60°C with swirling. After cooling to room temperature, the solids were collected and washed with 2L of hexane. The resulting solid was recrystallized from hot ethyl acetate and hexane to afford 32.3g (43% yield) of N-benzyloxycarbonyl-3(S)-amino-1-chloro-4-phenyl-2(S)-
25 butanol, mp 150-151°C and $M+Li^+ = 340$.

Part B: To a solution of 6.52g (0.116 mol, 1.2 equiv.) of potassium hydroxide in 968 mL of absolute ethanol at
30 room temperature, was added 32.3g (0.097 mol) of N-CBZ-

3(S)-amino-1-chloro-4-phenyl-2(S)-butanol. After stirring for fifteen minutes, the solvent was removed under reduced pressure and the solids dissolved in methylene chloride. After washing with water, drying
5 over magnesium sulfate, filtering and stripping, one obtains 27.9g of a white solid. Recrystallization from hot ethyl acetate and hexane afforded 22.3g (77% yield) of N-benzyloxycarbonyl-3(S)-amino-1,2(S)-epoxy-4-phenylbutane, mp 102-103°C and MH⁺ 298.


10

Part C: A solution of N-benzyloxycarbonyl 3(S)-amino-1,2-(S)-epoxy-4-phenylbutane (1.00g, 3.36 mmol) and isoamylamine (4.90g, 67.2 mmol, 20 equiv.) in 10 mL of isopropyl alcohol was heated to reflux for 1.5 hours.
15 The solution was cooled to room temperature, concentrated *in vacuo* and then poured into 100 mL of stirring hexane whereupon the product crystallized from solution. The product was isolated by filtration and air dried to give 1.18g, 95% of N=[3(S)-
20 phenylmethylcarbamoyl)amino-2(R)-hydroxy-4-phenylbutyl]N-[(3-methylbutyl)amine mp 108.0-109.5°C, MH⁺ m/z = 371.

EXAMPLE 20

5 Preparation of phenylmethyl [2R-hydroxy-3-[(3-
methylbutyl) (phenylsulfonyl)amino]-1S-
(phenylmethyl)propyl]carbamate

From the reaction of N[3(S)-benzyloxycarbonylamino-
 2(R)-hydroxy-4-phenylbutyl] N-isoamylamine (1.47 gm, 3.8
 10 mmol), triethylamine (528 uL, 3.8 mmol) and
 benzenesulfonyl chloride (483 uL, 3.8 mmol) one obtains
 phenylmethyl [2R-hydroxy-3-[(3-methylbutyl)
 (phenylsulfonyl)amino]-1S-(phenylmethyl)propyl]-
 carbamate. Column chromatography on silica gel eluting
 15 with chloroform containing 1% ethanol afforded the pure
 product. Anal. Calcd for C₂₉H₃₆N₂O₅S: C, 66.39; H, 6.92;
 N, 5.34. Found: C, 66.37; H, 6.93; N, 5.26.

EXAMPLE 21

5 Preparation of 2R-hydroxy-3-[[[(4-aminophenyl)sulfonyl]
 (2-methylpropyl)amino]-1S-(phenylmethyl)propylamine

Part A: Preparation of Carbamic acid, 2R-hydroxy-3-
 [[[(4-nitrophenyl)sulfonyl](2-methylpropyl)amino]-1S-
 (phenylmethyl)propyl-, phenylmethyl ester

10


To a solution of 4.0g (10.8 mmol) of N-[3S-benzyloxy
 carbonylamino-2R-hydroxy-4-phenyl]-N-isobutylamine in
 50mL of anhydrous methylene chloride, was added 4.5mL
 (3.27g, 32.4 mmol) of triethylamine. The solution was
 15 cooled to 0°C and 2.63g (11.9 mmol) of 4-nitrobenzene
 sulfonyl chloride was added, stirred for 30 minutes at
 0°C, then for 1 hour at room temperature. Ethyl acetate
 was added, washed with 5% citric acid, saturated sodium
 bicarbonate, brine, dried and concentrated to yield 5.9g
 20 of crude material. This was recrystallized from ethyl
 acetate/hexane to afford 4.7g of pure carbamic acid,
 [2R-hydroxy-3-[[[(4-nitrophenyl)sulfonyl](2-methylpropyl)
 amino]-1S-(phenylmethyl)propyl-, phenylmethyl ester,
 m/e=556(M+H).

25

Part B: Preparation of 2R-hydroxy-3-[[[(4-aminophenyl)
 sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)
 propylamine

A solution of 3.0g (5.4 mmol) of carbamic acid, 2R-hydroxy-3-[[(4-nitrophenyl) sulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl-, phenylmethyl ester in 20 mL of ethyl acetate was hydrogenated over 1.5g of 10% palladium-on-carbon catalyst under 35 psig of hydrogen for 3.5 hours. The catalyst was removed by filtration and the solution concentrated to afford 2.05g of the desired 2R-hydroxy-3-[[(4-aminophenyl) sulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propylamine, m/e=392 (M+H).

EXAMPLE 22



15 Preparation of 2R-hydroxy-3-[[(3-aminophenyl) sulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propylamine.


Part A: Preparation of Carbamic acid, [2R-hydroxy-3-
20 [(3-nitrophenyl)sulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl-, phenylmethyl ester

To a solution of 1.1g (3.0 mmol) of N-[3S-benzyloxy carbonylamino-2R-hydroxy-4-phenyl]-N-isobutylamine in 25 15mL of anhydrous methylene chloride, was added 1.3mL (0.94g, 9.3 mmol) of triethylamine. The solution was cooled to 0°C and 0.67g (3.0 mmol) of 3-nitrobenzene sulfonyl chloride was added, stirred for 30 minutes at 0°C, then for 1 hour at room temperature. Ethyl acetate 30 was added, washed with 5% citric acid, saturated sodium

bicarbonate, brine, dried and concentrated to yield 1.74g of crude material. This was recrystallized from ethyl acetate/hexane to afford 1.40g of pure carbamic acid, [2R-hydroxy-3-[(3-nitrophenylsulfonyl)(2-methylpropyl) amino]-1S-(phenylmethyl)propyl-,
5 phenylmethyl ester, m/e=562(M+Li).

Part B: Preparation of [2R-hydroxy-3-[[3-aminophenyl)sulfonyl](2-methylpropyl) amino]-1S-
10 (phenylmethyl)propylamine

A solution of 1.33g (2.5 mmol) of carbamic acid, [2R-hydroxy-3-[(3-nitrophenylsulfonyl)(2-methylpropyl) amino]-1S-(phenylmethyl)propyl-,
15 phenylmethyl ester in 40 mL of 1:1 methanol/tetrahydrofuran was hydrogenated over 0.70g of 10% palladium-on-carbon catalyst under 40 psig of hydrogen for 1.5 hours. The catalyst was removed by filtration and the solution concentrated to afford 0.87g
20 of the desired [2R-hydroxy-3-[[3-aminophenyl)sulfonyl](2-methylpropyl) amino]-1S-(phenylmethyl)propylamine.

EXAMPLE 23

- 5 Preparation of 2S-[(pyrrolidin-1-yl)acetylamino]-N-[2R-
hydroxy-3-[N¹-(2-methylpropyl)-N¹-(2,3-
dihydrobenzofuran-5-ylsulfonyl)amino]-1S-
(phenylmethyl)propyl]-3S-methylpentanamide
- 10 Part A: Preparation of pyrrolidineacetic acid
hydrochloride
- A solution of 19.6g (101 mmol) of t-butyl bromoacetate
in 150 mL of THF was cooled in an ice bath and treated
15 dropwise over about 0.5 hour with a solution of 14.4g
(202 mmol) of pyrrolidine in 75 mL of THF, to produce a
white precipitate. The bath was removed and the
reaction slurry stirred for two hours. The solid was
removed by filtration and the filtrate was concentrated
20 under reduced pressure to yield a clear liquid over an
orange-colored solid. The liquid was cooled in an ice
bath, then treated with 40 mL (80 mmol) of 4N HCl in
dioxane and stirred for 15 hours. The solvents were
removed *in vacuo*, and the residue was triturated with
25 diethyl ether, then filtered to yield 12.9g of the
desired acid as an off-white solid.

Part B: Preparation of 5-(2,3-dihydrobenzofuranyl)
sulfonyl chloride

To a solution of 3.35g of anhydrous N,N-dimethylformamide at 0°C under nitrogen was added 6.18g of sulfonyl chloride, whereupon a solid formed. After stirring for 15 minutes, 4.69g of 2,3-dihydrobenzofuran
5 was added, and the mixture heated at 100°C for 2 hours. The reaction was cooled, poured into ice water, extracted with methylene chloride, dried over magnesium sulfate, filtered and concentrated the crude material. This was recrystallized from ethyl acetate to afford
10 2.45g of 5-(2,3-dihydrobenzofuranyl)sulfonyl chloride.

Part C: Preparation of Carbamic acid, 2R-hydroxy-3-[[(2,3-dihydrobenzofuran-5-yl)sulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl-, phenylmethyl ester

15

To a solution of 1.11g (3.0 mmol) of N-[3S-benzyloxy carbonylamino-2R-hydroxy-4-phenyl]-N-isobutylamine in 20mL of anhydrous methylene chloride, was added 1.3mL (0.94g, 9.3 mmol) of triethylamine. The solution was
20 cooled to 0°C and 0.66g of 5-(2,3-dihydrobenzofuranyl) sulfonyl chloride was added, stirred for 15 minutes at 0°C, then for 2 hour at room temperature. Ethyl acetate was added, washed with 5% citric acid, saturated sodium bicarbonate, brine, dried and concentrated to yield
25 1.62g of crude material. This was recrystallized from diethyl ether to afford 1.17g of pure carbamic acid, [2R-hydroxy-3-[[(2,3-dihydrobenzofuran-5-yl)sulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl-, phenylmethyl ester.

30

Part D: Preparation of [2R-hydroxy-3-[[(2,3-dihydro benzofuran-5-yl)sulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propylamine

35 A solution of 2.86g of carbamic acid, [2R-hydroxy-3-[[(2,3-dihydrobenzofuran-5-yl)sulfonyl] (2-methylpropyl)

amino]-1S-(phenylmethyl)propyl-, phenylmethyl ester in 30 mL of tetrahydrofuran was hydrogenated 0.99g of 10% palladium-on-carbon under 50 psig of hydrogen for 16 hours. The catalyst was removed by filtration and the filtrate concentrated to afford 1.99g of the desired [2R-hydroxy-3-[(2,3-dihydrobenzofuran-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propylamine.

Part E: Preparation of 2S-[(carbobenzyloxy)amino]-N-[2R-hydroxy-3-[(3-methylpropyl)(2,3-dihydrobenzofuran-5-yl)sulfonyl]amino]-1S-(phenylmethyl)propyl]-3S-methylpentanamide

A solution of 5.8g (22.0 mmol) of N-CBZ-L-isoleucine in 45 mL of anhydrous N,N-dimethylformamide (DMF) was cooled to 0°C and charged with 3.9g (28.7 mmol) of N-hydroxybenzotriazole (HOBT) and 4.2g (22.0 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC). The ice bath was removed after 20 minutes and stirring was continued for an additional 40 minutes. The reaction solution was then charged with a solution of 8.0g (19.1 mmol) of 2R-hydroxy-3-[(2,3-dihydrobenzofuran-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propylamine and 2.2g (22.0 mmol) of 4-methylmorpholine in 25 mL of anhydrous DMF and stirred for 15 hours. The solvents were removed *in vacuo* and the residue was partitioned between 300 mL of ethyl acetate and 120 mL of 5% potassium hydrogen sulfate solution. The layers were separated, and the organic layer was washed with 120 mL each of saturated sodium bicarbonate solution, water and brine, then dried over anhydrous magnesium sulfate, filtered and concentrated *in vacuo* to afford 16.7g of crude material. The crude material was crystallized from ethanol to yield 12.0g (94%) of 2S-[(carbobenzyloxy)amino]-N-[2R-hydroxy-3-[(3-methylpropyl)(2,3-dihydrobenzofuran-5-

ylsulfonyl)amino]-1S-(phenylmethyl)propyl]-3S-methylpentanamide: $m/e = 672$ (M+Li).


Part F: Preparation of 2S-amino-N-[2R-hydroxy-3-[(3-methylpropyl)(2,3-dihydrobenzofuran-5-ylsulfonyl)amino]-1S-(phenylmethyl)propyl]-3S-methylpentanamide

A Fischer-Porter bottle equipped with a magnetic stir bar was charged with 11.9g (17.9 mmol) of 2S-[(carbobenzyloxy)amino]-N-[2R-hydroxy-3-[(3-methylpropyl)(2,3-dihydrobenzofuran-5-ylsulfonyl)amino]-1S-(phenylmethyl)propyl]-3S-methylpentanamide and 75 mL of tetrahydrofuran (THF). The solution was hydrogenated in the presence of 5g of 10% palladium-on-carbon catalyst (50% water by weight) under 50 psig of hydrogen for 4 hours at room temperature. The catalyst was removed by filtration, and the solvent removed *in vacuo*. The residue was dissolved in 300 mL of ethyl acetate and washed with 120 mL each of saturated sodium bicarbonate solution and brine, then dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to afford 8.8g of the desired product, $m/e = 532$ (M+H).

Part G: Preparation of 2S-[(pyrrolidin-1-yl)acetylamino]-N-[2R-hydroxy-3-[N¹-(2-methylpropyl)-N¹-(2,3-dihydrobenzofuran-5-ylsulfonyl)amino]-1S-(phenylmethyl)propyl]-3S-methylpentanamide

A solution of 3.7g (22.1 mmol) of pyrrolidineacetic acid hydrochloride in 45 mL of anhydrous DMF was cooled to 0°C and charged with 3.4g (24.7 mmol) of HOBT and 3.6g (19.0 mmol) of EDC. The ice bath was removed after 20 minutes and stirring was continued for an additional 40 minutes. The reaction solution was then charged with a solution of 8.8g (16.5 mmol) of 2S-amino-N-[2R-hydroxy-

3-[(3-methylpropyl)(2,3-dihydro benzofuran-5-ylsulfonyl)amino]-1S-(phenylmethyl)propyl]-3S-methylpentanamide and 4.5g (44.1 mmol) of 4-methylmorpholine in 25 mL of anhydrous DMF and stirred
5 for 16 hours. The solvents were removed *in vacuo* and the residue was partitioned between 300 mL of ethyl acetate and 120 mL of 5% potassium hydrogen sulfate solution. The layers were separated, and the organic layer was washed with 120 mL each of saturated sodium
10 bicarbonate solution, water and brine, then dried over anhydrous magnesium sulfate, filtered and concentrated *in vacuo* to afford 9.9g of crude material. The coupling reaction was run again using 2.5g (15.1 mmol) of pyrrolidineacetic acid hydrochloride, 2.3g (17.0 mmol)
15 of HOBt, 2.45g (12.8 mmol) of EDC, 3.0g (30.0 mmol) of 4-methylmorpholine, and the 9.9g of crude product in place of the amine from Part B. The reaction work-up was repeated and yielded 10.2g of crude product. Purification was accomplished using a Prep 2000
20 chromatograph on silica gel using 70-100% (5% methanol/95% ethyl acetate)/hexane to yield the desired product as a white solid, $m/e = 649$ (M+Li).


EXAMPLE 24

5 Preparation of N-[(1,1-dimethylethoxy)carbonyl]-N-[2-
methylpropyl]-3S-[N¹-(phenylmethoxycarbonyl)amino]-2R-
hydroxy-4-phenylbutylamine

To a solution of 7.51g (20.3 mmol) of N-[3S-
 10 [(phenylmethoxycarbonyl)amino]-2R-hydroxy-4-
 phenylbutyl]-2-methylpropylamine in 67 mL of anhydrous
 tetrahydrofuran was added 2.25g (22.3 mmol) of
 triethylamine. After cooling to 0°C, 4.4g (20.3 mmol)
 of di-tert-butylidicarbonate was added and stirring
 15 continued at room temperature for 21 hours. The
 volatiles were removed *in vacuo*, ethyl acetate added,
 then washed with 5% citric acid, saturated sodium
 bicarbonate, brine, dried over magnesium sulfate,
 filtered and concentrated to afford 9.6g of crude
 20 product. Chromatography on silica gel using 30% ethyl
 acetate/hexane afforded 8.2g of pure N-[[3S-
 (phenylmethylcarbamoyl)amino]-2R-hydroxy-4-phenyl]-1-
 [(2-methylpropyl)amino-2-(1,1-
 dimethylethoxy)carbonyl]butane, mass spectrum m/e = 477
 25 (M+Li).

EXAMPLE 25


Preparation of 2S-[[bromoacetyl]amino]-N-[2R-hydroxy-3-
 [N¹-(3-methyl-butyl)-N¹-(phenylsulfonyl)amino]-1S-
 5 (phenylmethyl)propyl]-3,3-dimethylbutaneamide



Part A: To a solution of N-CBZ-L-tert-leucine (450 mg,
 10 1.7 mmol) and N-hydroxybenzotriazole (260 mg, 1.7 mmol)
 in DMF (10 mL) was added EDC (307 mg, 1.6 mmol). The
 solution was stirred for 60 minutes at room temperature
 and then 2R-hydroxy-3-[N-(3-methylbutyl)-N-
 (phenylsulfonyl)amino]-1S-(phenylmethyl)propylamine
 15 (585 mg, 1.5 mmol) in DMF (2 mL) was added. The
 reaction was stirred for 16 hours at room temperature,
 then poured into a 50% saturated solution of sodium
 bicarbonate (200 mL). The aqueous mixture was extracted
 thrice with ethyl acetate (50 mL). The combined ethyl
 20 acetate layers were washed with water (50 mL) and
 saturated NaCl solution (50 mL), then dried over
 magnesium sulfate. Filtration and concentration
 produced an oil which was chromatographed on silica gel
 (50 gm) eluting with 20% ethyl acetate in hexane. The
 25 phenylmethyl [1S-[[[2R-hydroxy-3-[(3-methylbutyl)
 (phenylsulfonyl)amino]-1S-(phenylmethyl)propyl]amino]
 carbonyl]-2,2-dimethylpropyl]carbamate was obtained as a
 solid Anal. Calcd for C₃₅H₄₇N₃O₆S: C, 65.91; H, 7.43; N,
 6.59. Found: C, 65.42; H, 7.24; N, 6.55.

Part B: A solution of phenylmethyl [1S-[[[2R-hydroxy-3-
[(3-methylbutyl) (phenylsulfonyl)-amino]-1S-
(phenylmethyl)propyl]amino]carbonyl]-2,2-
dimethylpropyl]carbamate (200 mg, 0.31 mmol) in methanol
5 (15 mL) was hydrogenated over 10% palladium on carbon
for 2 hours. The reaction was filtered through
diatomaceous earth and concentrated to an oil.

Part C: The resulting free amine from part B (150 mg,
10 0.3 mmol) was combined with diisopropylethylamine
(114 uL, 0.33 mmol) in dichloromethane (5 mL). To this
was added bromoacetyl chloride (27 uL, 0.33 mmol)
dropwise. The reaction was stirred for 30 minutes at
room temperature, then diluted with dichloromethane
15 (30 mL) and extracted with 1 N HCl, water, and then
saturated NaCl solution (25 mL each). The organic
solution was dried over MgSO₄ and concentrated to a
solid. The 2S-[[bromoacetyl]amino]-N-[2R-hydroxy-3-[(3-
methylbutyl) (phenylsulfonyl)amino]-1S-
20 (phenylmethyl)propyl]-3,3-dimethylbutaneamide was
sufficiently pure for use in the next step. This
material can also be prepared by substituting
bromoacetic anhydride for bromoacetyl chloride, or one
can use chloroacetyl chloride or chloroacetic anhydride.

EXAMPLE 26

5 Preparation of 2S-[chloroacetylamino]-N-[2R-hydroxy-3-
[N¹-(2-methylbutyl)-N¹-(phenylsulfonyl)amino]-1S-
(phenylmethyl)propyl]-3S-methylpentanamide

Part A: To a solution of 2R-hydroxy-3-[N-(3-
 10 methylbutyl)-N-(phenylsulfonyl)amino]-1S-(phenylmethyl)
 propylamine (2.79g, 7.1 mmol) in 27 mL of dioxane was
 added (2.3g, 7.1 mmol) of N-t-butylcarbonyl-L-
 isoleucine-N-hydroxysuccinamide ester, and the reaction
 15 was stirred under nitrogen atmosphere for 16 hours. The
 contents of the reaction were concentrated *in vacuo*, and
 the residue dissolved in ethyl acetate, washed with
 potassium hydrogen sulfate (5% aqueous), saturated
 sodium bicarbonate, and saturated sodium chloride. The
 organic layer was dried over magnesium sulfate, filtered
 20 and concentrated to yield 4.3g of crude material which
 was chromatographed using 3:1 ethyl acetate: hexane to
 obtain 3.05g, 72% yield of Pentanamide, 2S-[[1,1-
 dimethylethoxy)carbonyl]amino]-N-[2R-hydroxy-3-[(3-
 methylbutyl)phenylsulfonyl)amino]-1S-
 25 (phenylmethyl)propyl]-3-methyl-


Part B: (3.05g, 5.0 mmol) of the product from Part A
 was dissolved in 20 mL of 4N HCl in dioxane and stirred
 under nitrogen atmosphere for 1.5 hours. The contents

were concentrated *in vacuo*, and chased with diethyl ether. The crude hydrochloride salt was pumped on at 1 mm Hg until dry to yield 2.54g of product as its hydrochloride salt.

5

Part C: (2.54g, 5.0 mmol) of amine hydrochloride was dissolved in 50 mL of tetrahydrofuran and to this was added (1.01g, 10 mmol) of 4-methyl-morpholine, at which time a precipitate forms. To this suspension was added
10 chloroacetic anhydride (0.865g, 5.0 mmol) and stirred for 40 minutes. The contents were concentrated *in vacuo*, and the residue partitioned in ethyl acetate (200 mL) and 5% KHSO₄. The organic layer was washed with saturated sodium bicarbonate, and saturated sodium
15 chloride, dried over magnesium sulfate, filtered and concentrated to yield the crude product. Purification by silica gel chromatography using an eluant of 1:1 ethyl acetate: hexanes yielded 1.89g of pure
chloroacetamide.

20

EXAMPLE 27

- 5 Preparation of 2S-[(pyrrolidin-1-yl)
acetylamino]-N-[2R-hydroxy-3-[N¹-(2-methylpropyl)
-N¹-(4-methoxyphenyl sulfonyl)amino]-1S-
(phenylmethyl)propyl]-3S-methylpentanamide
- 10 Part A: To a cooled solution of N-t-Boc-L-isoleucine
 2.31g (10 mmol) and 2.00g (13.11 mmol) of N-
 hydroxybenzotriazole in 17 mL of N,N-dimethylformamide
 was added 1.91g (10 mmol) of EDC and stirred at 0°C for
 one hour. To this was added a solution of 4.0g
 15 (10 mmol) of 2R-hydroxy-3-[(2-methylpropyl)(4-
 methoxyphenylsulfonyl)amino]-1S-(phenylmethyl)
 propylamine in 6 mL of N,N-dimethylformamide and the
 solution stirred for 16 hours. The solvent was removed
 by rotary evaporation, replaced with ethyl acetate, and
 20 washed with saturated sodium bicarbonate, 5% citric acid
 and brine. The organics were dried over magnesium
 sulfate, filtered and concentrated to yield 6.1g of
 crude product, which was chromatographed on silica gel
 using and eluant of 1:1 ethyl acetate:hexane to produce
 25 5.12g (83% yield) of 2S-[(tert-butoxycarbonyl)amino]-N-
 [2R-hydroxy-3-[(3-methylpropyl)(4-methoxyphenylsulfonyl)
 amino]-1S-(phenylmethyl)propyl]-3S-methylpentanamide.
- Part B: 5.00g (8.0 mmol) of the product from Part A was
 30 dissolved in 20 mL of 4N HCl in dioxane and stirred for


20 minutes. The precipitated product was stripped two times from diethyl ether to yield 2S-(amino)-N-[2R-hydroxy-3-[(3-methylpropyl)(4-methoxyphenylsulfonyl)amino]-1S-(phenylmethyl)propyl]-3S-methylpentanamide hydrochloride, which was used in Part C without further purification.

Part C: The amine hydrochloride from part B was dissolved in 45 mL of methylene chloride and 3.0g N,N-diisopropylethylamine was added, followed by 1.22g (7.11 mmol) of chloroacetic anhydride. The solution was stirred at room temperature for 30 minutes. The contents were concentrated *in vacuo* and the residue was partitioned between ethyl acetate and water. The organic layer was washed with 5% citric acid, saturated sodium bicarbonate and brine. The organics were dried over magnesium sulfate filtered and concentrated *in vacuo* to yield 2S-[(chloroacetyl)amino]-N-[2R-hydroxy-3-[(3-methylpropyl)(4-methoxyphenylsulfonyl)amino]-1S-(phenylmethyl)propyl]-3S-methylpentanamide as a crude white foam, which was used in Part D without further purification.

Part D: 4.8g (8.0 mmol) of 2S-[(chloroacetyl)amino]-N-[2R-hydroxy-3-[(3-methylpropyl)(4-methoxyphenylsulfonyl)amino]-1S-(phenylmethyl)propyl]-3S-methylpentanamide was dissolved in 15 mL of tetrahydrofuran and to this was added water followed by 2.8 mL (40 mmol) of pyrrolidine and the reaction stirred for 1.5 hours. The solvents were removed *in vacuo* and the residue was dissolved in ethyl acetate. The mixture was washed successively with saturated sodium bicarbonate and brine, dried over magnesium sulfate filtered and concentrated *in vacuo* to yield 5.6g of crude product. Purification by silica gel flash chromatography using an eluant of 1-3% methanol in dichloromethane yielded 3.2g of 2S-[(pyrrolidin-1-


yl)acetylamino]-N-[2R-hydroxy-3-[N¹-(2-methylpropyl)-N¹-(4-methoxyphenylsulfonyl)amino]-1S-(phenylmethyl)propyl]-3S-methylpentanamide as a white solid.

5

EXAMPLE 28

Preparation of Carbamic acid, 2R-hydroxy-3-[[[2-
 10 aminobenzothiazol-6-yl)sulfonyl](2-methylpropyl)amino]-
1S-(phenylmethyl)propyl-, phenylmethyl ester

Carbamic acid, 2R-hydroxy-3-[[[4-
 aminophenyl)sulfonyl](2-methylpropyl)amino]-1S-
 15 (phenylmethyl)propyl-, phenylmethyl ester 0.30g
 (0.571 mmol) was added to a well mixed powder of
 anhydrous copper sulfate (1.20 g) and potassium
 thiocyanate (1.50 g) followed by dry methanol (6 mL) and
 the resulting black-brown suspension was heated at
 20 reflux for 2 hrs. The reaction mixture was filtered and
 the filtrate was diluted with water (5 mL) and heated at
 reflux. Ethanol was added to the reaction mixture,
 cooled and filtered. The filtrate upon concentration
 afforded a residue which was chromatographed (ethyl
 25 acetate:hexane 80:20) to afford 0.26g (78%) of the
 desired compound as a solid.

EXAMPLE 29

5 Preparation of Carbamic acid, 2R-hydroxy-3-[[[(2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-, phenylmethyl ester


Method 1: Carbamic acid, 2R-hydroxy-3-[[[(2-aminobenzothiazol-6-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-, phenylmethyl ester (0.25g,
 10 0.429 mmol) was added to a solution of isoamyl nitrite (0.116 mL, 0.858 mmol) in dioxane (5 mL) and the mixture was heated at 85°C. After the cessation of evolution of
 15 nitrogen, the reaction mixture was concentrated and the residue was purified by chromatography (hexane:ethyl acetate 5:3) to afford 0.130g (53%) of the desired product as a solid.

20 Method 2: Crude benzothiazole-6-sulfonyl chloride in ethyl acetate (100 mL) was added to N-[3S-benzyloxycarbonyl amino-2R-hydroxy-4-phenyl]-N-isobutylamine (1.03g, 2.78 mmol) followed by N-methylmorpholine (4 mL). After stirring at room
 25 temperature for 18 hr., the reaction mixture was diluted with ethyl acetate (100 mL), washed with citric acid (5%, 100 mL), sodium bicarbonate (saturated, 100 mL) and brine (100 mL), dried (MgSO₄) and concentrated *in vacuo*. The residue was chromatographed (silica gel, ethyl


acetate: hexane 1:1) to afford 0.340g (23%) of desired product.

EXAMPLE 30

5



and



10 Preparation of Carbamic acid, 2R-hydroxy-3-[[[(2-amino benzothiazol-5-yl)sulfonyl]](2-methylpropyl)amino]-1S-(phenylmethyl)propyl-, phenylmethyl ester; and Carbamic acid, 2R-hydroxy-3-[[[(2-aminobenzothiazol-7-yl)sulfonyl]](2-methylpropyl)amino]-1S-(phenylmethyl)propyl-, phenylmethyl ester

15


The carbamic acid, 2R-hydroxy-3-[(3-aminophenylsulfonyl)(2-methylpropyl)amino]-1S-(phenylmethyl)propyl-, phenylmethyl ester 0.36g (0.685 mmol) was added to a well mixed powder of anhydrous copper sulfate (1.44 g) and potassium thiocyanate (1.80 g) followed by dry methanol (10 mL) and the resulting black-brown suspension was heated at reflux for 2 hrs. The reaction mixture was filtered and the filtrate was diluted with

20

water (5 mL) and heated at reflux. Ethanol was added to the reaction mixture, cooled and filtered. The filtrate upon concentration afforded a residue which was chromatographed (ethyl acetate:hexane 1:1) to afford 0.18g (45%) of the 7-isomer as a solid. Further elution of the column with (ethyl acetate:hexane 3:2) afforded 0.80g (20%) afforded the 5-isomer as a solid.

EXAMPLE 31

10



Preparation of 3S-amino-1-[N-(2-methylpropyl)-N-(4-methoxyphenyl)sulfonyl]amino]-4-phenyl-2R-butanol

15

Part A: N-benzyloxycarbonyl-3(S)-amino-1-chloro-4-phenyl-2(S)-butanol

To a solution of N-benzyloxycarbonyl-L-phenylalanine chloromethyl ketone (75g, 0.2 mol) in a mixture of 800 mL of methanol and 800 mL of tetrahydrofuran was added sodium borohydride (13.17g, 0.348 mol, 1.54 equiv.) over 100 min. The solution was stirred at room temperature for 2 hours and then concentrated *in vacuo*. The residue was dissolved in 1000 mL of ethyl acetate and washed with 1N KHSO₄, saturated aqueous NaHCO₃, saturated aqueous NaCl, dried over anhydrous MgSO₄, filtered and concentrated *in vacuo* to give an oil. The crude product was dissolved in 1000 mL of hexanes at 60°C and allowed to cool to room temperature where upon

crystals formed that were isolated by filtration and washed with copious amounts of hexanes. This solid was then recrystallized from hot ethyl acetate and hexanes to provide 32.3g 43% of N-benzyloxycarbonyl-3(S)-amino-1-chloro-4-phenyl-2(S)-butanol, mp 150-151°C, FAB MS: MLi⁺ = 340.

Part B: 3(S)-[N-(benzyloxycarbonyl)amino]-1,2(S)-epoxy-4-phenylbutane

10

A solution of potassium hydroxide (6.52g, 0.116 mol, 1.2 equiv.) in 970 mL of absolute ethanol was treated with N-benzyloxycarbonyl-3(S)-amino-1-chloro-4-phenyl-2(S)-butanol (32.3g, 0.097 mol). This solution was stirred at room temperature for 15 minutes and then concentrated *in vacuo* to give a white solid. The solid was dissolved in dichloromethane and washed with water, dried over anhyd MgSO₄, filtered and concentrated *in vacuo* to give a white solid. The solid was crystallized from hexanes and ethyl acetate to give 22.3g, 77% of 3(S)-[N-(benzyloxycarbonyl)amino]-1,2(S)-epoxy-4-phenylbutane, mp 102-103°C, FAB MS: MH⁺ = 298.

Part C: N-[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenyl]N-isobutylamine

A solution of N-benzylcarbonyl-3(S)-amino-1,2-(S)-epoxy-4-phenyl butane (50.0g, 0.168 mol) and isobutylamine (246g, 3.24 mol, 20 equivalents) in 650 mL of isopropyl alcohol was heated to reflux for 1.25 hours. The solution was cooled to room temperature, concentrated *in vacuo* and then poured into 1 L of stirring hexane whereupon the product crystallized from solution. The product was isolated by filtration and air dried to give 57.56g, 92% of N[3(S)-benzyloxycarbonylamino-2(R)-


35

hydroxy-4-phenyl]-N-isobutylamine, mp 108.0-109.5°C, MH⁺
m/z=371.

Part D: phenylmethyl [2(R)-hydroxy-3-[N-(2-
5 methylpropyl)-N-(4-methoxyphenylsulfonyl)amino]-1S-
(phenylmethyl)propyl]carbamate

The amine from Part C (936.5 mg, 2.53 mmol) and
triethylamine (2.88.5 mg, 2.85 mmol) was dissolved in
20 mL of dichloromethane and treated with 4-
10 methoxybenzenesulfonyl chloride (461 mg, 2.61 mmol).
The solution was stirred at room temperature for 16
hours and then concentrated *in vacuo*. The residue was
dissolved in ethyl acetate and this solution was washed
with 1N KHSO₄, saturated aqueous NaHCO₃, brine, dried
15 over anhyd MgSO₄, filtered, and concentrated to give a
clear oil 1.234g. The oil was crystallized from a
mixture of ether and hexanes, 729.3 mg, 56.5% mp 95-
99°C, FAB MS: MH⁺ = 511.

20 Part E: 3S-amino-1-[N-(2-methylpropyl)-N-(4-
methoxyphenylsulfonyl)amino]-4-phenyl-2R-butanol
A solution of phenylmethyl [2(R)-hydroxy-3-[N-(2-
methylpropyl)-N-(4-methoxyphenylsulfonyl)amino]1-S-
(phenylmethyl) propyl carbamate (671.1 mg, 1.31 mmol)
25 from Part D in 10 mL of methanol was hydrogenated over
50 mg of 10% palladium on carbon at 40 psig at room
temperature for 15 hours. The catalyst was removed by
filtration through diatomaceous earth and the filtrate
concentrated to give a white foam, 474.5 mg, 96%, FAB
30 MS: MH⁺ = 377.

EXAMPLE 325 Preparation of 1,3-benzodioxole-5-sulfonyl chloride

Method 1: To a solution of 4.25g of anhydrous N,N-dimethylformamide at 0°C under nitrogen was added 7.84g of sulfonyl chloride, whereupon a solid formed. After
10 stirring for 15 minutes, 6.45g of 1,3-benzodioxole was added, and the mixture heated at 100°C for 2 hours. The reaction was cooled, poured into ice water, extracted with methylene chloride, dried over magnesium sulfate, filtered and concentrated to give 7.32g of crude
15 material as a black oil. This was chromatographed on silica gel using 20% methylene chloride/hexane to afford 1.9g of (1,3-benzodioxol-5-yl)sulfonyl chloride.


Method 2: To a 22 liter round bottom flask fitted with
20 a mechanical stirrer, a cooling condenser, a heating mantle and a pressure equalizing dropping funnel was added sulfur trioxide DMF complex (2778g, 18.1 moles). Dichloroethane (4 liters) was then added and stirring initiated. 1,3-Benzodioxole (1905g, 15.6 moles) as then
25 added through the dropping funnel over a five minute period. The temperature was then raised to 75°C and held for 22 hours (NMR indicated that the reaction was done after 9 hours.) The reaction was cooled to 26° and oxalyl chloride (2290g, 18.1 moles) was added at a rate
30 so as to maintain the temperature below 40°C (1.5 hours). The mixture was heated to 67°C for 5 hours followed by cooling to 16°C with an ice bath. The reaction was quenched with water (5l) at a rate which kept the temperature below 20°C. After the addition of

water was complete, the mixture was stirred for 10 minutes. The layers were separated and the organic layer was washed again twice with water (5l). The organic layer was dried with magnesium sulfate (500g) and filtered to remove the drying agent. The solvent was removed under vacuum at 50°C. The resulting warm liquid was allowed to cool at which time a solid began to form. After one hour, the solid was washed with hexane (400 mL), filtered and dried to provide the desired sulfonyl chloride (2823g). The hexane wash was concentrated and the resulting solid washed with 400 mL hexane to provide additional sulfonyl chloride (464g). The total yield was 3287g (95.5% based upon 1,3-benzodioxole).

Method 3: Dichloroethane (DCE), 2 liters, was added to a 30 L reactor fitted with condenser (0°C), two agitator mechanical stirrer, internal cooling coils heating mantel and nitrogen atmosphere/purge system. Sulfur trioxide•DMF complex (4856g, 31.7 moles) was then added over a 15 minute period. No temperature rise was observed. The reaction mixture was heated to 75°C. The material was completely dissolved in two hours. NMR analysis indicated that the reaction was complete in less than 5 hours. The reaction was allowed to cool overnight for convenience. The reaction mass was cooled to 15°C. A caustic scrubber (a 4L Erlenmeyer flask containing 2 L of 25% NaOH with subsurface addition) was attached to the top of the condenser. (The scrubber was changed when NaCl precipitation was significant). Oxalyl chloride (4041g, 31.84 moles) was added over a 1.5 hour period while maintaining the temperature between 11° and 15°C. The reaction mixture was allowed to come to room temperature over 30 minutes at which time gas evolution had ceased. NMR analysis after an additional hour at room temperature indicated that the

reaction was complete. The reaction mass was then cooled to 15°C and water (2 L) was added very slowly while keeping the temperature below 25°C. CAUTION: the initial addition of water is very exothermic. The first
5 50 mL of water caused the temperature to rise to 25°C. After the initial 2 L of water was added, an additional 6 L was then added quickly. The reaction mixture was stirred for 10 minutes. The stirring was stopped and the layers were allowed to separate. The water layer
10 was removed and the layers allowed to separate. The water layer was removed and the organic layer was washed twice with water (8 L). The organic layer was then dried over magnesium sulphate (1 Kg) which clarified the solution. The solution was filtered through a sintered
15 glass funnel in two batches and the residue from each was washed with DCE (1 L). The solvent was removed at 50°C in vacuo (ca. 100 mm of Hg to remove the majority of the solvent then 2 mm of Hg). The material solidified as it cooled to room temperature to yield the
20 desired sulfonyl chloride (5337g, 91.65% yield) which was used in the subsequent step without further purification.

Method 4: 1,4-benzodioxan-6-sulfonyl chloride was
25 prepared according to the procedure disclosed in EP 583960, incorporated herein by reference.

EXAMPLE 33

5 Preparation of 1-[N-[(1,3-benzodioxol-5-yl)
sulfonyl]-N-(2-methylpropyl)amino]-3(S)-
[bis(phenylmethyl)amino]-4-phenyl-2(R)-butanol


Method 1: To a 5000 mL, 3-necked flask fitted with a
 10 mechanical stirrer was added N-[3(S)-[N,N-
 bis(phenylmethyl)amino]-2(R)-hydroxy-4-phenylbutyl]-N-
 isobutylamine•oxalic acid salt (354.7g, 0.7 mole) and
 1,4-dioxane (2000 mL). A solution of potassium
 carbonate (241.9g, 1.75 moles) in water (250 mL) was
 15 then added. The resultant heterogeneous mixture was
 stirred for 2 hours at room temperature followed by the
 addition of 1,3-benzodioxole-5-sulfonyl chloride
 (162.2g, 0.735 mole) dissolved in 1,4-dioxane (250 mL)
 over 15 minutes. The reaction mixture was stirred at
 20 room temperature for 18 hours. Ethyl acetate (1000 mL)
 and water (500 mL) were charged to the reactor and
 stirring continued for another 1 hour. The aqueous
 layer was separated and further extracted with ethyl
 acetate (200 mL). The combined ethyl acetate layers
 25 were washed with 25% brine solution (500 mL) and dried
 over anhydrous magnesium sulfate. After filtering and
 washing the magnesium sulfate with ethyl acetate
 (200 mL), the solvent in the filtrate was removed under
 reduced pressure yielding the desired sulfonamide as an

107

viscous yellow foamy oil (440.2g 105% yield). HPLC/MS (electrospray) (m/z 601 $[M+H]^+$).

EXAMPLE 34

5



Preparation of 1-[N-[(1,3-benzodioxol-5-yl)sulfonyl]-N-(2-methylpropyl)amino]-3(S)-amino-4-phenyl-2(R)-butanol•methanesulfonic acid salt

Method 1: Crude 1-[N-[(1,3-benzodioxol-5-yl)sulfonyl]-N-(2-methylpropyl)amino]-3(S)-[bis(phenylmethyl)amino]-4-phenyl-2(R)-butanol (6.2g, 0.010 moles) was dissolved in methanol (40 mL). Methanesulfonic acid (0.969g, 0.010 moles) and water (5 mL) were then added to the solution. The mixture was placed in a 500 mL Parr hydrogenation bottle containing 20% Pd(OH)₂ on carbon (255 mg, 50% water content). The bottle was placed in the hydrogenator and purged 5 times with nitrogen and 5 times with hydrogen. The reaction was allowed to proceed at 35°C with 63 PSI hydrogen pressure for 18 hours. Additional catalyst (125 mg) was added and, after purging, the hydrogenation continued for an additional 20 hours. The mixture was filtered through celite which was washed with methanol (2 X 10 mL). Approximately one third of the methanol was removed under reduced pressure. The remaining methanol was removed by azeotropic distillation with toluene at 80 torr. Toluene was added in 15, 10, 10 and 10 mL

portions. The product crystallized from the mixture and was filtered and washed twice with 10 mL portions of toluene. The solid was dried at room temperature at 1 torr for 6 hours to yield the amine salt (4.5g, 84%).

5 HPLC/MS (electrospray) was consistent with the desired product (m/z 421 $[M+H]^+$).


Method 2:

10 Part A: N-[3(S)-[N,N-bis(phenylmethyl)amino]-2(R)-hydroxy-4-phenylbutyl]-N-isobutylamine•oxalic acid salt (2800g, 5.53 moles) and THF (4L) were added to a 22L round bottom flask fitted with a mechanical stirrer. Potassium carbonate (1921g, 13.9 moles) was dissolved in
15 water (2.8L) and added to the THF slurry. The mixture was then stirred for one hour. 1,3-benzodioxole-5-sulfonyl chloride (1281g, 5.8 moles) was dissolved in THF (1.4L) and added to the reaction mixture over 25 minutes. An additional 200 mL of THF was used to rinse
20 the addition funnel. The reaction was allowed to stir for 14 hours and then water (4 L) was added. This mixture was stirred for 30 minutes and the layers allowed to separate. The layers was removed and the aqueous layer washed twice with THF (500 mL). The
25 combined THF layers were dried with magnesium sulfate (500 g) for one hour. This solution was then filtered to remove the drying agent and used in subsequent reactions.

30 Part B: To the THF solution of crude 1-[N-[(1,3-benzodioxol-5-yl)sulfonyl]-N-(2-methylpropyl)amino]-3(S)-[bis(phenylmethyl)amino]-4-phenyl-2(R)-butanol was added water (500 mL) followed by methane sulfonic acid (531g, 5.5 moles). The solution was stirred to insure
35 complete mixing and added to a 5 gallon autoclave. Pearlman's catalyst (200g of 20% Pd(OH)₂ on C/ 50%

water) was added to the autoclave with the aid of THF (500 mL). The reactor was purged four times with nitrogen and four times with hydrogen. The reactor was charged with 60 psig of hydrogen and stirring at 450 rpm started. After 16 hours, HPLC analysis indicated that a small amount of the mono-benzyl intermediate was still present. Additional catalyst (50g) was added and the reaction was allowed to run overnight. The solution was then filtered through celite (500g) to remove the catalyst and concentrated under vacuum in five portions. To each portion, toluene (500 mL) was added and removed under vacuum to azeotropically removed residual water. The resulting solid was divided into three portions and each washed with methyl *t*-butyl ether (2 L) and filtered. The residual solvent was removed at room temperature in a vacuum oven at less than 1 torr to yield the 2714g of the expected salt.

If desired, the product can be further purified by the following procedure. A total of 500 mL of methanol and 170g of material from above was heated to reflux until it all dissolved. The solution was cooled, 200 mL of isopropanol added and then 1000-1300 mL of hexane, whereupon a white solid precipitated. After cooling to 0°C, this precipitate was collected and washed with hexane to afford 123g of the desired material. Through this procedure, the original material which was a 95:5 mixture of alcohol diastereomers was greater than 99:1 of the desired diastereomer.

EXAMPLE 35

5 Preparation of 2R-hydroxy-3-[[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl) propylamine


Part A: Preparation of 2R-hydroxy-3-[[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl) propylcarbamic acid phenylmethyl ester
10

To a solution of 3.19 g (8.6 mmol) of N-[3S-benzyloxy carbonylamino-2R-hydroxy-4-phenyl]-N-isobutylamine in
15 40mL of anhydrous methylene chloride, was added 0.87g of triethylamine. The solution was cooled to 0°C and 1.90g of (1,3-benzodioxol-5-yl)sulfonyl chloride was added, stirred for 15 minutes at 0°C, then for 17 hours at room temperature. Ethyl acetate was added, washed with 5%
20 citric acid, saturated sodium bicarbonate, brine, dried and concentrated to yield crude material. This was recrystallized from diethyl ether/hexane to afford 4.77g of pure 2R-hydroxy-3-[[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl) propylcarbamic acid phenylmethyl ester.
25

Part B: Preparation of 2R-hydroxy-3-[[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl) propylamine

A solution of 4.11g of carbamic acid, 2R-hydroxy-3-
[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-
1S-(phenylmethyl)propyl-, phenylmethyl ester in 45 mL of
tetrahydrofuran and 25 mL of methanol was hydrogenated
5 over 1.1g of 10% palladium-on-carbon under 50 psig of
hydrogen for 16 hours. The catalyst was removed by
filtration and the filtrate concentrated to afford 1.82g
of the desired 2R-hydroxy-3-[[(1,3-benzodioxol-5-
yl)sulfonyl](2-methylpropyl)amino]-1S-
10 (phenylmethyl)propylamine.

EXAMPLE 36



15

Preparation of Benzothiazole-6-sulfonyl Chloride

Part A: Preparation of N-(4-Sulfonamidophenyl)thiourea

20 A mixture of sulfanilamide (86g, 0.5 mole), ammonium
thiocyanate (76.0g, 0.5 mole) and dilute hydrochloric
acid (1.5 N, 1 L) was mechanically stirred and heated at
reflux for 2 hr. About 200 mL of water was distilled
off and concentration of the reaction mixture afforded a
25 solid. The solid was filtered and was washed with cold
water and air dried to afford 67.5g (59%) of the desired
product as a white powder.

30 Part B: Preparation of 2-Amino-6-
sulfonamidobenzothiazole

Bromine (43.20g, 0.27 mol) in chloroform (200 mL) was
added over 1 hr. to a suspension of N-(4-
sulfonamidophenyl)-thiourea (27.72, 0.120 mol) in

chloroform (800 mL). After the addition, the reaction mixture was heated at reflux for 4.5 hr. The chloroform was removed *in vacuo* and the residue was repeatedly distilled with additional amounts of chloroform. The solid obtained was treated with water (600 mL) followed by ammonium hydroxide (to make it basic), then was heated at reflux for 1 hr. The cooled reaction mixture was filtered, washed with water and air dried to afford 22.0g (80%) of the desired product as a white powder.

10

Part C: Preparation of Benzothiazole-5-sulfonic acid

A suspension of 2-amino-6-sulfonamido-benzothiazole (10.0g, 43.67 mmol) in dioxane (300 mL) was heated at reflux. Isoamylnitrite (24 mL) was added in two portions to the reaction mixture. Vigorous evolution of gas was observed (the reaction was conducted behind a shield as a precaution) and after 2 hr., a red precipitate was deposited in the reaction vessel. The reaction mixture was filtered hot, and the solid was washed with dioxane and was dried. The solid was recrystallized from methanol-water. A small amount of a precipitate was formed after 2 days. The precipitate was filtered off and the mother liquor was concentrated *in vacuo* to afford a pale red-orange solid (8.0g, 85%) of pure product.

20

25

Part D: Preparation of 6-Chlorosulfonylbenzothiazole


Thionyl chloride (4 mL) was added to a suspension of the benzothiazole-6-sulfonic acid (0.60g, 2.79 mmol) in dichloroethane (15 mL) and the reaction mixture was heated at reflux and dimethylformamide (5 mL) was added to the reaction mixture to yield a clear solution. After 1.5 hr. at reflux, the solvent was removed *in*

35

vacuo and excess HCl and thionyl chloride was chased by evaporation with dichloroethane.


EXAMPLE 37

5



Preparation of N-[2R-hydroxy-3-[[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[[(pyrrolidin-1-yl)acetyl]amino]-3,3-
 10 dimethylbutanamide

Part A: Preparation of N-[2R-hydroxy-3-[[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[[(phenylmethoxycarbonyl)amino]-3,3-
 15 dimethylbutanamide




To a solution of 118.8g (0.776 mol) of N-hydroxybenzotriazole and 137.1g (0.52 mol) of N-carbobenzyloxycarbonyl-L-tert-leucine in 750 mL of anhydrous DMF at 0°C under a nitrogen atmosphere, was added 109.1g (0.57 mol) of EDC. After stirring at 0°C for 2 hours, a solution of 273g (0.53 mol) of 2R-hydroxy-3-[[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propylamine

20
25

methanesulfonate, previously neutralized with 228 mL (210g, 2.08 mol) of 4-methylmorpholine, in 250 mL of anhydrous DMF was added. After stirring at 0°C for 30 minutes, the mixture stirred at room temperature for 18
5 hours. The solvents were removed under reduced pressure at 45°C, 1.5 L of ethyl acetate added, washed with 5% citric acid, saturated sodium bicarbonate, brine, dried over anhydrous magnesium sulfate, filtered and concentrated to afford 400g of crude material. This was
10 chromatographed in 3 batches on a Prep 2000 Chromatogram on silica gel using 20%-50% ethyl acetate/hexane as eluent to yield 320g of purified material, m/e=674 (M+Li), 98% by HPLC.


15 Part B: Preparation of N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl)sulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl) propyl]-2S-amino-3,3-dimethylbutanamide



20 A solution of 312g of the Cbz compound from above in 1L of tetrahydrofuran was hydrogenated in the presence of 100g of 4% palladium-on-carbon catalyst under 60 psig of hydrogen for 6 hours at room temperature. The catalyst was removed by filtration and the solvents removed under
25 reduced pressure to afford 240g of the desired compound.

Part C: Preparation of N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl)sulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl) propyl]-2S-[(chloroacetyl) amino]-3,3-
30 dimethylbutanamide


115



To a solution of 234.3g (0.439 mol) of the amine from above in 1L of methylene chloride, was added 80 mL
 5 (59.5g, 0.46 mol) of diisopropylethylamine, followed by the slow addition at room temperature of 78.8g (0.46 mol) of chloroacetic anhydride while maintaining the temperature below 35°C. After stirring for an additional 1 hour, analysis by HPLC indicated a small
 10 amount of starting material was still present, and 1.5g of chloroacetic anhydride was added. After 10 minutes, the solvents were removed under reduced pressure, 1 L ethyl acetate added, washed with 5% citric acid, saturated sodium bicarbonate, brine, dried over
 15 anhydrous magnesium sulfate, filtered and concentrated to yield 314g of crude material. This was chromatographed in 3 portions on a Prep 2000 Chromatogram on silica gel using 20-50% ethyl acetate/hexane to afford 165g of the desired compound,
 20 m/e=616 (M+Li), 98% by HPLC.

Part D: Preparation of N-[2R-hydroxy-3-[[1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl) propyl]-2S-[[pyrrolidin-1-yl)acetyl]amino]-3,3-dimethylbutanamide
 25

116




To 164.2g (0.27 mol) of chloroacetyl compound from above was added 500 mL of tetrahydrofuran, the solvent removed under reduced pressure to remove any ethyl acetate, and
5 then 350 mL of tetrahydrofuran was added. To this solution at 10°C was added 130 mL (1.56 mol) of pyrrolidine. After 1 hour, the solvents were removed under reduced pressure, 1 L ethyl acetate added, washed with saturated sodium bicarbonate, brine, dried over
10 anhydrous magnesium sulfate, filtered and concentrated to afford 185g of crude material, which was assayed by HPLC to be 98.9% purity. This was split into 3 portions and chromatographed on a Prep 2000 Chromatogram using first 50% ethyl acetate/hexane, followed by 5%
15 methanol/ethyl acetate to afford 160g of purified material (99% by HPLC). This was then recrystallized from 460 mL of diethyl ether and 70 mL of hexane to afford 121g of the desired product (>99% by HPLC),
m/e=651(M+Li), mp=112-114°C.


20

EXAMPLE 38

Preparation of N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl) sulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl]-2S-[[(pyrrolidino) acetyl] amino]-3S-methylpentanamide



Part A: Preparation of N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl) sulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl]-2S-[[(1,1-dimethylethoxy) carbonyl] amino]-3S-methylpentanamide




15

To a cooled solution of N-t-Boc-L-isoleucine 2.02g (8.74 mmol) and 2.00g (13.11 mmol) of N-hydroxybenzotriazole in 17 mL of N,N-dimethylformamide was added 1.84g (9.61 mmol) of EDC and stirred at 0°C for one hour. To this was added a solution of 3.67g (8.74 mmol) of 2R-hydroxy-3-[[(1,3-benzodioxol-5-yl) sulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl amine in 6 mL of N,N-dimethylformamide and the solution stirred for 16 hours. The solvent was removed in vacuo, replaced

with ethyl acetate, and washed with saturated sodium bicarbonate, 5% citric acid and brine. The organic layers were dried over magnesium sulfate, filtered and concentrated to yield 6.1g of crude product, which was chromatographed on silica gel using 1:1 ethyl acetate:hexane eluant to produce 4.3g (78% yield) of N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl) sulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl]-2S-[[(1,1-dimethylethoxy) carbonyl]amino]-3S-methylpentanamide.

10

Part B: Preparation of N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl) sulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl]-2S-amino-3S-methylpentanamide•hydrochloride salt




15

N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl) sulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl]-2S-[[(1,1-dimethylethoxy) carbonyl]amino]-3S-methylpentanamide (4.29g, 6.77 mmol) was dissolved in 20 mL of 4N HCl in dioxane and stirred for 20 minutes. The precipitated product was stripped two times from diethyl ether and the crude hydrochloride salt was used in subsequent reactions.

25

Part C: Preparation of N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl) sulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl]-2S-[(chloroacetyl) amino]-3S-methylpentanamide


119



N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl) sulfonyl] (2-
 methylpropyl) amino]-1S-(phenylmethyl)propyl]-2S-amino-
 5 3S-methylpentanamide•hydrochloride salt (3.62g, 6.77
 mmol) was dissolved in 45 mL of methylene chloride and
 to this was added 1.3g (10.15 mmol) of N,N-
 diisopropylethyl amine to neutralize the salt, and
 another 0.923g (7.10 mmol) of diisopropylethyl amine
 10 followed by 1.22g (7.11 mmol) of chloroacetic anhydride.
 The solution was stirred at room temperature for 30
 minutes. The contents were concentrated on a rotory
 evaporator and the residue was partitioned between ethyl
 acetate and water. The organic layer was washed with 5%
 15 citric acid and then saturated sodium bicarbonate and
 brine. The organic layers were dried over magnesium
 sulfate filtered and concentrated to yield 4.12g of
 crude product. Recrystallization from ethyl acetate
 hexane yielded 3.5g (85% yield) of N-[2R-hydroxy-3-
 20 [[(1,3-benzodioxol-5-yl) sulfonyl] (2-methylpropyl) amino]-
 1S-(phenylmethyl)propyl]-2S-[(chloroacetyl) amino]-3S-
 methylpentanamide, as a white solid; mass spectrum
 m/z=616 (M+Li).

25 Part D: Preparation of N-[2R-hydroxy-3-[[(1,3-
 benzodioxol-5-yl) sulfonyl] (2-methylpropyl-amino)-1S-
 (phenylmethyl)propyl]-2S-[[(pyrrolidino) acetyl] amino]-
 3S-methylpentanamide

120




N-[2R-hydroxy-3-[[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-
 5 [(chloroacetyl)amino]-3S-methylpentanamide (5.18g, 8.49 mmol) was dissolved in 15 mL of tetrahydrofuran and to this was added 0.5 mL of water followed by 3.62g (50.9 mmol) of pyrrolidine and the reaction stirred for 1.5 hours. The solvents were removed by rotary evaporation
 10 and replaced with ethyl acetate. The solution was washed successively with saturated sodium bicarbonate and brine, dried over magnesium sulfate, filtered and concentrated to yield 5.6g of crude product. Purification by silica gel flash chromatography using an eluant of 1-3% methanol
 15 in dichloromethane yielded 3.8g of N-[2R-hydroxy-3-[[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[pyrrolidin-1-yl]acetyl]amino]-3S-methylpentanamide as a white solid.

20


EXAMPLE 39

Preparation of N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[pyrrolidin-1-yl]acetyl]amino]-3-methylbutaneamide
 25

121



Part A : Preparation of N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[(phenylmethoxycarbonyl)amino]-3-methylbutaneamide



10 A 250 mL round bottom flask equipped with magnetic stir bar was charged with N-Cbz-L-Valine (4.22g, 16.8 mmol) in 20 mL DMF. The solution was cooled to 0°C and charged with HoBt (2.96, 21.9 mmol) and EDC (3.22g, 16.8 mmol) and stirred 1 hour. The reaction was then charged


15 with N-methylmorpholine (1.7g, 16.8 mmol), 2R-hydroxy-3-[[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propylamine (7.55g, 14.6 mmol) in 30 mL of DMF. The reaction was stirred overnight at room temperature then concentrated *in vacuo* and partitioned

20 between ethyl acetate and 5% Citric acid. The combined organic layers were washed with saturated sodium bicarbonate and brine, and dried over sodium sulfate. Concentration *in vacuo* yielded 10g crude product. Purification by Prep HPLC (20-40% ethyl acetate/hexane)

25 yielded 5.8g (61 %) of the desired compound.


Part B : Preparation of N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-amino-3-methylbutaneamide

5



A 300 mL Fisher-Porter vessel equipped with magnetic stir bar was charged with N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[(phenylmethoxycarbonyl)amino]-3-methylbutaneamide (5.8 g), 2.3g of 10% Pd-C in 75 mL tetrahydrofuran. The reaction was charged with 50 psi H₂ and hydrogenated overnight. The reaction mixture was filtered thru Celite and concentrated *in vacuo* to yield 4.4g of white foam that was used in subsequent reactions without further purification.

Part C : Preparation of N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[(chloroacetyl)amino]-3-methylbutaneamide




A 250 mL round bottom flask equipped with magnetic stir bar was charged with crude N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-amino-3-methylbutaneamide (4.35 g) in 60 mL CH₂Cl₂. The reaction was charged with 1.19g diisopropylamine followed by 1.5g of chloroacetic anhydride and stirred until TLC indicated no remaining starting material (about 1.5 hours). The reaction was concentrated *in vacuo* and partitioned between ethyl acetate and saturated sodium bicarbonate. The combined organic layers were washed with brine, and dried over sodium sulfate. Concentration *in vacuo* yielded 5.17g of desired product that was used in subsequent reactions without further purification.

15

Part D : Preparation of N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[pyrrolidin-1-yl]acetyl]amino]-3-methylbutaneamide

20




A 250 mL round bottom flask equipped with magnetic stir bar was charged with crude N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[chloroacetyl]amino]-3-methylbutaneamide (4.99 g) and 3.57g pyrrolidine in 20 mL tetrahydrofuran and 0.5 mL H₂O. After 45 minutes at room temperature, TLC analysis indicated complete reaction. The reaction was concentrated *in vacuo* and

30

partitioned between ethyl acetate and saturated sodium bicarbonate. The combined organic layers were washed with brine and dried over sodium sulfate. Concentration *in vacuo* yielded 5.2g crude product. Purification by
 5 Prep HPLC (3 % MeOH/ 57 % ethyl acetate/40 % hexane) gave 4.3g pure N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[pyrrolidin-1-yl]acetyl]amino]-3-methylbutaneamide.


10

EXAMPLE 40

Preparation of N-[[2R-hydroxy-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[pyrrolidin-1-yl]acetyl]amino]-3-methylbutaneamide
 15

To a solution of 2.4g N-[[2R-hydroxy-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[chloroacetyl]amino]-3-methylbutaneamide in 65 mL THF was added 0.68 mL (2.0 eq.) of pyrrolidine and the reaction mixture was stirred at room temperature overnight. The reaction was
 25 concentrated *in vacuo* and partitioned between ethyl acetate and saturated aqueous sodium bicarbonate. The combined organics were washed with brine, dried, and concentrated *in vacuo* to a white foam. Trituration with diethyl ether yielded 1.0g product (98 % pure by HPLC).

30

EXAMPLE 41

Preparation of N-[2R-hydroxy-3-[(phenylsulfonyl)(2-
 5 methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-
 [[pyrrolidin-1-yl]acetyl]amino]-3S-methylpentanamide

Part A: Preparation of N-[2R-hydroxy-3-[[1,3-
 benzodioxol-5-yl]sulfonyl](2-methylpropyl)amino]-1S-
 10 (phenylmethyl)propyl]-2S-[[phenylmethoxy]
 carbonyl]amino]-3S-methylpentanamide

A solution of 6.0g (22.6 mmol) of N-CBZ-L-isoleucine in
 45 mL of anhydrous DMF was cooled to 0°C and charged
 15 with 4.0g (29.5 mmol) of HOBT and 4.3g (22.6 mmol) of
 EDC. The ice bath was removed after 20 minutes and
 stirring was continued for an additional 40 minutes.
 The reaction solution was then charged with a solution
 of 7.4g (19.7 mmol) of 2R-hydroxy-3-[(phenylsulfonyl)
 20 (2-methylpropyl)amino]-1S-(phenylmethyl)propylamine and
 2.3g (22.6 mmol) of 4-methylmorpholine in 25 mL of
 anhydrous DMF and stirred for 18 hours. The solvents
 were removed *in vacuo* and the residue was partitioned
 between 300 mL of ethyl acetate and 120 mL of 5%
 25 potassium hydrogen sulfate solution. The layers were
 separated, and the organic layer was washed with 120 mL
 each of saturated sodium bicarbonate solution, water and
 brine, then dried over anhydrous magnesium sulfate,
 filtered and concentrated *in vacuo* to afford 13g of
 30 crude material. The crude material was crystallized in

ethanol. The solid was isolated by filtration, rinsed with one 50 mL portion of hexane, and air-dried to yield 10.3g (84%) of the desired product, m/e = 630 (M+Li).

5 Part B: Preparation of N-[2R-hydroxy-3-[[1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-amino-3S-methylpentanamide

A Fischer-Porter bottle equipped with a magnetic stir
10 bar was charged with 10.2g (16.4 mmol) of the product from Part A and 75 mL of tetrahydrofuran (THF). The solution was hydrogenated in the presence of 4g of 10% palladium-on-carbon catalyst (50% water by weight) under 50 psig of hydrogen for 3 hours at room temperature.
15 The catalyst was removed by filtration, and the solvents removed under reduced pressure. The residue was dissolved in 300 mL of ethyl acetate and washed with 120 mL each of saturated sodium bicarbonate solution and brine, then dried over anhydrous magnesium sulfate,
20 filtered and concentrated under reduced pressure to afford 7.4g of the desired product, m/e = 490 (M+H).


Part C: Preparation of N-[2R-hydroxy-3-
25 [(phenylsulfonyl)(2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[(pyrrolidin-1-yl)acetyl]amino]-3S-methylpentanamide

A solution of 3.4g (20.2 mmol) of pyrrolidineacetic acid hydrochloride in 45 mL of anhydrous DMF was cooled to
30 0°C and charged with 3.1g (22.7 mmol) of HOBT and 3.3g (17.4 mmol) of EDC. The ice bath was removed after 20 minutes and stirring was continued for an additional 40 minutes. The reaction solution was then charged with a solution of 7.4g (16.5 mmol) of the amine from Part B
35 and 4.1g (40.4 mmol) of 4-methylmorpholine in 25 mL of anhydrous DMF and stirred for 17 hours. The solvents

were removed *in vacuo* and the residue was partitioned between 300 mL of ethyl acetate and 120 mL of 5% potassium hydrogen sulfate solution. The layers were separated, and the organic layer was washed with 120 mL
5 each of saturated sodium bicarbonate solution, water and brine, then dried over anhydrous magnesium sulfate, filtered and concentrated to afford 8.7g of crude material. The coupling reaction was run again using 2.3g (13.9 mmol) of pyrrolidinylacetic acid
10 hydrochloride, 2.1 grams (15.5 mmol) of HOBT, 2.3 grams (12.0 mmol) of EDC, 2.8 grams (27.3 mmol) of 4-methylmorpholine, and the 8.7 grams of crude product in place of the amine from Part B. The reaction work-up was repeated and yielded 8.3 grams of crude product.
15 Purification was accomplished using a Prep 2000 chromatograph on silica gel using 40-70% (5% methanol/95% ethyl acetate)/hexane and yielded 5.2 grams (57%) of the desired product as a white solid, m/e = 607 (M+Li).

EXAMPLE 42


Preparation of N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[pyrrolidin-1-yl]acetyl]amino]-3-(methylsulfonyl)propaneamide•hydrochloride salt



10

Part A: Preparation of N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[1,1-dimethylethoxy]carbonyl]amino]-3-(methylthio)propaneamide

15




N-t-Boc-S-methyl-(L)-cysteine (2.80 g, 11.9 mmol), 1-Hydroxybenzotriazole hydrate (1.92 g, 12.5 mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.27 g, 11.9 mmol) were mixed in N,N-dimethylformamide (30.0 mL) at 0°C for 10 min. N-Methylmorpholine (3.03 g, 33.0 mmol) was added and the solution stirred an additional 10 min at 0°C. 2R-Hydroxy-3-[[1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propylamine (5.00

25

g, 11.9 mmol) was added and the solution was warmed to room temperature and stirred for 2 hours. The reaction mixture was poured into ethyl acetate (500 mL) and washed with 10% aqueous hydrochloric acid (3 X 100 mL),
 5 saturated aqueous sodium bicarbonate (3 X 100 mL) and brine (2 X 100 mL). The organic layer was dried over sodium sulfate and percolated through a bed of silica gel (50 g). The desired product (7.13 g, 11.19 mmol, 93% yield) was obtained as a white solid by removal of
 10 the solvent at reduced pressure; m/e calcd 637; found (M + Li) 644.


Part B: Preparation of N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[1,1-dimethylethoxy) carbonyl]amino]-3-(methylsulfonyl)propaneamide
 15



N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[1,1-dimethylethoxy) carbonyl]amino]-3-(methylthio)propaneamide (7.10 g, 11.1 mmol) was dissolved in methanol (150 mL). A solution of oxone® (20.8 g, 33.9 mmol) in water (150 mL) was added dropwise
 25 to the solution at room temperature over 1.5 hours. The solution became cloudy and a precipitate formed during the addition. The reaction was stirred for an additional 1 hour and tetrahydrofuran (200 mL) was added. After an additional 1 hour of mixing the
 30 solution was poured into ethyl acetate (1000 mL) and

washed with water (3 x 200 mL) followed by brine (2 x 300 ml). The organic layer was dried over anhydrous sodium sulfate and solvent removed at reduced pressure. The desired product (5.75 g, 8.86 mmol, 79% yield) was
 5 obtained as an off white solid; m/e calcd 669; found (M+H) 670.


Part C: Preparation of N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-amino-3-(methylsulfonyl)propaneamide•hydrochloride salt
 10



N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[(1,1-dimethylethoxy)carbonyl]amino]-3-(methylsulfonyl)propaneamide (5.5 g, 8.20 mmol) was dissolved in dichloromethane (100 mL) at room temperature. Anhydrous hydrochloric acid was bubbled through the solution for 15 min. The solution was stirred at room temperature
 15
 20 for 2 hours and the solvent was removed at reduced pressure. The desired product (4.91 g, 8.10 mmol, 99 % yield) was obtained as a white solid; m/e calcd 569; found (M+Li) 576.


25 Part D: Preparation of N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[(chloroacetyl)amino]-3-(methylsulfonyl)propaneamide

131



N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-amino-3-(methylsulfonyl)propaneamide•hydrochloride salt (4.00 g, 5
6.59 mmole) was mixed at room temperature in acetonitrile (40 mL). Triethylamine (2.10 g, 21.0 mmol) and chloroacetic anhydride (1.12 g, 6.59 mmol) were added. The solution was stirred at room temperature for 16 hours and poured into ethyl acetate (250 mL). The
10 solution was washed with 10% aqueous acetic acid (2 x 100 mL), saturated aqueous sodium bicarbonate (2 x 100 mL), and brine (2 x 100 mL). The organic layer was dried over anhydrous sodium sulfate and solvent removed at reduced pressure. The product (1.20 g, 1.85 mmol,
15 28% yield) was obtained as a white solid by crystallization from ethyl acetate and hexanes; m/e calcd 645; found (M+Li) 652.

Part E: Preparation of N-[[2R-hydroxy-3-[(1,3-
20 benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[pyrrolidin-1-yl)acetyl]amino]-3-(methylsulfonyl)propaneamide



N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[(chloroacetyl)amino]-3-(methylsulfonyl)propaneamide (1.2 g, 1.85 mmol) and pyrrolidine (0.79 g, 11.14 mmol) were mixed together in tetrahydrofuran (12.0 mL) at room temperature for 5 hours. The solvent was removed at reduced pressure and the residue was taken up in ethyl acetate (150 mL). The solution was washed with saturated sodium bicarbonate (1 x 100 mL), saturated ammonium chloride (1 x 100 mL), and finally saturated sodium bicarbonate (1 x 100 mL). The organic layer was dried over anhydrous sodium sulfate and solvent removed at reduced pressure. A white foam was collected. The product (653 mg, 0.95 mmol, 52% yield) was obtained as a white solid; m/e calcd 680; found (M+Li) 687.

Part F: Preparation of N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[pyrrolidin-1-yl]acetyl]amino]-3-(methylsulfonyl)propaneamide hydrochloride salt

N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[pyrrolidin-1-yl]acetyl]amino]-3-(methylsulfonyl)propaneamide (300 mg, 0.44 mmol) was dissolved in acetonitrile (15.0 mL). Concentrated aqueous hydrochloric acid (100 uL, 1.2 mmol) was added and the solvent was removed at reduced pressure. The residue was taken up in acetonitrile (30 mL) and solvent removed at reduced pressure. The residue was taken up in water (10 mL) and solvent removed at reduced pressure. The aqueous solvent treatment was repeated two more times. The resulting white foam was dried for 16 hours at reduced pressure (0.5 mm Hg) at room temperature and the further dried over phosphorous pentoxide at reduced pressure (0.5 mm Hg) for 72 hours.


The hydrochloric acid salt (313 mg, 0.44 mmol) was obtained as a white foam; m/e calcd 680; found (M+Li) 687.

5


EXAMPLE 43

Preparation of N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[pyrrolidin-1-yl]acetyl]amino]-3-methyl-3-(methylsulfonyl)butaneamide•hydrochloride salt

10



15 Part A: Preparation of N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[1,1-dimethylethoxy]carbonyl]amino]-3-methyl-3-(methylthio)butaneamide




20 The N-t-boc-S-methyl-L-penicillamine dicyclohexylamine salt (4.00g, 9.00 mmol), 1-Hydroxybenzotriazole hydrate (1.69 g, 11.00 mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.71 g, 9.00 mmol) were mixed in dimethylformamide (60.0 mL) at room

temperature. The heterogeneous mixture was stirred for 1 hour and 2R-hydroxy-3-[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propylamine (3.78 g, 9.00 mmol) was added
 5 and the heterogenous mixture was stirred for 16 hours. The solution was poured into ethyl acetate (600 mL) and washed with 10% aqueous acetic acid (2 x 300 mL), saturated aqueous sodium bicarbonate (2 x 300 mL) and brine (300 mL). The solution was dried over sodium
 10 sulfate and the solvent was removed *in vacuo*. The desired product was purified by flash chromatography (0-80% ethyl acetate/hexanes on silica gel). The product (5.21 g, 7.83 mmol, 87% yield) was obtained as a white foam; m/e calcd 665; found (M+Li) 672.

15

Part B: Preparation of N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[(1,1-dimethylethoxy)carbonyl] amino]-3-methyl-3-(methylsulfonyl)butaneamide




20

N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[(1,1-dimethylethoxy)carbonyl] amino]-3-methyl-3-(methylthio)butaneamide (5.01 g, 7.53 mmol) was
 25 dissolved in tetrahydrofuran (250 mL). A solution of oxone[®] (13.8 g, 22.6 mmol) in water (250 mL) was added dropwise to the solution at room temperature over 2 hours. The solution became cloudy and a precipitate formed during the addition. The solution was poured
 30 into ethyl acetate (500 mL) and washed with water (3 x

200 mL) followed by brine (2 x 300 mL). The organic layer was dried over anhydrous sodium sulfate and solvent removed *in vacuo*. The product (4.72 g, 6.77 mmol, 89% yield) was obtained as a white foam; m/e calcd
 5 697; found (M+Li) 704.


Part C: Preparation of N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-amino-3-methyl-3-
 10 (methylsulfonyl)butaneamide hydrochloride salt



N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[(1,1-dimethylethoxy)carbonyl] amino]-3-methyl-3-
 15 (methylsulfonyl)butaneamide (4.51 g, 6.46 mmol) was dissolved in dichloromethane (200 mL) at room temperature. Anhydrous hydrochloric acid was bubbled through the solution for 30 min. The solution was stirred at room temperature for 1 hour and the solvent
 20 was removed *in vacuo*. The product (4.02 g, 6.35 mmol, 99% yield) was obtained as a white solid; m/e calcd 697; found (M+Li) 704.


Part D: Preparation of N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[(chloroacetyl)amino]-3-methyl-3-(methylsulfonyl)butaneamide
 25

136



N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-amino-3-methyl-3-(methylsulfonyl)butaneamide hydrochloride salt
 5 (3.90 g, 6.15 mmol) was mixed at room temperature in acetonitrile (40 mL). Triethylamine (1.86 g, 18.45 mmol) and chloroacetic anhydride (1.05 g, 6.15 mmol) were added. The solution was stirred at room temperature for 16 hours and poured into ethyl acetate
 10 (250 mL). The solution was washed with 10% aqueous acetic acid (2 x 100 mL), saturated aqueous sodium bicarbonate (2 x 100 mL), and brine (2 x 100 mL). The organic layer was dried over anhydrous sodium sulfate and solvent was removed *in vacuo*. A yellow oil (4.3 g)
 15 was obtained and purified by flash chromatography (silica gel, 50-75% ethyl acetates in hexanes. The product (2.15 g, 3.18 mmol, 52% Yield) was obtained as a white foam; m/e calcd 674; found (M+Li) 681.

20 Part E: Preparation of N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[pyrrolidin-1-yl]acetyl]amino]-3-methyl-3-(methylsulfonyl)butaneamide



N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[(chloroacetyl)amino]-3-methyl-3-(methylsulfonyl)butaneamide (2.06 g, 3.05 mmol) and pyrrolidine (2.16 g, 5 30.5 mmol) were mixed together in tetrahydrofuran (30.0 mL) at room temperature for 3 hours. The solvent was removed at reduced pressure. A light yellow oil was obtained which was dissolved in methanol (20 mL) and the solvent was removed *in vacuo*. The product (2.09 g, 2.95 10 mmol, 96% yield) was obtained as a yellow foam; m/e calcd 708; found (M+H) 709.

Part F: Preparation of N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S- 15 (phenylmethyl)propyl]-2S-[[pyrrolidin-1-yl]acetyl]amino]-3-methyl-3-(methylsulfonyl)butaneamide•hydrochloride salt


N-[[2R-hydroxy-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S- 20 [[pyrrolidin-1-yl]acetyl]amino]-3-methyl-3-(methylsulfonyl)butaneamide (300 mg, 0.42 mmol) was dissolved in dichloromethane (10 mL). Anhydrous hydrochloric acid was added for 1 min and the dichloromethane solution was 25 reduced to a volume of about 2 mL. The solution was added dropwise to hexanes (50 mL) and the product precipitated. The desired salt (295 mg, 0.40 mmol) was collected in a buchner funnel by vacuum filtration as a yellow solid; m/e calcd 708; found (M+H) 709.

30


EXAMPLE 44

Preparation of N-[[2R-hydroxy-3-[[[(1,1-dimethylethoxy)carbonyl](2-methylpropyl)amino]-1S- 35 (phenylmethyl)propyl]-2S-[[pyrrolidin-1-yl]acetyl]amino]-3,3-dimethylbutanamide

138




Part A: Preparation of N-[(1,1-
 5 dimethylethoxy)carbonyl]-N-[2-methylpropyl]-3S-[N¹-
 (phenylmethoxycarbonyl)amino]-2R-hydroxy-4-
 phenylbutylamine



A solution of N-[3S-[N¹-(benzyloxycarbonyl)amino]-2R-
 10 hydroxy-4-phenylbutyl]-N-(2-methylpropyl)amine (18.5 g,
 50 mmol), BOC-ON (12.35 g, 50 mmol) and triethylamine (7
 mL) in tetrahydrofuran (400 mL) was stirred at room
 temperature for 18 hours and then concentrated *in vacuo*.
 The residue was dissolved in dichloromethane (1 L) and
 15 washed with sodium hydroxide (5 % (2 X 200 mL) and
 brine, dried (MgSO₄) and then concentrated *in vacuo* to
 afford 23.5 g (quantitative yield) of the pure desired
 product.

20 Part B: Preparation of N-[2R-hydroxy-3-[[(1,1-
 dimethylethoxy) carbonyl] (2-methylpropyl)amino]-1S-
 (phenylmethyl)propyl]-2S-[(phenylmethoxycarbonyl)amino]-
 3,3-dimethylbutanamide


139



N-[(1,1-dimethylethoxy)carbonyl]-N-[2-methylpropyl]-3S-[N¹-(phenylmethoxycarbonyl)amino]-2R-hydroxy-4-phenylbutylamine in ethanol was hydrogenated at 45 psig
 5 of hydrogen in the presence of 5% pd(C) catalyst to yield N-[(1,1-dimethylethoxy)carbonyl]-N-[2-methylpropyl]-3S-[N¹-(phenylmethoxycarbonyl)amino]-2R-hydroxy-4-phenylbutylamine. Following standard workup, the crude amine (12.24 g, 36.42 mmol) was added to a
 10 mixture of N-carbobenzyloxycarbonyl-L-tert-leucine (9.67 g, 36.42 mmol), HOBT (4.92 g, 36.42 mmol) and EDC (6.98 g, 36.42 mmol) in DMF (300 mL) after the mixture was stirred at room temperature for 1 hour. The mixture was stirring for an additional 18 hours. The DMF was
 15 removed *in vacuo*, the residue was dissolved in dichloromethane (500 mL), washed with sodium hydroxide (5%, 2 X 200 mL) and brine (200 mL), dried and concentrated to afford 21 g (quantitative) of the desired product.


20

Part C: Preparation of N-[2R-hydroxy-3-[[1,1-dimethylethoxy) carbonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-amino-3,3-dimethylbutanamide



N-[2R-hydroxy-3-[[(1,1-dimethylethoxy) carbonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl]-2S-[(phenylmethoxycarbonyl) amino]-3,3-dimethylbutanamide (20 g, 34.29 mmol) in methanol (250 mL) was hydrogenated
 5 at room temperature in the presence of Pd/C (10%, 5 g). The catalyst was filtered off and the filtrate was concentrated to afford 13.8 g (90%) of the pure desired product.

10 Part D: Preparation of N-[2R-hydroxy-3-[[(1,1-dimethylethoxy) carbonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl]-2S-[(chloroacetyl) amino]-3,3-dimethylbutanamide



15 To N-[2R-hydroxy-3-[[(1,1-dimethylethoxy) carbonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl]-2S-amino-3,3-dimethylbutanamide (12.45 g, 27.70 mmol) in dichloromethane (200 mL) was added chloroacetic anhydride (5.21 g, 30.48 mmol) and the reaction mixture
 20 was stirred for 18 hours. The reaction mixture was washed with citric acid (5%, 100 mL), sodium bicarbonate (saturated, 100 mL) and brine, dried (MgSO₄) and concentrated to afford 12.0 g (82%) of the pure desired product.

25

Part E: Preparation of N-[2R-hydroxy-3-[[(1,1-dimethylethoxy) carbonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl]-2S-[(pyrrolidin-1-yl) acetyl] amino]-3,3-dimethylbutanamide

30


141

A mixture of N-[2R-hydroxy-3-[[(1,1-dimethylethoxy) carbonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl]-2S-[(chloroacetyl) amino]-3,3-dimethylbutanamide (10.42 g, 19.82 mmol) in
5 tetrahydrofuran (100 mL) was cooled to 0°C, and pyrrolidine (7.1 g, 100 mmol) was added. The reaction mixture was stirred for 18 hours. The reaction mixture was concentrated and the residue was dissolved in ethyl acetate (500 mL), washed with sodium bicarbonate
10 (saturated, 200 mL) and brine (200 mL), dried (MgSO₄) and concentrated to afford 11.0 g (quantitative) of the desired product.

EXAMPLE 45

15

Preparation of N-[2R-hydroxy-3-[[phenylsulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl]-2S-[[(pyrrolidin-1-yl) acetyl] amino]-3,3-dimethylbutanamide



20


N-[2R-hydroxy-3-[[(1,1-dimethylethoxy) carbonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl]-2S-[[(pyrrolidin-1-yl) acetyl] amino]-3,3-dimethylbutanamide
25 (2 g, 3.57 mmol) in Dioxane/HCl (4N, 10 mL) was stirred for 2 hours at room temperature. The solvent was removed and the residue was dried *in vacuo*. The residue was stirred in ethyl acetate (50 mL) then benzenesulfonyl chloride (0.692 g, 3.57 mmol) was added
30 followed by triethylamine (1.587 g, 15.71 mmol) and the mixture was stirred for 18 hours at room temperature. The reaction mixture was diluted with ethyl acetate (100

142

mL), washed with saturated sodium bicarbonate (saturated, 100 mL) and brine (100 mL), dried (MgSO₄), and concentrated. The residue was chromatographed in ethyl acetate to afford 5.0 g (47%) of the desired product as a white powder; m/e=601 (M+H).

EXAMPLE 46


Preparation of N-[2R-hydroxy-3-[[4-methoxyphenyl]sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[pyrrolidin-1-yl]acetyl]amino]-3,3-dimethylbutanamide



N-[2R-hydroxy-3-[[1,1-dimethylethoxy) carbonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[pyrrolidin-1-yl]acetyl]amino]-3,3-dimethylbutanamide (2 g, 3.57 mmol) in Dioxane/HCl (4N, 10 mL) was stirred for 2 hours at room temperature. The solvent was removed and the residue was dried *in vacuo*. The residue was stirred in ethyl acetate (50 mL) then 4-methoxybenzene sulfonyl chloride (0.737 g, 3.57 mmol) was added followed by triethylamine (1.587 g, 15.71 mmol) and the mixture was stirred for 18 hours at room temperature. The reaction mixture was diluted with ethyl acetate (100 mL), washed with saturated sodium bicarbonate (saturated, 100 mL) and brine (100 mL), dried (MgSO₄), and concentrated. The residue was chromatographed in ethyl acetate to afford 1.0 g (44%) of the desired product as a white powder; m/e=631(M+H).

EXAMPLE 47

Preparation of N-[2R-hydroxy-3-[[(2,3-dihydrobenzofuran-
 5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)
 5 propyl]-2S-[[(pyrrolidino)acetyl]amino]-3,3-
 dimethylbutanamide




10


N-[2R-hydroxy-3-[[(1,1-dimethylethoxy) carbonyl](2-
 methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-
 15 [[(pyrrolidin-1-yl)acetyl]amino]-3,3-dimethylbutanamide
 (2 g, 3.57 mmol) in Dioxane/HCl (4N, 10 mL) was stirred
 for 2 hours at room temperature. The solvent was
 removed and the residue was dried *in vacuo*. The residue
 was stirred in ethyl acetate (50 mL) then 2,3-dihydro
 benzofuran-5-ylsulfonyl chloride (0.737 g, 3.57 mmol)
 was added followed by triethylamine (1.587 g, 15.71
 20 mmol) and the mixture was stirred for 18 hours at room
 temperature. The reaction mixture was diluted with
 ethyl acetate (100 mL), washed with saturated sodium
 bicarbonate (saturated, 100 mL) and brine (100 mL),
 dried (MgSO₄), and concentrated. The residue was
 25 chromatographed in ethyl acetate to afford the desired
 product as a white powder.

EXAMPLE 48

Preparation of 2R-hydroxy-3-[[[1,4-benzodioxan-6-yl]sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl
5 carbamic acid phenylmethyl ester




To a solution of the N-[3S-[(phenylmethoxycarbonyl)
10 amino]-2R-hydroxy-4-phenylbutyl]-N-(2-methylpropyl)amine
(0.5 g, 1.35 mmol) in CH₂Cl₂ (5.0 mL) containing Et₃N
(0.35 mL, 2.5 mmol) was added 1,4-benzodioxan-6-sulfonyl
chloride (0.34 g, 1.45 mmol) and stirred at 0°C for 30
min. After stirring at room temperature for 1 hour, the
15 reaction mixture was diluted with CH₂Cl₂ (20 mL), washed
with cold 1N HCl (3 x 20 mL), water (2 x 20 mL), satd.
NaHCO₃ (2 x 20 mL) and water (3 x 20 mL), dried (Na₂SO₄)
and concentrated under reduced pressure. The resulting
residue was purified by flash chromatography using 35%
20 EtOAc in hexane to give the desired product as a white
amorphous solid which crystallized from MeOH as a white
powder (0.65g, 84% yield): m.p. 82-84°C, HRMS-FAB :
calcd for C₃₀H₃₇N₂O₇S 569.2321 (MH⁺), found 569.2323.

EXAMPLE 49

5 Preparation of 2S-[[[(pyrrolidino)acetyl]amino]-N-[2R-
hydroxy-3-[[[(1,3-benzodioxol-5-yl)sulfonyl]](2-
methylpropyl)amino]-1S-(phenylmethyl)propyl]-3-
methylpent-4-ynamide

10 Part A . Preparation of 2S-[[[(1,1-dimethylethoxy)
 carbonyl]amino]-N-[2R-hydroxy-3-[[[(1,3-benzodioxol-5-
 yl)sulfonyl]](2-methylpropyl)amino]-1S-(phenylmethyl)
 propyl]pent-4-ynamide




15 To a cooled solution of N-t-Boc-L-propargyl glycine (5.0
 g, 23.4 mmol) and 4.7g (1.5 equiv.) of N-hydroxy
 benzotriazole in 40 mL of N,N-dimethylformamide was
 added 4.6g (23.4 mmol) of EDC and stirred at 0°C for one
 hour. To this was added a solution of 12.10g (23.4
 20 mmol) of 2R-hydroxy-3-[[[(1,3-benzodioxol-5-
 yl)sulfonyl]](2-methyl propyl)amino]-1S-
 (phenylmethyl)propylamine in 6 mL of N,N-
 dimethylformamide and the solution stirred for 16 hours.
 The solvent was removed by rotory evaporation, replaced

with ethyl acetate, and washed with saturated sodium bicarbonate, 5% citric acid and brine. The organics were dried over magnesium sulfate, filtered and concentrated to yield 13.3 grams of crude product, which was


- 5 crystallized from diethyl ether: ethyl acetate to yield 6.9g of 2S-[[(1,1-dimethylethoxy) carbonyl] amino]-N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl) sulfonyl] (2-methyl propyl) amino]-1S-(phenylmethyl) propyl]pent-4-ynamide.

- 10 Part B. Preparation of 2S-amino-N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl) sulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl) propyl]pent-4-ynamide



- 15 5.0g (8.12 mmol) of the product from Part A. was dissolved in 20 mL of 4N HCl in dioxane and stirred for 30 minutes. The precipitated product was stripped two times from diethyl ether and this crude hydrochloride salt was used in Part C.

- 20 Part C. Preparation of 2S-[(chloroacetyl) amino]-N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl) sulfonyl] (2-methyl propyl) amino]-1S-(phenylmethyl) propyl]pent-4-ynamide



4.4g (8.12 mmol) of amine hydrochloride from Part B was dissolved in 60 mL of methylene chloride and to this was added 3.0g (24 mmol) of N,N-diisopropylethyl amine, followed by 1.38g (8.1 mmol) of chloroacetic anhydride.


5 The solution was stirred at room temperature overnight. The contents were concentrated on a rotary evaporator and the residue was partitioned between ethyl acetate and water. The organic layer was washed with 5% citric acid and then saturated sodium bicarbonate and brine.

10 The organics were dried over magnesium sulfate filtered and concentrated to yield 4.3g of crude product. Recrystallization from ethyl acetate hexane yielded 3.6 g (75% yield) of 2S-[(chloroacetyl)amino]-N-[2R-hydroxy-3-[[[(1,3-benzodioxol-5-yl)sulfonyl](2-

15 methylpropyl)amino]-1S-(phenylmethyl)propyl]pent-4-ynamide as a white solid.

Part D. Preparation of 2S-[[[(pyrrolidino)acetyl]amino]-N-[2R-hydroxy-3-[[[(1,3-benzodioxol-5-yl)sulfonyl](2-

20 methyl propyl)amino]-1S-(phenylmethyl)propyl]pent-4-ynamide



2S-[(Chloroacetyl)amino]-N-[2R-hydroxy-3-[[[(1,3-

25 benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]pent-4-ynamide (3.5 g, 6.0 mmol) was dissolved in 30 mL of tetrahydrofuran and to this was added 2.3 g (5 equiv.) of pyrrolidine and the reaction stirred for 1.5 hours. The solvents were removed by rotary evaporation and replaced with ethyl acetate. The


30 organics were washed successively with saturated sodium

148

bicarbonate, and brine, dried over magnesium sulfate filtered and concentrated to yield 3.4 grams of crude product. Purification by crystallization from diethyl ether yielded 3.0 grams of 2S-[[pyrrolidino)acetyl] amino]-N-[2R-hydroxy-3-[[1,3-benzodioxol-5-yl)sulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl]pent-4-ynamide as a white solid.

EXAMPLE 50

10

Preparation of 5-chlorosulfonyl-2-carbomethoxyamino-benzimidazole


15 A solution of 2-carbomethoxyamino-benzimidazole (5.0 g, 0.026 mole) in chlorosulfonic acid (35.00 mL) was stirred at 0°C for 30 minutes and at room temperature for 3 hours. The resulting dark colored reaction mixture was poured into an ice-water mixture (200 mL),
 20 and stirred at room temperature for 30 minutes. The resulting precipitate was filtered and washed with cold water (500 mL). The solid was dried overnight under high vacuum in a desiccator over NaOH pellets to give 5-chlorosulfonyl-2-carbomethoxyamino-benzimidazole (5.9 g,
 25 78%) as a gray powder. ¹H NMR (DMSO-d₆) δ: 3.89 (s, 3H), 7.55 (d, J = 8.4 Hz, 1H), 7.65 (d, J = 8.4 Hz, 1H), 7.88 (s, 1H). (German Patent DE 3826036)

EXAMPLE 51

30

Preparation of N-[2R-hydroxy-3-[N¹-(2-carbomethoxyamino-benzimidazol-5-yl)sulfonyl]-N¹-(2-


methylpropyl) amino]-1S-(phenylmethyl) propyl] carbamic acid phenylmethyl ester



- 5 To a cold solution of N-[3S-[(phenylmethoxycarbonyl) amino]-2R-hydroxy-4-phenylbutyl]-N-(2-methylpropyl)amine (5.0 g, 13.5 mmol) in dichloromethane (70 mL) was added triethylamine (5.95 g, 54.0 mmol) followed by the addition of 5-chlorosulfonyl-2-carbomethoxyamino-
- 10 benzimidazole (4.29 g, 14.85 mmol) in small portions as a solid. The reaction mixture was stirred at 0°C for 30 minutes and at room temperature for 2.5 hours when reaction of the amino alcohol was complete. The mixture was cooled and filtered, and the filtrate was
- 15 concentrated. The resulting residue was dissolved in EtOAc (200mL), washed successively with cold 5% citric acid (3 x 50 mL), saturated aqueous sodium bicarbonate (3 x 50 mL) and water (3 x 100 mL), then dried (Na₂SO₄), concentrated and dried under vacuum. The residue was
- 20 triturated with methanol, cooled, filtered, washed with MeOH-EtOAc (1:1, v/v) and dried in a desiccator to give pure N-[2R-hydroxy-3-[[2-carbomethoxyamino-benzimidazol-5-yl)sulfonyl](2-methylpropyl)-amino]-1S-(phenylmethyl) propyl]carbamic acid phenylmethyl ester
- 25 (6.02 g, 72 %) as a light brown powder: FABMS: m/z = 630 (M+Li); HRMS: calcd. for C₃₁H₃₈N₅O₇S (M+H) 624.2492, found 624.2488.

EXAMPLE 52


5 Preparation of 2R-hydroxy-3-[[(2-amino-benzimidazol-5-yl) sulfonyl] (2-methyl-propyl) amino]-1S-(phenylmethyl) propylamine



A solution of N-[2R-hydroxy-3-[[(2-carbomethoxyamino-benzimidazol-5-yl) sulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl]carbamic acid phenylmethyl ester
10 (0.36 g, 0.58 mmol) in 2.5 N methanolic KOH (2.00 mL) was heated at 70°C under a nitrogen atmosphere for 3 hours. The reaction mixture was diluted with water (10 mL) and extracted with EtOAc (3 x 15 mL). The combined organic extracts were washed with brine, dried (Na₂SO₄)
15 and concentrated. The resulting residue was purified by reverse-phase HPLC using a 10-90% CH₃CN/H₂O gradient (30 min) at a flow rate of 70 mL/min. The appropriate fractions were combined and freeze dried to give pure
20 2R-hydroxy-3-[[(2-amino-benzimidazol-5-yl) sulfonyl] (2-methylpropyl) amino]-1S-(phenyl-methyl)propylamine (0.22 g, 58%) as a white powder: FAB-MS *m/z* = 432 (M+H); HRMS: calcd. for C₂₁H₃₀N₅O₃S (M+H) 432.2069, found 432.2071.

EXAMPLE 53


Preparation of N-[2R-hydroxy-3-[[(2-amino-benzimidazol-5-yl)sulfonyl](2-methylpropyl)-amino]-1S-(phenylmethyl)propyl]carbamic acid phenylmethyl ester



To a solution of 2R-hydroxy-3-[[(2-amino-benzimidazol-5-yl)sulfonyl](2-methyl-propyl)amino]-1S-(phenylmethyl)propylamine (0.22 g, 0.33 mmol) in THF (3.00 mL), triethylamine (0.11 g, 1.1 mmol) and benzyloxycarbonyl succinimide (0.09 g, 0.36 mmol) were added, and the reaction mixture was stirred at room temperature for 16 hours. The solution was concentrated, and the residue was partitioned between EtOAc (15 mL) and saturated aqueous sodium bicarbonate. The organic phase was washed with brine, dried (Na₂SO₄), and concentrated. The resulting residue was purified by reverse-phase HPLC using a 10-90% CH₃CN/H₂O gradient (30 min) at a flow rate of 70 mL/min. The appropriate fractions were combined and freeze dried to give pure N-[2R-hydroxy-3-[[(2-amino-benzimidazol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]carbamic acid phenylmethyl ester (0.12 g, 61%) as a white powder: FAB-MS *m/z* = 566 (M+H); HRMS: calcd. for C₂₉H₃₆N₅O₅S 566.2437 (M+H), found 566.2434.

EXAMPLE 54


5 Preparation of 2R-hydroxy-3-[[(2-carbomethoxyamino-
benzimidazol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-
(phenylmethyl)propylamine




A solution of N-[2R-hydroxy-3-[[(2-carbomethoxyamino-
benzimidazole-5-yl)sulfonyl](2-methylpropyl)-amino]-1S-
10 (phenylmethyl)propyl]carbamic acid phenylmethyl ester
(2.5 g, 0.4 mmol) in MeOH (10 mL) and THF (50 mL) was
hydrogenated in the presence of 10% Pd/C (1.2 g) at room
temperature at 60 psi for 16 hours. The catalyst was
removed by filtration, and the filtrate was concentrated
15 under reduced pressure. The resulting residue was
trituated with ether and filtered. The solid substance
thus obtained was washed with ether and dried *in vacuo*
to afford pure 2R-hydroxy-3-[[(2-carbomethoxyamino-
benzimidazol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-
20 (phenylmethyl)propylamine (1.5 g, 77%) as an off white
powder: $R_t = 12.8$ min; FAB-MS $m/z = 490$ (M+H); HRMS:
calcd. for $C_{23}H_{32}N_5O_5S$ 490.2124 (M+H), found 490.2142.

EXAMPLE 55

Preparation of N-[2R-hydroxy-3-[[2-carbomethoxyamino-
benzimidazol-5-yl) sulfonyl](2-methylpropyl)amino]-1S-
 5 (phenylmethyl)propyl]-2S-amino-3,3-dimethylbutanamide



Part A: Preparation of N-[2R-hydroxy-3-[N¹-[(2-
 carbomethoxyamino-benzimidazol-5-yl) sulfonyl]-N¹-(2-
 10 iethylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-
 [(phenylmethoxy-carbonyl)amino]-3,3-dimethylbutanamide



To a solution of N-carbobenzyloxycarbonyl-L-tert-
 leucine (0.65 g, 2.45 mmol) in DMF (10 mL) was added
 15 HOBT (0.5 g, 3.22 mmol) and EDC (0.49 g, 2.55 mmol),
 and the resulting mixture was stirred at 0°C for 2
 hours. Then a solution of 2R-hydroxy-3-[[2-
 carbomethoxyamino-benzimidazol-5-yl) sulfonyl](2-
 methylpropyl)amino]-1S-(phenylmethyl) propylamine (1.2
 20 g, 2.45 mmol) in DMF (4 mL) and N-methyl morpholine
 (0.74 g, 7.3 mmol) was added, and the mixture was
 stirred at room temperature for 16 hours. The DMF was
 then distilled away *in vacuo*, and the remaining residue
 was partitioned between cold 1N aqueous HCl (100 mL)
 25 and EtOAc (200 mL). The organic phase was washed
 successively with cold 1N HCl (2 x 50 mL), brine (2 x

50 mL), 0.25 N NaOH (3 x 50 mL), brine, dried (Na₂SO₄) and concentrated *in vacuo*. The resulting residue was purified by silica gel flash column chromatography using EtOAc as the eluent to afford 1.5 g (83%) of pure
5 N-[2R-hydroxy-3-[[(2-carbomethoxyamino-benzimidazol-5-yl)sulfonyl](2-methylpropyl) amino]-1S-(phenylmethyl) propyl-2S-[(phenylmethoxy-carbonyl) amino]-3,3-dimethyl butanamide: R_t = 21.2 min; FAB-MS m/z = 737 (M+H), HRMS: calcd. for C₃₇H₄₉N₆O₈S 737.3333 (M+H), found
10 737.3334.

Part B: Preparation of N-[2R-hydroxy-3-[[(2-carbomethoxyamino-benzimidazol-5-yl) sulfonyl](2-methylpropyl) amino]-1S-(phenylmethyl) propyl]-2S-amino-
15 3,3-dimethylbutanamide


A solution of N-[2R-hydroxy-3-[[(2-carbomethoxyamino-benzimidazol-5-yl)sulfonyl](2-methylpropyl) amino]-1S-(phenylmethyl) propyl-2S-[(phenylmethoxycarbonyl) amino]-
20 3,3-dimethylbutanamide (4.0 g, 5.4 mmol) in MeOH (15 mL) and THF (65 mL) was hydrogenated in the presence of 10% Pd/C (2.0 g) at room temperature at 50 psi for 16 hours. The catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure. The resulting
25 residue was triturated with ether and filtered. The solid residue was washed with ether and dried *in vacuo* to afford N-[2R-hydroxy-3-[[(2-carbomethoxyamino-benzimidazol-5-yl)sulfonyl](2-methylpropyl) amino]-1S-(phenylmethyl) propyl]-2S-amino-3,3-dimethylbutanamide
30 (2.9 g, 88%) as a pale yellow powder. A portion of the material was purified by reverse-phase HPLC using a 10-90% CH₃CN/H₂O gradient (30 min) at a flow rate of 70 mL/min. The appropriate fractions were combined and freeze dried to give pure N-[2R-hydroxy-3-[[(2-
35 carbomethoxyamino-benzimidazol-5-yl) sulfonyl](2-methylpropyl) amino]-1S-(phenylmethyl) propyl-2S-amino-

3,3-dimethylbutanamide as a white powder: $R_t = 13.9$ min; FAB-MS $m/z = 609$ (M+Li), 603 (M+H); HRMS: calcd. for $C_{29}H_{43}N_6O_6S$ 603.2965 (M+H), found 603.2972.


5

EXAMPLE 56

Preparation of N-[2R-hydroxy-3-[[N¹-(2-carbomethoxyamino-benzimidazol-5-yl)sulfonyl]-N¹-(2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-
 10 [[(pyrrolidin-1-yl)acetyl] amino]-3,3-dimethylbutanamide



Part A: Preparation of N-[2R-hydroxy-3-[[2-carbomethoxy amino-benzimidazol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl-2S-
 15 [(chloroacetyl)amino]-3,3-dimethylbutanamide



A mixture of chloroacetic acid (0.32 g, 3.39 mmol), HOBt (0.78 g, 5.0 mmol), and EDC (0.65 g, 3.39 mmol) in
 20 DMF (5 mL) was stirred at 0°C for 1 hour, and was then added to a solution of N-[2R-hydroxy-3-[[2-carbomethoxyamino-benzimidazol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-amino-3,3-dimethylbutanamide (2.0 g, 3.3 mmol) in DMF (5 mL).
 25 The resulting mixture was stirred at 0°C for 2 hours, and at room temperature for 1 hour when the reaction

was complete. The DMF was removed *in vacuo*. The resulting residue was dissolved in EtOAc (50 mL) and washed successively with saturated aqueous sodium bicarbonate (3 x 25 mL), brine, dried (Na₂SO₄), and concentrated under reduced pressure. The resulting material was crystallized from EtOAc to give 1.2 g (53%) of pure N-[2R-hydroxy-3-[[2-carbomethoxy amino-benzimidazol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[(chloroacetyl)amino]-3,3-dimethylbutanamide as a white powder: m.p. 253°C (decomp); R_t 18.1 min; FAB-MS m/z = 679 (M+H), HRMS: calcd. for C₃₁H₄₄N₆O₇SCl 679.2681 (M+H), found 679.2690.

Part B. Preparation of N-[2R-hydroxy-3-[[2-carbomethoxyamino-benzimidazol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[pyrrolidin-1-yl)acetyl]amino]-3,3-dimethylbutanamide.

N-[2R-hydroxy-3-[[2-carbomethoxyamino-benzimidazol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[(chloroacetyl)amino]-3,3-dimethylbutanamide (0.5 g, 0.74 mmol) was dissolved in THF (2.00 mL), pyrrolidine (0.3 g, 4.2 mmol) was added, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, and the residue was dried *in vacuo*. The resulting material was triturated with 10% EtOAc in ether and filtered. The solid was washed with ether and dried to give 0.42 g of crude product as a pale yellow powder. This was purified by reverse-phase HPLC using a 5)70% CH₃CN/H₂O gradient (30 min) at a flow rate of 70 mL/min. The appropriate fractions were combined and freeze dried to give pure N-[2R-hydroxy-3-[[2-carbomethoxyamino-benzimidazol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-


157

[[(pyrrolidin-1-yl) acetyl] amino]-3,3-dimethylbutanamide (0.41 g, 77%) as a white powder: $R_t = 14.8$ min; FAB-MS $m/z = 714$ (M+H), HRMS: calcd. for $C_{35}H_{52}N_7O_7S$ 714.3649 (M+H), found 714.3666.


5

EXAMPLE 57

Preparation of N-[2R-hydroxy-3-[[(benzothiazol-6-yl) sulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl]-2S-[[(pyrrolidin-1-yl) acetyl] amino]-3,3-dimethyl butanamide•dihydrochloride



Part A: Preparation of N-[2R-hydroxy-3-[(2-methylpropyl) amino]-1S-(phenylmethyl)propyl]-2S-[[(pyrrolidin-1-yl) acetyl] amino]-3,3-dimethylbutanamide•dihydrochloride




A solution of hydrochloric acid in dioxane (4N, 10 mL) was added to N-[2R-hydroxy-3-[[(1,1-dimethylethoxy) carbonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl]-2S-[[(pyrrolidin-1-yl) acetyl] amino]-3,3-dimethylbutanamide (2.80 g, 5.0 mmol), and the mixture was stirred for 2 hours at room temperature. The solvent was removed, and the residue was dried *in vacuo* to afford 2.60 g of the desired dihydrochloride product as a crystalline solid.

Part B: Preparation of N-[2R-hydroxy-3-
[[benzothiazol-6-yl)sulfonyl](2-methylpropyl)amino]-
1S-(phenylmethyl) propyl]-2S-[[pyrrolidin-1-
5 yl)acetyl]amino]-3,3-dimethylbutanamide•dihydrochloride


To a solution of 6-chlorosulfonylbenzothiazole in
dichloromethane (100 mL) was added N-[2R-hydroxy-3-[(2-
methylpropyl)amino]-1S-(phenylmethyl)-propyl]-2S-
10 [[pyrrolidin-1-yl)acetyl]amino]-3,3-
dimethylbutanamide•dihydrochloride (1.00 g, 1.875 mmol)
and neat triethylamine (3 mL). After stirring at room
temperature for 18 hours, the reaction mixture was
diluted with dichloromethane (100 mL), washed with
15 saturated aqueous sodium bicarbonate (100 mL), brine
(100 mL), dried (MgSO₄), filtered and concentrated. The
resulting residue was purified by flash column
chromatography on silica gel, eluting with 5% methanol
in ethyl acetate to afford pure N-[2R-hydroxy-3-
20 [[benzothiazol-6-yl) sulfonyl](2-methylpropyl)amino]-
1S-(phenylmethyl)propyl]-2S-[[pyrrolidin-1-
yl)acetyl]amino]-3,3-dimethyl butanamide (0.180 g,
15%). This was converted to the dihydrochloride salt
by concentrating an acetonitrile solution with 1N HCl
25 (2 mL). The residue was then dried to afford the
desired dihydrochloride salt: FAB-MS C₃₃H₄₇N₅O₅S₂: m/z =
657.

EXAMPLE 58

Preparation of N-[2R-hydroxy-3-[[(benzothiazol-6-yl) sulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl]-2S-[(chloroacetyl) amino]-3,3-dimethylbutanamide




Part A: Preparation of [2R-hydroxy-3-[(4-aminophenylsulfonyl) (2-methylpropyl) amino]-1S-(phenylmethyl)propyl]carbamic acid t-butyl ester



A mixture of [2R-hydroxy-3-[(4-aminophenylsulfonyl) (2-methylpropyl)-amino]-1S-(phenylmethyl)propylamine 3.7 g (9.45 mmol) and BOC-ON (2.33 g, 9.45 mmol) and triethylamine (0.954 g, 9.45 mmol) in tetrahydrofuran (60 mL) was stirred for 16 h and concentrated *in vacuo*. The residue was dissolved in dichloromethane (200 mL), washed with sodium hydroxide (1N, 100 mL), citric acid (5%, 100 mL), dried (MgSO₄), and concentrated to afford 1.18 g (94%) of the desired product as a white solid.

Part B: Preparation of [2R-Hydroxy-3-[(2-aminobenzothiazole-6-sulfonyl)-(2-methylpropyl) amino]-1S-(phenylmethyl)propyl]carbamic acid t-butyl ester


160



The [2R-hydroxy-3-[(4-aminophenylsulfonyl)(2-methylpropyl)amino]-1S-(phenylmethyl)propyl]carbamic acid t-butyl ester 1.12 g (2.279 mmol) was added to a well mixed powder of anhydrous copper sulfate (4.48 g) and potassium thiocyanate (5.60 g) followed by dry methanol (35 mL) and the resulting black-brown suspension was heated at reflux for 2h. The reaction mixture turned gray. The reaction mixture was filtered and the filtrate was diluted with water (50 mL) and heated at reflux. Ethanol was added to the reaction mixture, cooled and filtered. The filtrate upon concentration afforded a residue which was chromatographed (ethyl acetate:methanol 90:10) to afford 0.80 g (78%) of the deprotected compound as a solid. This was directly reprotected via the following procedure; (2.25 g, 5.005 mmol) BOC-ON (1.24 g), and triethylamine (0.505 g, 5.005 mmol) in tetrahydrofuran (20 mL) was stirred at room temperature for 18h. The reaction mixture was concentrated and the residue was dissolved in dichloromethane (200 mL) and was washed with sodium hydroxide (1N, 100 mL), citric acid (5%, 100 mL) dried (Mg SO₄) and concentrated to afford a residue which was chromatographed (ethyl acetate:hexane 3:1) to afford 1.8 g (65%) of the desired product as a solid.

Part C: Preparation of [2R-hydroxy-3-[(benzothiazole-6-sulfonyl)(2-methylpropyl)amino]-1S-(phenylmethyl)propyl]carbamic acid t-butyl ester

161




The product of part B above (1.80 g, 3.2755 mmol) was added to a solution of isoamylnitrite (0.88 mL) in dioxane (20 mL) and the mixture was heated at 85°C.

- 5 After the cessation of evolution of nitrogen, the reaction mixture was concentrated and the residue was purified by chromatography (hexane:ethyl acetate 1:1) to afford 1.25 g (78%) of the desired product as a solid.

10


Part D: Preparation of [2R-hydroxy-3-[(benzothiazole-6-sulfonyl)(2-methylpropyl)amino]-1S-(phenylmethyl)propylamine]hydrochloride



- 15 The product of part C above was deprotected via the following procedure; (1.25 g, 2.3385 mmol) was added dioxane/HCl (4N, 10 mL) and was stirred at room temperature for 2h and concentrated. Excess HCl was chased with toluene to afford 1.0 g (quantitative
- 20 yield) of the desired product as its HCl salt.


- Part E: Preparation of N-[2R-hydroxy-3-[[[(benzothiazol-6-yl)sulfonyl](2-methylpropyl)-amino]-1S-(phenylmethyl)propyl]-2S-[[N-(benzyloxy)carbonyl]amino]-3,3-dimethyl butanamide
- 25

162



A mixture of N-benzyloxycarbonyl-*t*-butylglycine (2.0 g, 7.538 mmol), HOBT (1.02 g, 7.55 mmol), and EDC (1.45 g, 7.55 mmol) in DMF (20 mL) was stirred at room
 5 temperature for 1 hour. Then [2R-hydroxy-3-
 [[(benzothiazol-6-yl)sulfonyl](2-methylpropyl)amino]-1S-
 (phenylmethyl) propylamine hydrochloride (3.825 g, 7.54
 mmol) and N-methylmorpholine (3.80 g) were added and the
 stirring continued for 18 hours. The DMF was removed *in*
 10 *vacuo*, the residue was dissolved in dichloromethane (500
 mL), and washed with citric acid (1N, 100 mL), sodium
 bicarbonate (100 mL), brine (200 mL), dried, filtered,
 and concentrated to afford 4.69 g (91%) of pure N-[2R-
 hydroxy-3-[[[(benzothiazol-6-yl)sulfonyl](2-methylpropyl)
 15 amino]-1S-(phenylmethyl)propyl]-2S-[N-(phenylmethoxy
 carbonyl)amino]-3,3-dimethylbutanamide.

Part F: Preparation of N-[2R-hydroxy-3-
 [[(benzothiazol-6-yl)sulfonyl](2-methylpropyl)amino]-
 20 1S-(phenylmethyl) propyl]-2S-(amino)-3,3-
 dimethylbutanamide•dihydrobromide



A solution of N-[2R-hydroxy-3-[[[(benzothiazol-6-
 yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)
 25 propyl]-2S-[N-(phenylmethoxycarbonyl)amino]-3,3-
 dimethyl butanamide (4.69 g, 6.89 mmol) in


dichloroethane (200 mL) was treated with HBr (48% in acetic acid, 7.1 mL), and the reaction mixture was stirred for 2 hours at room temperature. The reaction mixture was concentrated and the residue was washed
5 with diethyl ether several times to afford 4.88 g of the desired dihydrobromide product as a powder: high resolution FAB-MS Calcd for $C_{27}H_{38}N_4O_4S_2$: 547.2413, found: 547.2429 (M+H).

10 Part G: Preparation of N-[2R-hydroxy-3-
[[(benzothiazol-6-yl)sulfonyl](2-methylpropyl)amino]-
1S-(phenylmethyl) propyl]-2S-[(chloroacetyl)amino]-3,3-
dimethylbutanamide

15 A mixture of N-[2R-hydroxy-3-[[(benzothiazol-6-
yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)
propyl]-2S-(amino)-3,3-dimethylbutanamide
dihydrobromide (3.5 g, 4.9388 mmol), chloroacetic
anhydride (0.929 g, 5.44 mmol) and triethylamine (1.097
20 g, 10.86 mmol) in dichloromethane (35 mL) was stirred
at room temperature for 16 hours. The reaction mixture
was washed with citric acid (1N, 30 mL), sodium
bicarbonate (30 mL), brine (30 mL), dried, filtered and
concentrated to afford 3.0 g of the desired product.
25


EXAMPLE 59

Following the procedures of the previous Examples, the compounds set forth in Tables 2 through 19 can be prepared.

TABLE 2

Entry	R ³	R ⁴
	isobutyl	4-aminophenyl
10	isobutyl	3-aminophenyl
	cyclopentylmethyl	phenyl
	cyclohexylmethyl	phenyl
	cyclopentylmethyl	1,3-benzodioxol-5-yl
	cyclohexylmethyl	1,3-benzodioxol-5-yl
15	cyclopentylmethyl	benzofuran-5-yl
	cyclohexylmethyl	benzofuran-5-yl
	cyclopentylmethyl	2,3-dihydrobenzofuran-5-yl
	cyclohexylmethyl	2,3-dihydrobenzofuran-5-yl
	isobutyl	1,3-benzodioxol-5-yl
20	isobutyl	benzofuran-5-yl
	isobutyl	2,3-dihydrobenzofuran-5-yl
	isobutyl	1,4-benzodioxan-6-yl
	isoamyl	1,3-benzodioxol-5-yl
	isoamyl	2,3-dihydrobenzofuran-5-yl
25	isoamyl	1,4-benzodioxan-6-yl
	isobutyl	benzothiazol-6-yl
	isobutyl	2-amino-benzothiazol-6-yl
	isobutyl	benzoxazol-5-yl
	cyclopentylmethyl	4-methoxyphenyl
30	cyclohexylmethyl	4-methoxyphenyl

165

TABLE 3A

5



Entry**A**


TABLE 3B




5

Entry


A



167


TABLE 4A

Entry	R ²	
5	(CH ₃) ₂ CHCH ₂ -	(4-FC ₆ H ₅)CH ₂ -
	CH ₃ CH ₂ CH ₂ CH ₂ -	(naphth-2-yl)CH ₂ -
	CH ₃ SCH ₂ CH ₂ -	C ₆ H ₁₁ CH ₂ -
	C ₆ H ₅ CH ₂ -	C ₆ H ₅ SCH ₂ -
10	(4-CH ₃ OC ₆ H ₅)CH ₂ -	(naphth-2-yl)SCH ₂ -

TABLE 4B

Entry	R ²	
15	(CH ₃) ₂ CHCH ₂ -	(4-FC ₆ H ₅)CH ₂ -
	CH ₃ CH ₂ CH ₂ CH ₂ -	(naphth-2-yl)CH ₂ -
	CH ₃ SCH ₂ CH ₂ -	C ₆ H ₁₁ CH ₂ -
	C ₆ H ₅ CH ₂ -	C ₆ H ₅ SCH ₂ -
20	(4-CH ₃ OC ₆ H ₅)CH ₂ -	(naphth-2-yl)SCH ₂ -


TABLE 5A



5	Entry	R ³		
	-CH ₂ CH ₂ CH ₃			
	-CH ₂ CH ₂ CH ₂ CH ₃			
	-CH ₂ CH(CH ₃) ₂			
	-CH ₂ CH ₂ CH(CH ₃) ₂			


TABLE 5B

























10



15	Entry	R ³		
	-CH ₂ CH ₂ CH ₃			
	-CH ₂ CH ₂ CH ₂ CH ₃			
	-CH ₂ CH(CH ₃) ₂			
	-CH ₂ CH ₂ CH(CH ₃) ₂			


TABLE 6



5	Entry	R ¹
		
		
		
		
		
		
		
		
		
		
		
		

170


TABLE 7A



Entry


R⁴

5



171


TABLE 7B



Entry


R⁴

5



172

TABLE 7C



Entry

R⁴

5





TABLE 7D



Entry

R⁴

5






TABLE 7E



Entry


R⁴

5



175

TABLE 7F



Entry

R⁴

5





TABLE 8



5

Entry

R¹






TABLE 9



5


Entry

R¹



178


TABLE 10A



Entry	R ⁴


179

TABLE 10B




Entry

R⁴



180


TABLE 10C



Entry	R ⁴


181

TABLE 10D





















Entry	R ⁴

TABLE 10E




Entry

R⁴




183

TABLE 10F

Entry	R ⁴

TABLE 11A



Entry

R⁴

5





TABLE 11B



Entry

R⁴

5






TABLE 11C



Entry	R ⁴
5	

TABLE 11D



Entry

R⁴

5






TABLE 11E




Entry	R ⁴
5	

TABLE 11F



Entry	R ⁴
5	

TABLE 12A



5 **Entry**

A





TABLE 12B



5 **Entry**

A





TABLE 13A



5 **Entry**

A





TABLE 13B



5 **Entry**

A





TABLE 14A



5 **Entry**

A





TABLE 14B



5 **Entry**

A





TABLE 15



5 **Entry**

R¹





TABLE 16A



5 **Entry**

A


















TABLE 16B



5 **Entry**

A






TABLE 17A


Entry	R ²	
5	(CH ₃) ₂ CHCH ₂ -	(4-FC ₆ H ₅)CH ₂ -
	CH ₃ CH ₂ CH ₂ CH ₂ -	(naphth-2-yl)CH ₂ -
	CH ₃ SCH ₂ CH ₂ -	C ₆ H ₁₁ CH ₂ -
	C ₆ H ₅ CH ₂ -	C ₆ H ₅ SCH ₂ -
10	(4-CH ₃ OC ₆ H ₅)CH ₂ -	(naphth-2-yl)SCH ₂ -

TABLE 17B

15

Entry	R ²	
20	(CH ₃) ₂ CHCH ₂ -	(4-FC ₆ H ₅)CH ₂ -
	CH ₃ CH ₂ CH ₂ CH ₂ -	(naphth-2-yl)CH ₂ -
	CH ₃ SCH ₂ CH ₂ -	C ₆ H ₁₁ CH ₂ -
	C ₆ H ₅ CH ₂ -	C ₆ H ₅ SCH ₂ -
	(4-CH ₃ OC ₆ H ₅)CH ₂ -	(naphth-2-yl)SCH ₂ -

TABLE 18A



5

Entry

R³

-CH₂CH₂CH₃

-CH₂CH₂CH₂CH₃

-CH₂CH(CH₃)₂

-CH₂CH₂CH(CH₃)₂









TABLE 18B



10

Entry






R³

-CH₂CH₂CH₃


-CH₂CH₂CH₂CH₃

-CH₂CH(CH₃)₂

-CH₂CH₂CH(CH₃)₂



15

TABLE 19

5	Entry	R ¹

EXAMPLE 60

10

The compounds of the present invention are effective HIV protease inhibitors. Utilizing an enzyme assay as described below, the compounds set forth in the examples herein disclosed inhibited the HIV enzyme.

15 The preferred compounds of the present invention and their calculated IC₅₀ (inhibiting concentration 50%, i.e., the concentration at which the inhibitor compound reduces enzyme activity by 50%) values are shown in Tables 20 and 21. The enzyme method is described below.

20 The substrates is 2-Ila-Nle-Pha(p-NO₂)Gln-ArgJH₂. The

positive control is MVT-101 (Miller, M. et al, Science,
246, 1149 (1989)] The assay conditions are as follows:

Assay buffer: 20 mM sodium phosphate, pH 6.4
20% glycerol
5 1 mM EDTA
1 mM DTT
0.1% CHAPS

The above described substrate is dissolved in DMSO, then
diluted 10 fold in assay buffer. Final substrate
10 concentration in the assay is 80 μ M. HIV protease is
diluted in the assay buffer to a final enzyme
concentration of 12.3 nanomolar, based on a molecular
weight of 10,780.

15 The final concentration of DMSO is 14% and the
final concentration of glycerol is 18%. The test
compound is dissolved in DMSO and diluted in DMSO to 10x
the test concentration; 10 μ l of the enzyme preparation
is added, the materials mixed and then the mixture is
20 incubated at ambient temperature for 15 minutes. The
enzyme reaction is initiated by the addition of 40 μ l of
substrate. The increase in fluorescence is monitored at
4 time points (0, 8, 16 and 24 minutes) at ambient
temperature. Each assay is carried out in duplicate
25 wells.

The preceding examples can be repeated with similar
success by substituting the generically or specifically
described reactants and/or operating conditions of this
30 invention for those used in the preceding examples.

TABLE 20

Entry	Compound	IC ₅₀ (nM)
5		4
2		2
3		2

10

EXAMPLE 61

The effectiveness of various compounds were determined in the above-described enzyme assay and in a CEM cell assay. The HIV inhibition assay method of acutely infected cells is an automated tetrazolium based colorimetric assay essentially that reported by Pauwles et al, *J. Virol. Methods*, 20, 309-321 (1988). Assays were performed in 96-well tissue culture plates.

CEM cells, a CD4⁺ cell line, were grown in RPMI-1640 medium (Gibco) supplemented with a 10% fetal calf serum and were then treated with polybrene (2µg/ml). An 80 µl volume of medium containing 1 x 10⁴ cells was
 5 dispensed into each well of the tissue culture plate. To each well was added a 100µl volume of test compound dissolved in tissue culture medium (or medium without test compound as a control) to achieve the desired final concentration and the cells were incubated at
 10 37°C for 1 hour. A frozen culture of HIV-1 was diluted in culture medium to a concentration of 5 x 10⁴ TCID₅₀ per ml (TCID₅₀ = the dose of virus that infects 50% of cells in tissue culture), and a 20µL volume of the virus sample (containing 1000 TCID₅₀ of virus) was added
 15 to wells containing test compound and to wells containing only medium (infected control cells). Several wells received culture medium without virus (uninfected control cells). Likewise, the intrinsic toxicity of the test compound was determined by adding
 20 medium without virus to several wells containing test compound. In summary, the tissue culture plates contained the following experiments:

25	Cells	Drug	Virus
	1. +	-	-
	2. +	+	-
	3. +	-	+
30	4. +	+	+


In experiments 2 and 4 the final concentrations of test compounds were 1, 10, 100 and 500 µg/ml. Either azidothymidine (AZT) or dideoxyinosine (ddI) was
 35 included as a positive drug control. Test compounds were dissolved in DMSO and diluted into tissue culture medium so that the final DMSO concentration did not

exceed 1.5% in any case. DMSO was added to all control wells at an appropriate concentration.

Following the addition of virus, cells were
 5 incubated at 37°C in a humidified, 5% CO₂ atmosphere for
 7 days. Test compounds could be added on days 0, 2 and
 5 if desired. On day 7, post-infection, the cells in
 each well were resuspended and a 100µl sample of each
 cell suspension was removed for assay. A 20µL volume of
 10 a 5 mg/ml solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-
 diphenyltetrazolium bromide (MTT) was added to each
 100µL cell suspension, and the cells were incubated for
 4 hours at 27°C in a 5% CO₂ environment. During this
 incubation, MTT is metabolically reduced by living cells
 15 resulting in the production in the cell of a colored
 formazan product. To each sample was added 100µl of 10%
 sodium dodecylsulfate in 4.01 N HCl to lyse the cells,
 and samples were incubated overnight. The absorbance at
 590 nm was determined for each sample using a Molecular
 20 Devices microplate reader. Absorbance values for each
 set of wells is compared to assess viral control
 infection, uninfected control cell response as well as
 test compound by cytotoxicity and antiviral efficacy.

25

TABLE 21

Entry	Compound	IC ₅₀ (nM)	EC ₅₀ (nM)
1		3	7

30

TABLE 21 (cont'd)





5	Entry	Compound	IC ₅₀ (nM)	EC ₅₀ (nM)
	2		3	12
	3		8	120
10	4		4	12
	5		3	5

TABLE 21 (cont'd)

Entry	Compound	IC ₅₀ (nM)	EC ₅₀ (nM)	
5				
6		3	6	
7		2	29	
10	8		3	16
9		3	16	

TABLE 21 (cont'd)

Entry	Compound	IC ₅₀ (nM)	EC ₅₀ (nM)
5 10		4	39
11		4	21
12		2	11
10 13		3	18

The compounds of the present invention are effective antiviral compounds and, in particular, are effective retroviral inhibitors as shown above. Thus, the subject
5 compounds are effective HIV protease inhibitors. It is contemplated that the subject compounds will also inhibit other retroviruses such as other lentiviruses in particular other strains of HIV, e.g. HIV-2, human T-cell leukemia virus, respiratory syncytial virus, simia
10 immunodeficiency virus, feline leukemia virus, feline immuno-deficiency virus, hepadnavirus, cytomegalovirus and picornavirus. Thus, the subject compounds are effective in the treatment, prophylaxis of retroviral infections and/or the prevention of the spread of
15 retroviral infections.

The subject compounds are also effective in preventing the growth of retroviruses in a solution. Both human and animal cell cultures, such as T-
20 lymphocyte cultures, are utilized for a variety of well known purposes, such as research and diagnostic procedures including calibrators and controls. Prior to and during the growth and storage of a cell culture, the subject compounds may be added to the cell culture
25 medium at an effective concentration to prevent the unexpected or undesired replication of a retrovirus that may inadvertently, unknowingly or knowingly be present in the cell culture. The virus may be present originally in the cell culture, for example HIV is
30 known to be present in human T-lymphocytes long before it is detectable in blood, or through exposure to the virus. This use of the subject compounds prevents the unknowing or inadvertent exposure of a potentially lethal retrovirus to a researcher or clinician.

Compounds of the present invention can possess one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers as well as in the form of racemic or nonracemic mixtures thereof. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example by formation of diastereoisomeric salts by treatment with an optically active acid or base. Examples of appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric and camphorsulfonic acid and then separation of the mixture of diastereoisomers by crystallization followed by liberation of the optically active bases from these salts. A different process for separation of optical isomers involves the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers. Still another available method involves synthesis of covalent diastereoisomeric molecules by reacting compounds of Formula I with an optically pure acid in an activated form or an optically pure isocyanate. The synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomerically pure compound. The optically active compounds of Formula I can likewise be obtained by utilizing optically active starting materials. These isomers may be in the form of a free acid, a free base, an ester or a salt.

30

The compounds of the present invention can be used in the form of salts derived from inorganic or organic acids. These salts include but are not limited to the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate,

35

cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.

Examples of acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid. Other examples include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases.

Total daily dose administered to a host in single or divided doses may be in amounts, for example, from 0.001 to 10 mg/kg body weight daily and more usually 0.01 to 1 mg. Dosage unit compositions may contain such amounts of submultiples thereof to make up the daily dose.

The amount of active ingredient that may be combined with the carrier materials to produce a single

dosage form will vary depending upon the host treated and the particular mode of administration.

The dosage regimen for treating a disease condition with the compounds and/or compositions of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex, diet and medical condition of the patient, the severity of the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized and whether the compound is administered as part of a drug combination. Thus, the dosage regimen actually employed may vary widely and therefore may deviate from the preferred dosage regimen set forth above.

The compounds of the present invention may be administered orally, parenterally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. Topical administration may also involve the use of transdermal administration such as transdermal patches or iontophoresis devices. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques. Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.

Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or
5 suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

10 Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter and polyethylene glycols which are solid at ordinary temperatures but liquid at the rectal temperature and
15 will therefore melt in the rectum and release the drug.

 Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound may be
20 admixed with at least one inert diluent such as sucrose lactose or starch. Such dosage forms may also comprise, as in normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets,
25 and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

 Liquid dosage forms for oral administration may
30 include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and
35 sweetening, flavoring, and perfuming agents.


While the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more immunomodulators, antiviral agents or other antiinfective agents. For example, the compounds of the invention can be administered in combination with AZT, DDI, DDC or with glucosidase inhibitors, such as N-butyl-1-deoxynojirimycin or prodrugs thereof, for the prophylaxis and/or treatment of AIDS. When administered as a combination, the therapeutic agents can be formulated as separate compositions which are given at the same time or different times, or the therapeutic agents can be given as a single composition.

The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the appended claims. From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

WHAT IS CLAIMED IS:

1. A process for preparing a benzo fused heterocyclo sulfonyl halide comprising reacting a benzo fused heterocyclic compound with an SO₃ complex in the presence of a water immiscible, non-reactive solvent, at a temperature of from about 0°C to about 75°C, cooling, if necessary, to a temperature of from about -25°C to about 65°C and then adding an oxalyl halide.
2. The process of claim 1 wherein the SO₃ complex is SO₃DMF.
3. The process of claim 1 wherein the water immiscible solvent is dichloroethane, methylene chloride, trichloroethane, toluene, tetrachloroethane, or mixtures thereof.
4. The process of claim 3 wherein the water immiscible solvent is dichloroethane.
5. The process of claim 1 wherein the oxalyl halide is oxalyl chloride.
6. The process of claim 1 wherein the benzo fused heterocyclo sulfonyl halide is benzo fused heterocyclo sulfonyl chloride.

7. The process of claim 1 wherein the benzo fused heterocyclo compound has the formula:



wherein A and B each independently represent O or S;

R⁶ represents a hydrogen, deuterium, alkyl or halogen radical; and

R⁷ represents a hydrogen, deuterium, alkyl or halogen radical;

8. The process of claim 7 wherein A and B each represent O; R⁶ represents a hydrogen, deuterium, alkyl of 1-5 carbon atoms, fluoro or chloro radical; and R⁷ represents hydrogen, deuterium, alkyl of 1-3 carbon atoms, fluoro or chloro radical.
9. The process of claim 8 wherein R⁶ represents a hydrogen, deuterium, methyl, ethyl, propyl, isopropyl or fluoro radical; and R⁷ represents a hydrogen, deuterium, methyl or fluoro radical.
10. The process of claim 7 wherein A and B represent O; and R⁶ and R⁷ each independently represent a fluoro or chloro radical.

11. The process of claim 10 wherein R⁶ and R⁷ each represent a fluoro radical.
12. The process of claim 7 wherein R⁶ and R⁷ each represent a hydrogen.
13. The process of claim 7 wherein A and B represent O; and R⁶ and R⁷ each represent a hydrogen.
14. The process of claim 1 wherein the benzo fused heterocyclic compound is a benzodioxane, benzopyran, or benzodihydrofuran.
15. The process of claim 14 wherein the benzo fused heterocyclic compound is 1,4-benzodioxane, 2,3-benzodihdropyran, or 2,3-benzodihydrofuran.
16. The process of claim 1 comprising a single pot process.

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 99/07047

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C07D317/62 C07D319/18 C07D311/58 C07D339/06 C07D307/79

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	W0 97 18205 A (SEARLE) 22 May 1997 (1997-05-22) page 43; examples 35-2 ---	1-9, 12, 13, 16
X	W0 96 28418 A (SEARLE) 19 September 1996 (1996-09-19) page 101; examples 39-2 ---	1-9, 12, 13, 16
X	W0 96 22287 A (SEARLE) 25 July 1996 (1996-07-25) page 88 - page 89 ---	1-9, 12, 13, 16
A	EP 0 583 960 A (LILLY) 23 February 1994 (1994-02-23) claims; examples 1-4 -----	1

Further documents are listed in the continuation of box C. Patent family members are listed in annex.

Special categories of cited documents:

<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Date of the actual completion of the international search 5 August 1999	Date of mailing of the international search report 17/08/1999
---------------------------------------------------------------------------------------	-----------------------------------------------------------------------------

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer <p style="text-align: center; font-weight: bold;">Francois, J</p>
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------

INTERNATIONAL SEARCH REPORT

Information on patent family members

I. International Application No

PCT/US 99/07047

Patent document cited in search report	A	Publication date	Patent family member(s)	Publication date
WO 9718205	A	22-05-1997	AU 7722296	05-06-1997
			CA 2236236	22-05-1997
			EP 0861249	02-09-1998
WO 9628418	A	19-09-1996	US 5705500	06-01-1998
			AU 6695196	02-10-1996
			BR 9607450	30-06-1998
			CA 2215066	19-09-1996
			CN 1183767	03-06-1998
			CZ 9702822	18-02-1998
			EP 0813519	29-12-1997
			HU 9800294	28-07-1998
			JP 11503414	26-03-1999
			NO 974146	07-11-1997
			NZ 306026	28-01-1999
			PL 322169	19-01-1998
			SK 122397	04-02-1998
WO 9622287	A	25-07-1996	AU 4700896	07-08-1996
			CA 2210889	25-07-1996
			EP 0804428	05-11-1997
			JP 11500105	06-01-1999
EP 583960	A	23-02-1994	US 5387681	07-02-1995
			AT 153333	15-06-1997
			BR 9303223	01-03-1994
			CA 2103930	20-02-1994
			DE 69310836	26-06-1997
			DE 69310836	09-10-1997
			DK 583960	25-08-1997
			ES 2103434	16-09-1997
			GR 3024121	31-10-1997
			HU 64953	28-03-1994
			JP 6199825	19-07-1994
			MX 9304960	31-05-1994